



US 20150216828A1

(19) **United States**

(12) **Patent Application Publication**
Napier et al.

(10) **Pub. No.: US 2015/0216828 A1**

(43) **Pub. Date: Aug. 6, 2015**

(54) **PRODUCTION OF OMEGA-3 LONG CHAIN
POLYUNSATURATED FATTY ACIDS**

(71) Applicant: **Rothamsted Research Ltd.**,
Hertfordshire (GB)

(72) Inventors: **Johnathan Napier**, Hertfordshire (GB);
Olga Sayanova, Hertfordshire (GB);
Noemi Ruiz-Lopez, Utrera (ES);
Richard Haslam, Buckinghamshire
(GB)

(73) Assignee: **Rothamsted Research Ltd.**,
Hertfordshire (GB)

(21) Appl. No.: **14/391,818**

(22) PCT Filed: **Apr. 12, 2013**

(86) PCT No.: **PCT/GB2013/050955**

§ 371 (c)(1),

(2) Date: **Oct. 10, 2014**

(30) **Foreign Application Priority Data**

Apr. 12, 2012 (GB) 1206483.8

Dec. 10, 2012 (GB) 1222184.2

Publication Classification

(51) **Int. Cl.**

A61K 31/202 (2006.01)

A23K 1/16 (2006.01)

A23L 1/30 (2006.01)

A61K 8/36 (2006.01)

C12N 15/82 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/202** (2013.01); **A61K 8/361**
(2013.01); **C12N 15/8247** (2013.01); **A23L**
1/3006 (2013.01); **A23K 1/164** (2013.01); **A23V**
2002/00 (2013.01)

(57) **ABSTRACT**

A recombinant *camelina* plant or cell comprising one or more polynucleotides encoding a $\Delta 6$ -desaturase, a $\Delta 6$ -elongase and a $\Delta 5$ -desaturase operably linked with one or more regulatory sequences.

Fig 1

The biosynthetic pathway for long chain polyunsaturated fatty acids





Fig2 EPA-constructs



Simplified maps of the vector constructs used for Camelina transformation.

Cnl, conlinin 1promoter for the gene encoding the flax 2S storage protein conlinin; USP, promoter region of the unknown seed protein of *V.faba*; SBP1800; NP, napin; OtΔ6, a Δ6-desaturase from *O. taurii*; TcΔ5- a Δ5-desaturase from *Thraustochytrium* sp.; Pi ω3- an ω-3 desaturase from *P. infestans*; PsΔ12- a Δ12-desaturase from *P. sojae*; EhΔ4 – a Δ4-desaturases from *Emiliania huxleyi*; PSE1, a Δ6-elongase from *P. patens*, O1E1o5- Δ5-elongase from *Ostreococcus tauri*; OCS, 35S, E9 and CatpA – represent terminators.





Fig 3



Sample MS spectra showing positive precursor ion scan for 184 (PC)

Fig 5






Fig 6 – Distribution of acyl chains within phospholipids of WT and EPA- accumulating Camelina: phosphatidylcholine (PC)




Novel species of PC present in transgenic lines indicated with red boxes [classification based on total chain length for sn-1 and sn-2 positions, and number of double bonds]. PC species significantly reduced in transgenics are boxed in blue; orange box = increased above WT levels

Fig 7 – Distribution of acyl chains within phospholipids of WT and EPA- accumulating Camelina: phosphatidylethanolamine (PE)




Novel species of PE present in transgenic lines indicated with red boxes [classification based on total chain length for sn-1 and sn-2 positions, and number of double bonds]. PE species significantly reduced in transgenics are boxed in blue; orange =increased above WT

Fig 8 – Distribution of acyl chains within phospholipids of WT and EPA- accumulating Camelina: phosphatidic acid (PA) and phosphoinositol (PI)



Novel species of PA or PI present in transgenic lines indicated with red boxes [classification based on total chain length for sn-1 and sn-2 positions, and number of double bonds]. PA/PI species significantly reduced in transgenics are boxed in blue; orange =increased above WT

Fig 9 – Distribution of acyl chains within phospholipids of WT and EPA- accumulating Camelina: phosphatidylserine (PS) and phosphatidylglycerol (PG)



Novel species of PS or PG present in transgenic lines indicated with red boxes [classification based on total chain length for sn-1 and sn-2 positions, and number of double bonds]. PS/PG species significantly reduced in transgenics are boxed in blue

Fig 10. Analysis of Acyl CoA (LC - MS MS QTRAP) from Mid Development Arabidopsis & *Camelina* Seed





Fig 11: XIC of Acyl CoA MRM (26 pairs) *Camelina* Seed expressing MC (BBC0) construct



PRODUCTION OF OMEGA-3 LONG CHAIN POLYUNSATURATED FATTY ACIDS

FIELD OF THE INVENTION

[0001] The present invention relates to a recombinant oilseed plant or cell for producing omega-3 long chain polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The invention further relates to the oil produced by said recombinant oilseed plant or cell.

BACKGROUND TO THE INVENTION

[0002] Two main families of poly-unsaturated fatty acids are the omega-3 fatty acids, exemplified by EPA, and the omega-6 fatty acids, exemplified by arachidonic acid (FIG. 1).

[0003] The starting material for the omega-6 metabolic pathway is the fatty acid linoleic acid while the omega-3 pathway proceeds via linolenic acid. Linolenic acid is formed by the activity of an omega-3 desaturase (Tocher et al. 1998, *Prog. Lipid Res.* 37, 73-117; Domergue et al. 2002, *Eur. J. Biochem.* 269, 4105-4113).

[0004] Omega-3 highly unsaturated fatty acids are recognized as being important dietary compounds for preventing arteriosclerosis and coronary heart disease, for alleviating inflammatory conditions and for retarding the growth of tumor cells. These beneficial effects are a result both of omega-3 highly unsaturated fatty acids causing competitive inhibition of compounds produced from omega-6 fatty acids, and from beneficial compounds produced directly from the omega-3 highly unsaturated fatty acids themselves (Simopoulos et al. (1986) *Health Effects of Polyunsaturated Fatty Acids in Seafoods*, Academic Press, New York).

[0005] Omega-3 long chain polyunsaturated fatty acids are crucial to brain development and normal brain functioning (Neuringer, et al., (1988) *Annu Rev Nutr* 8, 517-541) with DHA particularly important to brain functioning due to its influence on neural membrane properties, which modulate cell signalling (Uauy, R., and Dangour, A. D. (2006) *Nutr Rev* 64, S24-33; discussion S72-91). DHA concentration in the brain decreases with age in humans, something that has been postulated to be consequential to the age-related deterioration in central nervous system functions (Soderberg et al. (1991) *Lipids* 26, 421-425). Evidence from animal studies supports this, with animals fed a low omega-3 long chain polyunsaturated fatty acid diet showing cognitive deficits (Suzuki et al. (1998) *Mech Ageing Dev* 101, 119-128) that are ameliorated by DHA supplementation (Moriguchi, T., and Salem, N., Jr. (2003) *J Neurochem* 87, 297-309; Chung, et al. (2008) *J Nutr* 138, 1165-1171).

[0006] In humans, it has been consistently reported that a higher intake of fish is related to reduced cognitive decline (van Gelder et al. (2007) *Am J Clin Nutr* 85, 1142-1147; Kalmijn et al. (1997) *Ann Neurol* 42, 776-782; Morris et al. (2005) *Arch Neurol* 62, 1849-1853; Kalmijn et al. (1997) *Am J Epidemiol* 145, 33-41) and incidence of dementia (Kalmijn et al. (1997) *Ann Neurol* 42, 776-782), and associated with better cognitive performance (Morris et al., (2005) *Arch Neurol* 62, 1849-1853; Kalmijn et al. (2004) *Neurology* 62, 275-280; Nurk et al. (2007) *Am J Clin Nutr* 86, 1470-1478; Dangour et al. (2009) *J Nutr Health Aging* 13, 198-202). Significant positive relationships between cognitive outcomes and dietary intake levels of omega-3 long chain polyunsaturated fatty acids have also been established (van Gelder

et al. (2007) *Am J Clin Nutr* 85, 1142-1147; Morris et al. (2003) *Arch Neurol* 60, 940-946; Kalmijn et al. (2004) *Neurology* 62, 275-280). These positive relationships are further strengthened if one considers the plasma or erythrocyte level/status of omega-3 long chain polyunsaturated fatty acids. Here, DHA/EPA levels have been associated with better cognitive function in normal older adult (Whalley et al. (2004) *Am J Clin Nutr* 80, 1650-1657; Whalley et al. (2008) *Am J Clin Nutr* 87, 449-454), better cognitive outcomes over time (Whalley et al. (2008) *Am J Clin Nutr* 87, 449-454), and reduced risk of cognitive decline (Heude et al. (2003) *Am J Clin Nutr* 77, 803-808) and a lower risk of developing dementia (Schaefer et al. (2006) *Arch Neurol* 63, 1545-1550).

[0007] Studies in cognitively healthy populations have failed to show efficacy in improving cognition (Dangour et al. (2010) *Am J Clin Nutr* 91, 1725-1732; van de Rest et al. (2008) *Neurology* 71, 430-438). However, omega-3 long chain polyunsaturated fatty acid supplementation has been shown to be efficacious in cognitively impaired individuals (primarily mild cognitively impaired; MCI), where interventions had a beneficial effect on cognitive outcomes (Chiu et al. (2008) *Prog Neuropsychopharmacol Biol Psychiatry* 32, 1538-1544; Freund-Levi et al. (2006) *Arch Neurol* 63, 1402-1408; Yurko-Mauro et al. (2010) *Alzheimers Dement* 6, 456-464). Furthermore, they have been shown to be beneficial in at risk AD individuals carrying the apolipoprotein E (ApoE) $\epsilon 4$ allele, with these individuals showing an improvement in sustained attention after 26 weeks intervention with both low (226 mg EPA, 176 mg DHA) and high (1093 mg EPA, 847 mg DHA) doses of fish oil.

[0008] Bacteria and yeast are not known to synthesize omega-3 highly unsaturated fatty acids and only a few fungi are known which can produce minor and trace amounts of omega-3 highly unsaturated fatty acids (Weete (1980) *Lipid Biochemistry of Fungi and Other Organism*. Plenum Press, New York; Wassef, M. (1977) "Fungal lipids." *Adv. Lipid Res.*).

[0009] Currently the primary dietary source of omega-3 highly unsaturated fatty acids is from certain fish oils which can contain up to 20-30% of these fatty acids in their triacylglycerides. Consequently large quantities of fish oil are processed and encapsulated each year for sale as a dietary supplement.

[0010] However, fish stocks may undergo natural fluctuations or may be depleted by overfishing. Furthermore, fish oils, can accumulate environmental pollutants and may contain high levels of fat-soluble vitamins that are found naturally in fish oils. When ingested, these vitamins are stored and metabolized in fat in the human body rather than excreted in urine. Additionally, fish oils have an unpleasant taste and odour when they undergo oxidation, and as such cannot be added to processed foods as a food additive, without impairing the taste of the food product. Moreover, the refining of pure omega-3 highly unsaturated fatty acids from crude extracts of fish oils is an involved and expensive process resulting in very high prices for pure forms of these fatty acids.

[0011] The primary natural source of omega-3 unsaturated fatty acids in fish oil is in fact marine unicellular microbes such as algae and diatoms, at the base of the aquatic food web. These highly unsaturated fatty acids are important components of photosynthetic membranes. Omega-3 highly unsaturated fatty acids accumulate in the food chain and are eventually incorporated into fish oils.

[0012] Owing to the positive characteristics of omega-3 polyunsaturated fatty acids, genes have been identified which are involved in the biosynthesis of these fatty acids in a variety of organisms.

[0013] Linoleic acid (LA, 18:2^{A9,12}) is converted to α -linolenic acid (ALA, 18:3^{A9,12,15}) the first of the omega-3 fatty acids, by the action of a Δ 15 desaturase. Subsequently, ALA is converted to stearodonic acid (SDA, 18:4^{A6,9,12,15}) by the activity of a Δ 6 desaturase; SDA is converted to eicosatetraenoic acid (ETA, 20:4^{A8,11,14,17}) by the activity of an elongase; and ETA is converted to eicosapentaenoic acid (EPA, 20:5^{A5,8,11,14,17}) by the activity of a Δ 5 desaturase. Alternatively, ETA and EPA can be produced from di-homo γ -linolenic acid (DGLA, 20:3^{A8,11,14}) and arachidonic acid (ARA, 20:4^{A5,8,11,14}) respectively, by the activity of a Δ 17 desaturase. EPA can be further converted to DHA by the activity of an elongase and a Δ 4 desaturase (see FIG. 1).

[0014] While higher plants comprise polyunsaturated fatty acids such as linoleic acid and linolenic acid, long-chain polyunsaturated fatty acids such as DHA and EPA are not found at all in the seed oil of such plants, or only in miniscule, nutritionally-irrelevant amounts. The production of long-chain polyunsaturated fatty acids, in particular omega-3 fatty acids, in higher plants would be advantageous since large amounts of high-quality long-chain polyunsaturated fatty acids (and associated triacylglycerides) for the food industry, animal nutrition and pharmaceutical purposes might be obtained economically.

[0015] Transgenic linseed oil plants have been shown to result in the accumulation of high levels of Δ 6 desaturated C₁₈ fatty acids. However, only very low levels of C₂₀ polyunsaturated fatty acids have been obtained. The synthesis and accumulation of omega-3 LC-PUFAs such as EPA and DHA in the seeds of transgenic plants has previously reported in the literature but with limited success and unpredictable results.

[0016] Abbadi et al. (Plant Cell. 2004 October; 16(10): 2734-48. Epub 2004 Sep. 17) described attempts to produce EPA in the seeds of transgenic linseed, using a three-gene construct containing a Δ 6-desaturase (D6D) from *Phaeodactylum tricorutum* (AY082393), Δ 6-elongase (D6E) from *Physcomitrella patens* (AF428243) and Δ 5-desaturase (D5D) from *Phaeodactylum tricorutum* (AY082392). Linseed was chosen as a host species for the seed-specific expression of these genes on account of the very high levels of endogenous substrate (ALA) for prospective conversion to EPA. However, despite the presence of almost 50% ALA in the seeds of developing linseed, less than 1% EPA (0.8% of total fatty acids) was generated. In addition, very high levels of the undesired biosynthetic intermediate the omega-6 fatty acid γ -linolenic acid (GLA) were reported (16.8% of total fatty acids). This simultaneous accumulation of high levels of GLA and low synthesis of EPA was ascribed by Abbadi et al. (Plant Cell. 2004 October; 16(10):2734-48. Epub 2004 Sep. 17) to the phospholipid-dependent substrate-requirements of the D6D.

[0017] Similar results were also reported by Wu et al. (Nat Biotechnol, 2005, 23:1013-7) who described the seed-specific expression of a 3 gene construct (D6D from *Pythium irregulare*, CAJ30866; D6E from *Physcomitrella patens*; D5D from *Thraustochytrium*, AX467713) in *Brassica juncea*, yielding 0.8% EPA but 27.7% of the undesirable omega-6 GLA. More complex gene constructs were also reported by Wu et al. in which they attempted to boost the accumulation of EPA in transgenic *B. juncea*. A four gene

construct comprising the same D6D, D6E, D5D activities and additionally the FAD2 Δ 12-desaturase from *Calendula officinalis* (AF343065) resulted in a small increase in EPA to 1.2% but also a concomitant increase in GLA to 29.4%. A five gene construct, comprising D6D, D6E, D5D, FAD2 and a second Δ 6-elongase D6E#2 from *Thraustochytrium* (AX214454) had equally marginal impact on the fatty acid composition of the seeds of transgenic *B. juncea*, yielding 1.4% EPA and 28.6% GLA. A six gene construct, comprising the same D6D, D6E, D5D, FAD2, D6E#2 and a w3-desaturase w3D from *Phytophthora infestans* (CS160901), yielded the best levels of EPA at 8.1%—however, the levels of GLA remained high at 27.1%. In a further iteration, Wu et al. (Nat Biotechnol, 2005, 23:1013-7) also attempted to engineer the accumulation of both EPA and DHA, through the seed-specific expression of nine genes (D6D, D6E, D5D, FAD2, D6E#2, w3D, and additionally a Δ 5-elongase (D5E) from fish (*Oncorhynchus mykiss*; CS020097), a Δ 4-desaturase (D4D) from *Thraustochytrium* (AF489589), and an acyltransferase also from the same organism). This yielded *B. juncea* seeds containing on average 8.1% EPA and 0.2% DHA. Again, GLA levels remained markedly higher (27.3%). Wu et al. reported a maximal level of EPA observed in transgenic *B. juncea* as 15% and a maximal DHA level of 1.5% (based on individual plants for their nine gene construct).

[0018] Similar experiments were carried out in the model oilseed species *Arabidopsis thaliana*: Robert et al. (Functional Plant Biol, 2005, 32: 473-479) reported the low level accumulation of EPA (3.2% of total fatty acids) in the seeds of *Arabidopsis* on the expression of two genes, a bifunctional D6D/D5D from zebrafish (*Danio rerio*, AF309556) and a D6E from the nematode *Caenorhabditis elegans* (Z68749). Interestingly, this construct also showed significantly reduced accumulation of GLA, a fact that Robert et al. attributed to the acyl-CoA-dependent substrate requirement of the D6D/D5D. Further transformation of this EPA-accumulating *Arabidopsis* line with genes for DHA synthesis (D4D and D5E from *Pavlova salina*, AY926605, AY926606) resulted in a mean level of 0.3% DHA, again with basal levels of the unwanted co-product GLA (0.3%).

[0019] Very similar results were reported by Hoffmann et al. (J Biol Chem, 2008, 283:22352-62) who postulated that the use of an “acyl-CoA-dependent” pathway in transgenic plants would decrease the build-up of biosynthetic intermediates such as GLA whilst simultaneously increase the accumulation of EPA. However, the seed-specific expression in *Arabidopsis* of acyl-CoA-dependent D6D and D5D activities from *Mantoniella squamata* (AM949597, AM949596) (in conjunction with the previously described D6E from *P. patens*) yielded barely detectable levels of EPA (<0.1% of total seed fatty acids and <0.05% GLA). Analogous data have been reported by Ruiz-Lopez et al. (Transgenic Res. 2012 (doi:10.1007/s11248-012-9596-0)) who expressed a number of different gene combinations in *Arabidopsis*. Notably, a six gene construct comprising a D6D from *Pythium irregulare*, (CAJ30866); D6E from *Physcomitrella patens* (AF428243); D5D from *Thraustochytrium*, (AX467713); a bifunctional D12/15 desaturase from *Acanthamoeba castellanii*, EF017656; w3D from *Phytophthora infestans* (CS160901) and a second D6E from *Thalassiosira pseudonana*, (AY591337) yielded 2.5% EPA of total seed fatty acids with the concomitant accumulation of 13.3% GLA. In contrast, a four gene construct that contained an acyl-CoA-dependent D6D from *Ostreococcus tauri* (AY746357), D6E from

Thalassiosira pseudonana (AY591337), D5D from *Thraustochytrium*, (AX467713) and FAD2 from *Phytophthora sojae* (CS423998) generated low levels of both EPA (2% of total fatty acids) and GLA (1.0%).

[0020] More recently, Cheng et al. (Transgenic Res, 2010, 19:221-9) reported the accumulation of EPA in transgenic *Brassica carinata*. For example, the seed-specific expression of 3 genes (D6D from *Pythium irregulare*, CAJ30866; D6E from *Thalassiosira pseudonana*, AY591337; D5D from *Thraustochytrium*, AX467713) resulted in a mean level of 2.3% EPA, with high level co-accumulation of GLA (17.6%). A four gene construct (D6D, D6E, D5D and w3D from *Claviceps purpurea*, EF536898) resulted in 4.2% EPA and 11.8% GLA, whilst a five gene construct (D6D, D6E, D5D, w3D and an additional w3-desaturase from *Pythium irregulare*, (FB753541)) yielded 9.7% EPA and 11.1% GLA. Such levels are very similar to that observed with five and six gene constructs in *B. juncea* (Wu et al. 2005, Nat Biotechnol, 2005, 23:1013-7). Cheng et al. introduced a different 5 gene construct (D6D from *Pythium irregulare*, CAJ30866; D6E from *Thraustochytrium*, HC476134; D5D from *Thraustochytrium*, AX467713; FAD2 from *Calendula officinalis*, AF343065 and w3D from *Pythium irregulare*, FB753541) into two different cultivars of *B. carinata*, differing in their accumulation of the C22 monounsaturated fatty acid erucic acid. Expression of this construct in conventional high erucic acid *B. carinata* resulted again in a mean accumulation of 9.3% EPA and 18.2% GLA. Expression in the zero-erucic acid genotype yielded an increase in EPA though this genotype also resulted in the co-accumulation of high levels of GLA (26.9%).

[0021] The present invention addresses the need for systems that produce commercially useful levels of omega-3 highly unsaturated fatty acids in the seeds of terrestrial plants.

SUMMARY OF THE INVENTION

[0022] *Camelina sativa* is a genus within the flowering plant family Brassicaceae. *Camelina* is a short season crop, and has gained notoriety for its ability to withstand water shortages in early stages of development. In recent years, there has been increasing interest in the use of *camelina* oil as a biofuel and bio-lubricant, mainly in view of this crop's low nitrogen requirements.

[0023] The present invention relates to the surprising finding that *camelina* can be transformed with desaturase and elongase enzymes to produce omega-3 fatty acids.

[0024] Indeed, following the introduction of these enzymes into *camelina*, it is not only possible to generate omega-3 fatty acids, but it is possible to create novel oil compositions.

[0025] According to a first aspect of the present invention there is provided a recombinant *camelina* plant or cell comprising one or more polynucleotides encoding a $\Delta 6$ -desaturase, a $\Delta 6$ -elongase and a $\Delta 5$ -desaturase operably linked with one or more regulatory sequences.

[0026] Thus, there is provided a *camelina* plant or cell transformed with genes encoding a $\Delta 6$ -desaturase, a $\Delta 6$ -elongase and a $\Delta 5$ -desaturase.

[0027] The $\Delta 6$ -desaturase, $\Delta 6$ -elongase and $\Delta 5$ -desaturase enzymes can be encoded by a single or separate polynucleotide(s). What is important is that the recombinant *camelina* plant or host according to the first aspect of the invention comprises polynucleotide sequences for all three enzymes.

[0028] In a preferred embodiment of the first aspect of the invention, the recombinant *camelina* plant or cell is produced by transforming a *camelina* plant or cell with a polynucle-

otide encoding a $\Delta 6$ -desaturase, a $\Delta 6$ -elongase and a $\Delta 5$ -desaturase operably linked with one or more regulatory sequences.

[0029] Alternatively, the recombinant *camelina* plant or cell may be produced by transforming a *camelina* plant or cell with separate polynucleotides each encoding a $\Delta 6$ -desaturase and/or a $\Delta 6$ -elongase and/or a $\Delta 5$ -desaturase.

[0030] The recombinant *camelina* plant or cell of this aspect of the invention may further comprise one or more polynucleotides encoding a $\Delta 12$ -desaturase and/or a $\omega 3$ desaturase operably linked with one or more regulatory sequences. Thus, there is provided a recombinant *camelina* plant or cell comprising one or more polynucleotides encoding $\Delta 6$ -desaturase, a $\Delta 6$ -elongase, a $\Delta 5$ -desaturase, a $\Delta 12$ -desaturase and $\omega 3$ desaturase operably linked to one or more regulatory elements. In a preferred embodiment, the recombinant *camelina* plant or cell is produced by transforming a *camelina* plant or cell with a polynucleotide encoding a $\Delta 6$ -desaturase, a $\Delta 6$ -elongase, a $\Delta 5$ -desaturase, a $\Delta 12$ -desaturase and a $\omega 3$ desaturase operably linked with one or more regulatory sequences.

[0031] According to a second aspect of the present invention there is provided a method for producing eicosapentaenoic acid (EPA) comprising growing a plant or cell according to the first aspect of the invention under conditions wherein said desaturase and elongase enzymes are expressed and EPA is produced in said plant or cell.

[0032] According to third aspect of the present invention there is provided a method for producing a plant seed oil comprising growing a recombinant *camelina* plant or cell of the first aspect of the invention whereby said desaturase and elongase enzymes are expressed and oil is produced in said plant or cell.

[0033] According to fourth aspect of the present invention there is provided a plant seed oil produced by the recombinant *camelina* plant or cell of the first aspect of the present invention.

[0034] According to a fifth aspect of the present invention there is provided a plant seed oil wherein EPA constitutes at least 5%, at least 10%, at least 20%, at least 25% or at least 30% (mol %) of the total of the total amount of fatty acid present in said oil. Said oil may be produced by a recombinant *camelina* plant or cell of the first aspect of the present invention.

[0035] In one embodiment, the EPA constitutes at least 15, 20, 25 or 30% (mol %) of the total fatty acid content of said oil, and the γ -linolenic (GLA) constitutes less than 10% (mol %) of the total fatty acid content of said oil.

[0036] In one embodiment, the EPA constitutes 20% to 35%, preferably 20 to 31% (mol %) of the total fatty acid content of said oil.

[0037] The GLA may constitute less than 7% (mol %) of the total fatty acid content of said oil. In one embodiment, the GLA constitutes 1% to 6% (mol %) of the total fatty acid content of said oil.

[0038] The ratio of the molar percentages of EPA to γ -linolenic (GLA) may be, for example, about 3:1 to about 22:1, preferably about 5:1 to about 20:1, preferably about 8:1 to about 20:1.

[0039] According to a sixth aspect of the present invention there is provided a recombinant *camelina* plant or cell comprising one or more polynucleotides encoding a $\Delta 6$ -desatu-

rase, a $\Delta 6$ -elongase, a $\Delta 5$ -desaturase, a $\Delta 5$ -elongase and a $\Delta 4$ -desaturase operably linked with one or more regulatory sequences.

[0040] Thus, there is provided a *camelina* plant or cell transformed with genes encoding a $\Delta 6$ -desaturase, a $\Delta 6$ -elongase, a $\Delta 5$ -desaturase, a $\Delta 5$ -elongase and a $\Delta 4$ -desaturase.

[0041] The $\Delta 6$ -desaturase, $\Delta 6$ -elongase, $\Delta 5$ -desaturase, $\Delta 5$ -elongase and $\Delta 4$ -desaturase can be encoded by a single or separate polynucleotide(s). What is essential is that the recombinant *camelina* plant or cell according to the sixth aspect of the invention comprises polynucleotide sequences for all five enzymes.

[0042] Preferably, the recombinant *camelina* plant or cell according to this aspect of the invention is produced by transforming a *camelina* plant or cell with a polynucleotide encoding a $\Delta 6$ -desaturase, a $\Delta 6$ -elongase, a $\Delta 5$ -desaturase, a $\Delta 5$ -elongase and a $\Delta 4$ -desaturase operably linked with one or more regulatory sequences.

[0043] Alternatively, the recombinant *camelina* plant or cell may be produced by transforming a *camelina* plant or cell with separate polynucleotides each encoding a $\Delta 6$ -desaturase, and/or $\Delta 6$ -elongase, and/or $\Delta 5$ -desaturase, and/or $\Delta 5$ -elongase and/or a $\Delta 4$ -desaturase.

[0044] The recombinant *camelina* plant or cell of this aspect of the invention may further comprise one or more polynucleotides encoding a $\Delta 12$ -desaturase and/or a $\omega 3$ desaturase operably linked with one or more regulatory sequences. Thus, there is provided a recombinant *camelina* plant or cell comprising one or more polynucleotides encoding a $\Delta 6$ -desaturase, a $\Delta 6$ -elongase, a $\Delta 5$ -desaturase, a $\Delta 12$ -desaturase, a $\Delta 5$ -elongase, a $\Delta 4$ -desaturase and a $\omega 3$ desaturase operably linked to one or more regulatory elements. In a preferred embodiment, the recombinant *camelina* plant or cell is produced by transforming a *camelina* plant or cell with a polynucleotide encoding a $\Delta 6$ -desaturase, a $\Delta 6$ -elongase, a $\Delta 5$ -desaturase, a $\Delta 5$ -elongase, a $\Delta 4$ -desaturase, a $\Delta 12$ -desaturase and a $\omega 3$ desaturase operably linked with one or more regulatory sequences.

[0045] According to a seventh aspect of the present invention there is provided a method for producing docosahexaenoic acid (DHA) and/or EPA comprising growing a plant or cell according to the sixth aspect of the invention under conditions wherein said desaturase and elongase enzymes are expressed and DHA and/or EPA is produced in said plant or cell.

[0046] According to eighth aspect of the present invention there is provided a method for producing a plant seed oil comprising growing a recombinant *camelina* plant or cell of the sixth aspect of the invention whereby said desaturase and elongase enzymes are expressed and oil is produced in said plant or cell.

[0047] According to a ninth aspect of the present invention there is provided a plant seed oil produced by the recombinant *camelina* plant or cell of the sixth aspect of the present invention.

[0048] According to a tenth aspect of the present invention there is provided a plant seed oil wherein DHA constitutes at least 1%, preferably at least 3%, more preferably at least 5%, still more preferably at least 7%, still more preferably at least 10%, still more preferably at least 13% or still more preferably at least 15% (mol %) of the total amount of fatty acid present in said oil. Said oil may be produced by a recombinant *camelina* plant or cell according to the sixth aspect of the present invention.

[0049] Preferably, according to this aspect of the invention the γ -linolenic (GLA) constitutes less than 5%, more preferably less than 4.5%, still more preferably less than 4%, still more preferably less than 3.5%, still more preferably less than 3%, still more preferably less than 2.5%, still more preferably less than 2% (mol %) of the total fatty acid content of said oil.

[0050] In one embodiment the DHA constitutes 5% to 20% (mol %) of the total fatty acid content of said oil.

[0051] In another embodiment the DHA constitutes 5% to 20% (mol %) of the total fatty acid content of said oil.

[0052] In another embodiment the DHA constitutes 10% to 20% (mol %) of the total fatty acid content of said oil.

[0053] In another embodiment the DHA constitutes 10 to 15% (mol %) of the total fatty acid content of said oil.

[0054] In another embodiment the DHA constitutes 10 to 13.7% (mol %) of the total fatty acid content of said oil.

[0055] Preferably the combined percentage of DHA and EPA is at least 20% of the total fatty acid content of said oil.

[0056] In one embodiment the combined percentage of DHA and EPA is 20 to 30% of the total fatty acid content of said oil.

[0057] In one embodiment the combined percentage of DHA and EPA is 21 to 27% of the total fatty acid content of said oil.

[0058] In one embodiment the DHA constitutes 4% to 10%, preferably 4% to 8%, preferably 5% to 7.5% (mol %) of the total fatty acid content of said oil.

[0059] In one embodiment the GLA constitutes 0% to 4.5% (mol %) of the total fatty acid content of said oil.

[0060] In one embodiment the GLA constitutes 0.5% to 4.5% (mol %) of the total fatty acid content of said oil.

[0061] In another embodiment the GLA constitutes 1.0% to 4.5% (mol %) of the total fatty acid content of said oil.

[0062] In another embodiment the GLA constitutes 1.5% to 4.5% (mol %) of the total fatty acid content of said oil.

[0063] In another embodiment the GLA constitutes 0% to 3.5% (mol %) of the total fatty acid content of said oil.

[0064] In another embodiment the GLA constitutes 0.5% to 3.5% (mol %) of the total fatty acid content of said oil.

[0065] In another embodiment the GLA constitutes 1.0% to 3.5% (mol %) of the total fatty acid content of said oil.

[0066] In another embodiment the GLA constitutes 1.5% to 3.5% (mol %) of the total fatty acid content of said oil.

[0067] In one embodiment the GLA constitutes 1.5% to 3.2% (mol %) of the total fatty acid content of said oil.

[0068] The ratio of the molar percentages of EPA to DHA may be, for example, about 0.8:1 to about 1.4:1, preferably about 1:1 to about 1:1.3.

[0069] In another embodiment the ratio of the molar percentages of the sum of (EPA+DHA) to GLA is about 20:1 to about 3:1, 5:1, 7:1 or 10:1.

[0070] In another embodiment the ratio of the molar percentages of the sum of (EPA+DHA) to GLA is about 17:1 to about 3:1, 5:1, 7:1 or 10:1.

[0071] In another embodiment the ratio of the molar percentages of the sum of (EPA+DHA) to GLA is about 16.4:1 to about 3:1, 5:1, 7:1 or 10:1.

[0072] In another embodiment the ratio of the molar percentages of the sum of (EPA+DHA) to GLA is about 8:1 to about 3:1.

[0073] According to an eleventh aspect of the present invention there is provided use of *camelina* in the manufacture of an omega-3 fatty acid, preferably EPA or DHA.

[0074] According to a twelfth aspect of the present invention there is provided a *camelina* seed comprising a phosphatidylcholine wherein the total number of carbon atoms of the fatty acid acyl groups of said phosphatidylcholine is 40. Preferably the seed is a seed of the plant of the first aspect of the invention.

[0075] According to a thirteenth aspect of the present invention there is provided a *camelina* seed comprising phosphatidylcholine, wherein the total number of carbon atoms: double bonds of the fatty acid acyl groups of said phosphatidylcholine species is selected from the group consisting of: 34:4, 34:0, 36:7, 38:11, 38:9, 38:8, 38:7, 38:6, 38:5, 40:11, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5 and 40:4. Preferably the seed comprises all the phosphatidylcholine species 34:4, 34:0, 36:7, 38:11, 38:9, 38:8, 38:7, 38:6, 38:5, 40:11, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5 and 40:4. Preferably the seed is a seed of the plant of the first aspect of the invention.

[0076] According to a fourteenth aspect of the present invention there is provided a *camelina* seed comprising one or more phosphatidylethanolamine species wherein the total number of carbon atoms: double bonds of the fatty acid acyl groups of said phosphatidylethanolamine species is selected from the group consisting of 34:4, 36:7, 38:8, 38:7, 38:6, 38:5, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5. Preferably the seed comprises all of the phosphatidylethanolamine species 34:4, 36:7, 38:8, 38:7, 38:6, 38:5, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5. Preferably the seed is a seed of the plant of the first aspect of the invention.

[0077] According to a fifteenth aspect of the present invention there is provided a *camelina* seed oil comprising the phosphatidylcholine species 34:4, 34:0, 36:7, 38:11, 38:9, 38:8, 38:7, 38:6, 38:5, 40:11, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5 and 40:4. Preferably the seed is a seed of the plant of the sixth aspect of the invention.

[0078] According to a sixteenth aspect of the present invention there is provided a *camelina* seed wherein the seed comprises one or more phosphatidylethanolamine species wherein the total number of carbon atoms: double bonds of the fatty acid acyl groups of said phosphatidylethanolamine species is selected from the group consisting of 34:4, 36:7, 38:8, 38:7, 38:6, 38:5, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5. Preferably the *camelina* oil comprises all of the phosphatidylethanolamine species 34:4, 36:7, 38:8, 38:7, 38:6, 38:5, 40:10, 40:9, 40:8, 40:7, 40:6, 40:5. Preferably the seed is a seed of the plant of the sixth aspect of the invention.

[0079] According to a seventeenth aspect of the present invention there is provided a *camelina* seed or oil wherein said seed or oil comprises triglycerides wherein the number of carbon atom double bonds of said triglycerides is 58:8, 58:9 and 58:10. The seed or oil may be derived from the transgenic *camelina* plant of the invention.

[0080] In addition to the specific elongase and desaturase enzymes referred to herein, the recombinant *camelina* plant or cell defined herein may further encode other enzymes involved in polyunsaturated fatty acid synthesis, in particular enzymes involved in omega-3 polyunsaturated fatty acid synthesis. Alternatively, the recombinant *camelina* plant may only be transformed with the fatty acid synthesis enzymes referred to herein.

[0081] The recombinant *camelina* plant defined herein may be in the form of a seed.

[0082] The desaturase and elongase enzymes used in the present invention may be derived from, for example, algae, bacteria, mould or yeast.

[0083] In one embodiment, the $\Delta 6$ -desaturase used in the present invention is derived from *Ostreococcus*, preferably OtD6 from *Ostreococcus tauri* (Domergue et al. Biochem. J. 389 (PT 2), 483-490 (2005)). In one embodiment, the $\Delta 6$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:1. In another embodiment, the $\Delta 6$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:2.

[0084] In another embodiment, the $\Delta 6$ -desaturase used in the present invention is O809D6 from *Ostreococcus* RCC809. In one embodiment, the $\Delta 6$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:19. In another embodiment, the $\Delta 6$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:20.

[0085] In one embodiment, the $\Delta 6$ -elongase used in the present invention is derived from *Physcomitrella*, and is preferably from *Physcomitrella patens*. Preferably the $\Delta 6$ -elongase is PSE1 derived from *Physcomitrella patens* (Zank, et al., Plant J. 31 (3), 255-268 (2002); AB238914). In one embodiment, the $\Delta 6$ -elongase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:3. In another embodiment, the $\Delta 6$ -elongase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:4.

[0086] In another embodiment, the $\Delta 6$ -elongase used in the present invention is FcElo6, a $\Delta 6$ fatty acid elongase from *Fragilariopsis cylindrus* CCMP 1102. In one embodiment, the $\Delta 6$ -elongase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:21. In another embodiment, the $\Delta 6$ -elongase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:22.

[0087] In another embodiment, the $\Delta 6$ -elongase used in the present invention is CeElo6, a $\Delta 6$ fatty acid elongase from *Caenorhabditis elegans* (Beaudoin et al., 2000, Proc Natl Acad Sci USA. 2000 Jun. 6; 97(12):6421-6). In one embodiment, the $\Delta 6$ -elongase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:23. In another embodiment, the $\Delta 6$ -elongase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:24.

[0088] In one embodiment, the $\Delta 5$ -desaturase used in the present invention is derived from *Thraustochytrium* sp. Preferably the $\Delta 5$ -desaturase is Tc $\Delta 5$ derived from *Thraustochytrium* sp. (Qiu et al. J Biol Chem. 2001 Aug. 24; 276 (34):31561-6; AF489588). In one embodiment, the $\Delta 5$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:5. In another embodiment, the $\Delta 5$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:6.

[0089] In another embodiment, the EMoD5 $\Delta 5$ -desaturase from *E. huxleyi* (Sequence ID 9, 10) can be used. In one embodiment, the $\Delta 5$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:9. In another embodi-

ment, the $\Delta 5$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:10.

[0090] In one embodiment, the $\Delta 5$ -elongase used in the present invention is derived from *Ostreococcus*, preferably *Ostreococcus tauri*. Preferably the $\Delta 5$ -elongase is OTElo5 derived from *Ostreococcus tauri* (WO 2005012316-A2; CS020123). In one embodiment, the $\Delta 5$ -elongase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:7. In another embodiment, the $\Delta 5$ -elongase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:8.

[0091] In one embodiment, the $\Delta 4$ -desaturase is derived from *Thraustochytrium* sp (ATCC21685). In one embodiment, the $\Delta 4$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:17. In another embodiment, the $\Delta 4$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:18.

[0092] In another embodiment the $\Delta 4$ -desaturase is EhD4 derived from *Emiliana huxleyi* (WO 2009133145-A1; HC086723; et al. *Phytochemistry*. 2011 May; 72(7):594-600). In one embodiment, the $\Delta 4$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID 15. In another embodiment, the $\Delta 4$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:16.

[0093] In another embodiment the $\Delta 4$ -desaturase is TpDesk, a $\Delta 4$ -desaturase from *Thalassiosira pseudonana* (Tonon et al, 2005 FEBS J. 2005 July; 272(13):3401-12). In one embodiment, the $\Delta 4$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID 25. In another embodiment, the $\Delta 4$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:26.

[0094] In one embodiment, the $\Delta 12$ -desaturase used in the present invention is derived from *Phytophthora*, and is preferably Ps $\Delta 12$ from *Phytophthora sojae* (WO 2006100241 A2; CS423998). In one embodiment, the $\Delta 12$ -desaturase is encoded by a polynucleotide sequence that has at least 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:11. In another embodiment, the $\Delta 12$ -desaturase comprises an amino acid sequence that has at least 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:12.

[0095] In a one embodiment, the $\omega 3$ -desaturase used in the present invention is derived from *phytophthora*, preferably *phytophthora infestans*. Preferably the $\omega 3$ -desaturase is pi($\omega 3$) derived from *phytophthora infestans* (JP 2007527716; DJ418322). In one embodiment, the $\omega 3$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:13. In another embodiment, the $\omega 3$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:14.

[0096] In another embodiment, the $\omega 3$ -desaturase used in the present invention is Hpw-3, a $\omega 3$ desaturase gene from *Hyaloperonospora parasitica*. In one embodiment, the $\omega 3$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:27. In another embodiment, the

$\omega 3$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:28.

[0097] Preferably the *camelina* referred to herein is *Camelina sativa*.

[0098] In one embodiment, the plant seed oil described herein comprises triglycerides wherein the number of carbon atoms:double bonds of said triglycerides is 58:8, 58:9 and 58:10.

DETAILED DESCRIPTION

[0099] Various preferred features and embodiments of the present invention will now be described by way of non-limiting examples.

[0100] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements; *Current Protocols in Molecular Biology*, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, *DNA Isolation and Sequencing: Essential Techniques*, John Wiley & Sons; J. M. Polak and James O'D. McGee, 1990, *In Situ Hybridization: Principles and Practice*; Oxford University Press; M. J. Gait (Editor), 1984, *Oligonucleotide Synthesis: A Practical Approach*, Irl Press; D. M. J. Lilley and J. E. Dahlberg, 1992, *Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA Methods in Enzymology*, Academic Press; and E. M. Shevach and W. Strober, 1992 and periodic supplements, *Current Protocols in Immunology*, John Wiley & Sons, New York, N.Y. Each of these general texts is herein incorporated by reference.

Camelina

[0101] *Camelina* is a genus within the flowering plant family Brassicaceae. *Camelina* is an emerging biofuel crop, in particular *Camelina sativa*. It is also known by other names such as German sesame, false-flax, gold-of-pleasure, and Siberian oilseed. Renewed interest in *C. sativa* as a biofuel feedstock is due in part to its drought tolerance and minimal requirements for supplemental nitrogen and other agricultural inputs (Gehring et al. (2006) *Genome* 49(12): 1555-63; Gugel and Falk (2006) *Canadian Journal of Plant Science* 86(4): 1047-1058).

[0102] Similar to other non-traditional, renewable oilseed feedstocks such as *Jatropha curcas* L. ("*jatropha*"), *C. sativa* grows on marginal land. Unlike *jatropha*, which is a tropical and subtropical shrub, *C. sativa* is native to Europe and is naturalized in North America, where it grows well in the northern United States and southern Canada.

[0103] In addition to its drought tolerance and broad distribution, several other aspects of *C. sativa* biology make it well suited for development as an oilseed crop. First, *C. sativa* is a member of the family Brassicaceae, and thus is a relative of both the genetic model organism *Arabidopsis thaliana* and the common oilseed crop *Brassica napus* (also known as canola). Second, the oil content of *C. sativa* seeds is comparable to that of *B. napus*, ranging from 30 to 40% (w/w)

(Budin et al. (1995). Journal of the American Oil Chemists' Society 72(3): 309-315; Gugel and Falk (2006) Canadian journal of plant science 86(4): 1047-1058). Finally, the properties of *C. sativa* biodiesel are already well described and both seed oil and biodiesel from *C. sativa* were used as fuel in engine trials with promising results (Bernardo et al. (2003) Industrial Crops and Products 17(3): 191-197; Frohlich and Rice (2005). Industrial Crops and Products 21(1): 25-31).

Oils, Lipids and Fatty Acids

[0104] Polyunsaturated fatty acids can be classified into two major families (depending on the position (n) of the first double bond nearest the methyl end of the fatty acid carbon chain. Thus, the omega-6 fatty acids have the first unsaturated double bond six carbon atoms from the omega (methyl) end of the molecule and additionally have a total of two or more double bonds, with each subsequent unsaturation occurring 3 additional carbon atoms toward the carboxyl end of the molecule. In contrast, the omega-3 fatty acids have the first unsaturated double bond three carbon atoms away from the omega end of the molecule and additionally have a total of three or more double bonds, with each subsequent unsaturation occurring 3 additional carbon atoms toward the carboxyl end of the molecule.

[0105] Table 1 summarizes the common names of omega-3 fatty acids and the abbreviations that will be used throughout the specification:

TABLE 1

Common Name	Abbreviation	Shorthand notation
oleic acid	OA	18:1 ^{Δ9}
Linoleic acid	LA	18:2 ^{Δ9, 12}
γ-Linolenic	GLA	18:3 ^{Δ6, 9, 12}
di-homo γ-linolenic acid	DGLA	20:3 ^{Δ8, 11, 14}
Arachidonic acid	ARA	20:4 ^{Δ5, 8, 11, 14}
α-linolenic acid	ALA	18:3 ^{Δ9, 12, 15}
stearidonic acid	SDA	18:4 ^{Δ6, 9, 12, 15}
eicosatetraenoic acid	ETA	20:4 ^{Δ8, 11, 14, 17}
eicosapentaenoic acid	EPA	20:5 ^{Δ5, 8, 11, 14, 17}
docosapentaenoic acid	DPA	22:5 ^{Δ7, 10, 13, 16, 19}
docosahexaenoic acid	DHA	22:6 ^{Δ4, 7, 10, 13, 16, 19}

[0106] The fatty acids produced by the processes of the present invention can be isolated from the *camelina* in the form of an oil, a lipid or a free fatty acid. One embodiment of the invention is therefore oils, lipids or fatty acids or fractions thereof which have been produced by the methods of the invention, especially preferably oil, lipid or a fatty acid composition comprising EPA or DHA and being derived from the transgenic *camelina*.

[0107] The term "oil", or "lipid" is understood as meaning a fatty acid mixture comprising unsaturated, preferably esterified, fatty acid(s). The oil or lipid is preferably high in omega-3 polyunsaturated or, advantageously, esterified fatty acid(s). In a particularly preferred embodiment the oil or lipid has a high ALA, ETA, EPA, DPA and/or DHA content, preferably a high EPA and/or DHA content.

[0108] For the analysis, the fatty acid content of the seed can, for example, be determined by gas chromatography after converting the fatty acids into the methyl esters by transesterification of lipids such as triacylglycerides and/or phospholipids.

[0109] The omega-3 polyunsaturated acids produced in the method of the present invention, for example EPA and DHA,

may be in the form of fatty acid derivatives, for example sphingolipids, phosphoglycerides, lipids, glycolipids, phospholipids, monoacylglycerol, diacylglycerol, triacylglycerol or other fatty acid esters.

[0110] The omega-3 and other polyunsaturated fatty acids which are present can be liberated for example via treatment with alkali, for example aqueous KOH or NaOH, or acid hydrolysis, advantageously in the presence of an alcohol such as methanol or ethanol, or via enzymatic cleavage, and isolated via, for example, phase separation and subsequent acidification via, for example, H₂SO₄. The fatty acids can also be liberated directly without the above-described processing step.

[0111] If further purification is necessary, standard methods can be employed. Such methods may include extraction, treatment with urea, fractional crystallization, HPLC, fractional distillation, silica gel chromatography, high-speed centrifugation or distillation, or combinations of these techniques. Protection of reactive groups, such as the acid or alkenyl groups, may be done at any step through known techniques (e.g., alkylation, iodination, use of butylated hydroxytoluene (BHT)). Methods used include methylation of the fatty acids to produce methyl esters. Similarly, protecting groups may be removed at any step. Desirably, purification of fractions containing, for example, ALA, STA, ETA, EPA, DPA and DHA may be accomplished by treatment with urea and/or fractional distillation.

[0112] The present invention encompasses the use of the oil, lipid, the fatty acids and/or the fatty acid composition in feedstuffs, foodstuffs, cosmetics or pharmaceuticals. The oils, lipids, fatty acids or fatty acid mixtures according to the invention can be used in the manner with which the skilled worker is familiar for mixing with other oils, lipids, fatty acids or fatty acid mixtures of animal origin, such as, for example, fish oils. Thus, the invention also provides feedstuffs, foodstuffs, cosmetics or pharmacologicals which comprise the oils, lipids, fatty acids or fatty acid mixtures of the present invention.

Total Fatty Acid Content

[0113] The term "total fatty acids content" herein refers to the sum of all cellular fatty acids that can be derivitized to fatty acid methyl esters by the base transesterification method in a given sample (as known in the art, for example as described in Sayanova et al., (1997) Proc Natl Acad Sci USA. 1997 Apr. 15; 94(8):4211-6; Sayanova et al., (2003) FEBS Lett. 2003 May 8; 542(1-3):100-4).

Polyunsaturated Fatty Acid Biosynthetic Genes

[0114] Microorganisms, including algae, bacteria, moulds and yeasts, can synthesize polyunsaturated fatty acids and omega fatty acids in the ordinary course of cellular metabolism. Particularly well-studied are fungi including *Schizochytrium aggregatum*, species of the genus *Thraustochytrium* and *Mortierella alpina*. Additionally, many dinoflagellates (Dinophyceae) naturally produce high concentrations of polyunsaturated fatty acids. As such, a variety of genes involved in oil production have been identified through genetic means and the DNA sequences of some of these genes are publicly available. Non-limiting examples are shown below:

Accession No.	Description
AY131238	<i>Argania spinosa</i> $\Delta 6$ desaturase
Y055118	<i>Echium pitardii</i> var. <i>pitardii</i> $\Delta 6$ desaturase
AY055117	<i>Echium gentianoides</i> $\Delta 6$ desaturase
AF296076	<i>Mucor rouxii</i> , $\Delta 6$ desaturase
AF007561	<i>Borago officinalis</i> $\Delta 6$ desaturase
L11421	<i>Synechocystis</i> sp. $\Delta 6$ desaturase
NM_031344	<i>Rattus norvegicus</i> $\Delta 6$ fatty acid desaturase
AF465283,	<i>Mortierella alpina</i> $\Delta 6$ fatty acid desaturase
AF465282	<i>Mortierella isabellina</i> $\Delta 6$ fatty acid desaturase
AF419296	<i>Pythium irregulare</i> $\Delta 6$ fatty acid desaturase
AB052086	<i>Mucor circinelloides</i> D6d mRNA for $\Delta 6$ fatty acid desaturase
AJ250735	<i>Ceratodon purpureus</i> mRNA for $\Delta 6$ fatty acid desaturase
AF126799	<i>Homo sapiens</i> $\Delta 6$ fatty acid desaturase
AF126798	<i>Mus musculus</i> $\Delta 6$ fatty acid desaturase
AF199596,	<i>Homo sapiens</i> $\Delta 5$ desaturase
AF320509	<i>Rattus norvegicus</i> liver $\Delta 5$ desaturase
AB072976	<i>Mus musculus</i> D5D mRNA for $\Delta 5$ desaturase
AF489588	<i>Thraustochytrium</i> sp. ATCC21685 $\Delta 5$ fatty acid desaturase
AJ510244	<i>Phytophthora megasperma</i> mRNA for $\Delta 5$ fatty acid desaturase
AF419297	<i>Pythium irregulare</i> $\Delta 5$ fatty acid desaturase
AF07879	<i>Caenorhabditis elegans</i> $\Delta 5$ fatty acid desaturase
AF067654	<i>Mortierella alpina</i> $\Delta 5$ fatty acid desaturase
AB022097	<i>Dictyostelium discoideum</i> mRNA for $\Delta 5$ fatty acid desaturase
AF489589.1	<i>Thraustochytrium</i> sp. ATCC21685 $\Delta 4$ fatty acid desaturase
AY332747	<i>Pavlova lutheri</i> $\Delta 4$ fatty acid desaturase (des1) mRNA
AAG36933	<i>Emericella nidulans</i> oleate $\Delta 12$ desaturase
AF110509,	<i>Mortierella alpina</i> $\Delta 12$ fatty acid desaturase mRNA
AAL13300	<i>Mortierella alpina</i> $\Delta 12$ fatty acid desaturase
AF417244	<i>Mortierella alpina</i> ATCC 16266 $\Delta 12$ fatty acid desaturase
AF161219	<i>Mucor rouxii</i> $\Delta 12$ desaturase mRNA
X86736 S	piruline platensis $\Delta 12$ desaturase
AF240777	<i>Caenorhabditis elegans</i> $\Delta 12$ desaturase
AB007640	<i>Chlamydomonas reinhardtii</i> $\Delta 12$ desaturase
AB075526	<i>Chlorella vulgaris</i> $\Delta 12$ desaturase
AP002063	<i>Arabidopsis thaliana</i> microsomal $\Delta 12$ desaturase
NP_441622,	<i>Synechocystis</i> sp. PCC 6803 $\Delta 15$ desaturase
AAL36934	<i>Perilla frutescens</i> $\Delta 15$ desaturase

[0115] Additionally, the patent literature provides many additional DNA sequences of genes (and/or details concerning several of the genes above and their methods of isolation) involved in polyunsaturated fatty acid production. See, for example: U.S. Pat. No. 5,968,809 ($\Delta 6$ desaturases); U.S. Pat. No. 5,972,664 and U.S. Pat. No. 6,075,183 ($\Delta 5$ desaturases); WO 91/13972 and U.S. Pat. No. 5,057,419 ($\Delta 9$ desaturases); WO 93/11245 ($\Delta 15$ desaturases); WO 94/11516, U.S. Pat. No. 5,443,974 and WO 03/099216 ($\Delta 12$ desaturases); U.S. 2003/0196217 A1 ($\Delta 17$ desaturase); WO 02/090493 ($\Delta 4$ desaturases); and WO 00/12720 and U.S. 2002/0139974A1 (elongases).

[0116] The term “desaturase” refers to a polypeptide component of a multi-enzyme complex that can desaturate, i.e., introduce a double bond in one or more fatty acids to produce a mono- or polyunsaturated fatty acid or precursor of interest. Some desaturases have activity on two or more substrates. It may be desirable to empirically determine the specificity of a fatty acid desaturase by transforming a suitable host with the gene for the fatty acid desaturase and determining its effect on the fatty acid profile of the host.

[0117] In the context of the present invention a $\omega 3$ desaturase catalyzes the conversion of LA to ALA (WO 2008022963-A 30 28 Feb. 2008; FB753570)

[0118] In the context of the present invention a $\Delta 6$ desaturase catalyzes the conversion of ALA to SDA and also LA to

GLA. $\Delta 6$ -Desaturases are described in WO 93/06712, U.S. Pat. No. 5,614,393, U.S. Pat. No. 5,614,393, WO 96/21022, WO0021557 and WO 99/27111 and their application to production in transgenic organisms is also described, e. g. in WO 9846763, WO 9846764 and WO 9846765. In one embodiment, the $\Delta 6$ -desaturase used in the present invention is derived from *Ostreococcus*, preferably OtD6 from *Ostreococcus tauri* (Domergue et al. Biochem. J. 389 (PT 2), 483-490 (2005); AY746357). In one embodiment, the $\Delta 6$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:1. In another embodiment, the $\Delta 6$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:2.

[0119] In the context of the present invention a $\Delta 5$ desaturase catalyzes the conversion of ETA to EPA. In one embodiment, the $\Delta 5$ -desaturase used in the present invention is derived from *Thraustochytrium* sp. Preferably the $\Delta 5$ -desaturase is Tc $\Delta 5$ derived from *Thraustochytrium* sp. (Qiu et al. J Biol Chem. 2001 Aug. 24; 276(34):31561-6; AF489588). In one embodiment, the $\Delta 5$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:5. In another embodiment, the $\Delta 5$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:6.

[0120] In the context of the present invention a $\Delta 12$ desaturase catalyzes the conversion OA to LA. In one embodiment, the $\Delta 12$ -desaturase used in the present invention is Ps $\Delta 12$ derived from *Phytophthora*, preferably *Phytophthora sojae* (WO 2006100241 A2; CS423998). In one embodiment, the $\Delta 12$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:11. In another embodiment, the $\Delta 12$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:12.

[0121] In the context of the present invention a $\Delta 4$ desaturase catalyzes the conversion of DPA to DHA. In one embodiment, the $\Delta 4$ -desaturase is derived from *Thraustochytrium* sp (ATCC21685). In one embodiment, the $\Delta 4$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:17. In another embodiment, the $\Delta 4$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:18.

[0122] In another embodiment the $\Delta 4$ -desaturase is EhD4 derived from *Emiliana huxleyi* (Sayanova et al. Phytochemistry. 2011 May; 72(7):594-600). In one embodiment, the $\Delta 4$ -desaturase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID 15. In another embodiment, the $\Delta 4$ -desaturase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:16.

[0123] The term “elongase” refers to a polypeptide that can elongate a fatty acid carbon chain to produce an acid two carbons longer than the fatty acid substrate that the elongase acts upon.

[0124] Examples of reactions catalyzed by elongase systems are the conversion of GLA to DGLA, SDA to ETA, ARA to DTA and EPA to DPA. In general, the substrate selectivity

of elongases is somewhat broad but segregated by both chain length and the degree and type of unsaturation.

[0125] For example, a C14/16 elongase will utilize a C14 substrate (e.g., myristic acid), a C16/18 elongase will utilize a C16 substrate (e.g., palmitate), a C18/20 elongase will utilize a C18 substrate (e.g., GLA, SDA, LA, ALA) and a C20/22 elongase (also referred to as a $\Delta 5$ elongase) will utilize a C20 substrate (e.g., ARA, EPA).

[0126] Since some elongases have broad specificity, a single enzyme may be capable of catalyzing several elongase reactions (e.g., thereby acting as both a C16/18 elongase and a C18/20 elongase). It may be desirable to empirically determine the specificity of a fatty acid elongase by transforming a suitable host with the gene for the fatty acid elongase and determining its effect on the fatty acid profile of the host.

[0127] In the context of the present invention a $\Delta 6$ elongase catalyzes the conversion of SDA to ETA. In one embodiment, the $\Delta 6$ -elongase used in the present invention is derived from *Physcomitrella*, and is preferably from *Physcomitrella patens*. Preferably the $\Delta 6$ -elongase is PSE1 derived from *Physcomitrella patens* (Zank, et al., Plant J. 31 (3), 255-268 (2002); AB238914). In one embodiment, the $\Delta 6$ -elongase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:3. In another embodiment, the $\Delta 6$ -elongase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:4.

[0128] In the context of the present invention a $\Delta 5$ elongase catalyzes the conversion of EPA to DPA. In one embodiment, the $\Delta 5$ -elongase used in the present invention is derived from *Ostreococcus*, preferably *Ostreococcus tauri*. Preferably the $\Delta 5$ -elongase is OtElo5 derived from *Ostreococcus tauri* (WO 2005012316-A2; CS020123). In one embodiment, the $\Delta 5$ -elongase is encoded by a polynucleotide sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:7. In another embodiment, the $\Delta 5$ -elongase comprises an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 97, 99% or 100% identity to SEQ ID NO:8.

[0129] Although the particular source of a polyunsaturated fatty acid desaturase or elongase is not critical in the invention herein, it will be obvious to one of skill in the art that heterologous genes will be expressed with variable efficiencies in an alternate host. Furthermore, it may be desirable to modify the expression of particular polyunsaturated fatty acid biosynthetic pathway enzymes to achieve optimal conversion efficiency of each, according to the specific polyunsaturated fatty acid product composition of interest. A variety of genetic engineering techniques are available to optimize expression of a particular enzyme. Two such techniques include codon optimization and gene mutation, as described below. Genes produced by e.g., either of these two methods, having desaturase and/or elongase activity(s) would be useful in the invention herein for synthesis of omega-3 polyunsaturated fatty acids.

Sequence Homology or Sequence Identity

[0130] "Sequence Homology or Sequence identity" is used herein interchangeably. The terms "identical" or percent "identity" in the context of two or more nucleic acid or protein sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using

one of the following sequence comparison algorithms or by visual inspection. If two sequences which are to be compared with each other differ in length, sequence identity preferably relates to the percentage of the nucleotide residues of the shorter sequence which are identical with the nucleotide residues of the longer sequence. Sequence identity can be determined conventionally with the use of computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive Madison, Wis. 53711). Bestfit utilizes the local homology algorithm of Smith and Waterman, *Advances in Applied Mathematics* 2 (1981), 482-489, in order to find the segment having the highest sequence identity between two sequences. When using Bestfit or another sequence alignment program to determine whether a particular sequence has for instance 95% identity with a reference sequence of the present invention, the parameters are preferably so adjusted that the percentage of identity is calculated over the entire length of the reference sequence and that homology gaps of up to 5% of the total number of the nucleotides in the reference sequence are permitted. When using Bestfit, the so-called optional parameters are preferably left at their preset ("default") values. The deviations appearing in the comparison between a given sequence and the above-described sequences of the invention may be caused for instance by addition, deletion, substitution, insertion or recombination. Such a sequence comparison can preferably also be carried out with the program "fasta20u66" (version 2.0u66, September 1998 by William R. Pearson and the University of Virginia; see also W. R. Pearson (1990), *Methods in Enzymology* 183, 63-98, appended examples and <http://workbench.sdsc.edu/>). For this purpose, the "default" parameter settings may be used.

[0131] Preferably, reference to a sequence which has a percent identity to any one of the SEQ ID NOs as detailed herein refers to a sequence which has the stated percent identity over the entire length of the SEQ ID NO referred to.

[0132] Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions.

Hybridization

[0133] Hybridization is the binding of complementary strands of DNA, DNA/RNA, or RNA.

[0134] Polynucleotides that hybridize to the polynucleotide sequences provided herein may also be used in the invention. Particularly preferred are polynucleotides that hybridize under stringent conditions to the polynucleotides described herein. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean hybridization occurring only if there is at least 90%, 95% and preferably at least 97% identity between the sequences. A specific example of stringent hybridization conditions is overnight incubation at 42° C. in a solution comprising: 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1×SSC at about 65° C.

[0135] The polynucleotides of the invention, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate other genes that have a high identity, particularly high sequence identity.

Codon-Optimization

[0136] Codon degeneracy refers to the nature in the genetic code permitting variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. As will be appreciated by one skilled in the art, it is frequently useful to modify a portion of the codons encoding a particular polypeptide that is to be expressed in a foreign host, such that the modified polypeptide uses codons that are preferred by the alternate host. Use of host-preferred codons can substantially enhance the expression of the foreign gene encoding the polypeptide.

[0137] In general, host-preferred codons can be determined within a particular host species of interest by examining codon usage in proteins (preferably those expressed in the largest amount) and determining which codons are used with highest frequency. Then, the coding sequence for a polypeptide of interest having desaturase or elongase activity can be synthesized in whole or in part using the codons preferred in the host species. All (or portions) of the DNA also can be synthesized to remove any destabilizing sequences or regions of secondary structure that would be present in the transcribed mRNA. All (or portions) of the DNA also can be synthesized to alter the base composition to one more preferable in the desired host cell.

[0138] In the present invention, it may be desirable to modify a portion of the codons encoding the polypeptide having the relevant activity e.g., desaturase or elongase activity, to enhance the expression of the gene in *camelina*.

Gene Mutation

[0139] Methods for synthesizing sequences and bringing sequences together are well established in the literature. For example, in vitro mutagenesis and selection, site-directed mutagenesis, error prone PCR (Melnikov et al., *Nucleic Acids Research*, 27(4):1056-1062 (Feb. 15, 1999)), “gene shuffling” or other means can be employed to obtain mutations of naturally occurring desaturase or elongase genes. This would permit production of a polypeptide having desaturase or elongase activity, respectively, in vivo with more desirable physical and kinetic parameters for function in the host cell such as a longer half-life or a higher rate of production of a desired PUFA.

[0140] If desired, the regions of a polypeptide of interest (i.e., a desaturase or an elongase) important for enzymatic activity can be determined through routine mutagenesis, expression of the resulting mutant polypeptides and determination of their activities. Mutants may include deletions, insertions and point mutations, or combinations thereof. A typical functional analysis begins with deletion mutagenesis to determine the N- and C-terminal limits of the protein necessary for function, and then internal deletions, insertions or point mutants are made to further determine regions necessary for function. Other techniques such as cassette mutagenesis or total synthesis also can be used. Deletion mutagenesis is accomplished, for example, by using exonucleases to sequentially remove the 5' or 3' coding regions. Kits are available for such techniques. After deletion, the coding region is completed by ligating oligonucleotides containing start or stop codons to the deleted coding region after the 5' or 3' deletion, respectively. Alternatively, oligonucleotides encoding start or stop codons are inserted into the coding

region by a variety of methods including site-directed mutagenesis, mutagenic PCR or by ligation onto DNA digested at existing restriction sites. Internal deletions can similarly be made through a variety of methods including the use of existing restriction sites in the DNA, by use of mutagenic primers via site-directed mutagenesis or mutagenic PCR. Insertions are made through methods such as linker-scanning mutagenesis, site-directed mutagenesis or mutagenic PCR, while point mutations are made through techniques such as site-directed mutagenesis or mutagenic PCR.

Transformation

[0141] The term “transgenic” or “recombinant” is preferably understood as meaning the expression of the nucleic acids encoding the enzymes involved in omega-3 fatty acid synthesis referred to herein at an unnatural locus in the genome, i.e. preferably, heterologous expression of the nucleic acids takes place. Thus, the genes introduced in to the *camelina* according to the present invention are preferably derived from a different organism.

[0142] The polynucleotides encoding the enzymes (e.g., desaturase and elongase enzymes) may be introduced into expression cassettes and/or vectors. In principal, the expression cassettes can be used directly for introduction into the *camelina*. However, preferably the nucleic acids are cloned into expression cassettes, which are then used for transforming *camelina* with the aid of vectors such as *Agrobacterium*.

[0143] After their introduction into the *camelina* plant cell or plant, the polynucleotides used in the present invention can either be present on a separate plasmid or, advantageously, integrated into the genome of the host cell.

[0144] As used in the present context, the term “vector” refers to a nucleic acid molecule which is capable of transporting another nucleic acid to which it is bound. One type of vector is a “plasmid”, a circular double-stranded DNA loop into which additional DNA segments can be ligated. A further type of vector is a viral vector, it being possible for additional DNA segments to be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they have been introduced. Other vectors are advantageously integrated into the genome of a host cell when they are introduced into the host cell, and thus replicate together with the host genome. Moreover, certain vectors can govern the expression of genes with which they are in operable linkage. These vectors are referred to in the present context as “expression vectors”. Usually, expression vectors which are suitable for DNA recombination techniques take the form of plasmids.

[0145] The recombinant expression vectors used in the present invention are suitable for expressing nucleic acids in a *camelina* host cell. The recombinant expression vectors/polynucleotides preferably comprise one or more regulatory sequences, which regulatory sequence(s) is/are operably linked with the nucleic acid sequence to be expressed.

[0146] The term “operably linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

[0147] The term “regulatory sequence” is intended to comprise promoters, enhancers and other expression control elements such as polyadenylation signals. These regulatory sequences are described, for example, in Goeddel: Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990), or see: Gruber and Crosby, in: Methods in Plant Molecular Biology and Biotechnology, CRC Press, Boca Raton, Fla., Ed.: Glick and Thompson, Chapter 7, 89-108, including the references cited therein.

[0148] Examples of plant expression vectors comprise those which are described in detail in: Becker, D., Kemper, E., Schell, J., and Masterson, R. (1992) “New plant binary vectors with selectable markers located proximal to the left border”, Plant Mol. Biol. 20:1195-1197; Bevan, M. W. (1984) “Binary *Agrobacterium tumefaciens* T-DNA, such as gene 3 of the Ti plasmid pTiACH5 (Gielen et al., EMBO J. 3 (1984) 835 et seq.), which is known as octopine synthase, or functional equivalents thereof, but other terminator sequences which are functionally active in plants are also suitable.

[0149] The polynucleotide/vector preferably comprises regulatory sequences which are capable of governing the expression of genes in plant cells and which are linked operably so that each sequence can fulfill its function, such as transcriptional termination, for example polyadenylation signals. Examples of polyadenylation signals are those which are derived from *Agrobacterium tumefaciens* T-DNA, such as gene 3 of the Ti plasmid pTiACH5 (Gielen et al., EMBO J. 3 (1984) 835 et seq.), which is known as octopine synthase, or functional equivalents thereof, but other terminator sequences which are functionally active in plants are also suitable.

[0150] Since plant gene expression is very often not limited to the transcriptional level, a plant expression cassette or vector preferably comprises other sequences which are linked operably, such as translation enhancers.

[0151] Plant gene expression is preferably linked operably with a suitable promoter which triggers gene expression with the correct timing or in a cell- or tissue-specific manner. Examples of promoters are constitutive promoters (Benfey et al., EMBO J. 8 (1989) 2195-2202), such as those which are derived from plant viruses, such as 35S CaMV (Franck et al., Cell 21 (1980) 285-294), 19S CaMV (see also U.S. Pat. No. 5,352,605 and WO 84/02913), or plant promoters, such as the promoter of the Rubisco subunit, which is described in U.S. Pat. No. 4,962,028. Other sequences for use in operable linkage in plant gene expression cassettes are targeting sequences, which are required for steering the gene product into its corresponding cell compartment (see a review in Kermode, Crit. Rev. Plant Sci. 15, 4 (1996) 285-423 and references cited therein), for example into the vacuole, into the nucleus, all types of plastids, such as amyloplasts, chloroplasts, chromoplasts, the extracellular space, the mitochondria, the endoplasmic reticulum, elaioplasts, peroxisomes and other compartments of plant cells.

[0152] Plant gene expression can also be achieved via a chemically inducible promoter (see review in Gatz 1997, Annu. Rev. Plant Physiol. Plant Mol. Biol., 48:89-108). Chemically inducible promoters are particularly suitable when it is desired that the gene expression takes place in a time-specific manner. Examples of such promoters are a salicylic acid-inducible promoter (WO 95/19443), a tetracyclin-inducible promoter (Gatz et al. (1992) Plant J. 2, 397-404) and an ethanol-inducible promoter.

[0153] Promoters which respond to biotic or abiotic stress conditions are also suitable, for example the pathogen-induced PRP1 gene promoter (Ward et al., Plant. Mol. Biol. 22 (1993) 361-366), the heat-inducible tomato hsp80 promoter (U.S. Pat. No. 5,187,267), the chill-inducible potato alpha-amylase promoter (WO 96/12814), the wound-inducible pinII promoter (EP-A-O 375 091) and the cis-jasmone-responsive promoter (Matthes M C, Bruce T J, Ton J, Verrier P J, Pickett J A, Napier J A. The transcriptome of cis-jasmone-induced resistance in *Arabidopsis thaliana* and its role in indirect defence. Planta. 2010 October; 232(5):1163-80).

[0154] Especially preferred are those promoters which bring about the gene expression in tissues and organs in which the biosynthesis of fatty acids, lipids and oils takes place, in seed cells, such as cells of the endosperm and of the developing embryo. Examples of such promoters are the oilseed rape napin promoter (U.S. Pat. No. 5,608,152), the Vicia faba USP promoter (Baeumlein et al., Mol Gen Genet, 1991, 225 (3):459-67), the *Arabidopsis oleosin* promoter (WO 98/45461), the *Phaseolus vulgaris* phaseolin promoter (U.S. Pat. No. 5,504,200), the *Brassica Bce4* promoter (WO 91/13980) or the legumine B4 promoter (LeB4; Baeumlein et al., 1992, Plant Journal, 2 (2):233-9). It is also envisaged that a mesocarp-specific promoter could direct the synthesis of the omega-3 trait in oil palm and similar crops.

[0155] Other promoters are those which bring about a plastid-specific expression, since plastids constitute the compartment in which the precursors and some end products of lipid biosynthesis are synthesized. Examples of promoters, such as the viral RNA polymerase promoter, are described in WO 95/16783 and WO 97/06250, and the clpP promoter from *Arabidopsis*, described in WO 99/46394.

[0156] To ensure the stable integration of the biosynthesis genes into the transgenic plant over a plurality of generations, it is usually necessary for each of the nucleic acids which encodes a protein of interest to be expressed under the control of a separate promoter, preferably a promoter which differs from the other promoters, since repeating sequence motifs can lead to instability of the T-DNA, or to recombination events. However, it is also possible to insert a plurality of nucleic acid sequences behind a promoter and, if appropriate, before a terminator sequence. Here, the insertion site, or the sequence, of the inserted nucleic acids in the expression cassette is not of critical importance, that is to say a nucleic acid sequence can be inserted at the first or last position in the cassette without its expression being substantially influenced thereby.

[0157] Preferably, each gene introduced into the *camelina* plant or cell is under the control of a specific promoter.

[0158] Vector DNA can be introduced into cells via conventional transformation or transfection techniques. The terms “transformation” and “transfection”, conjugation and transduction, as used in the present context, are intended to comprise a multiplicity of methods known in the prior art for the introduction of foreign nucleic acid (for example DNA) into a host cell, including calcium phosphate or calcium chloride coprecipitation, DEAE-dextran-mediated transfection, lipofection, natural competence, chemically mediated transfer, electroporation or particle bombardment. Suitable methods for the transformation or transfection of host cells, including plant cells, can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual., 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) and other laboratory textbooks

such as Methods in Molecular Biology, 1995, Vol. 44, *Agrobacterium* protocols, Ed.: Gartland and Davey, Humana Press, Totowa, New Jersey.

[0159] Transformation systems for *camelina* are known in the art. For example, US 2009/0151023 describe a method which involves:

- [0160] (a) Providing sterilized *Camelina sativa* seeds collected from a plants grown in controlled conditions;
- [0161] (b) Germinating the seeds on agar in sterilized conditions and growing in vitro seedlings;
- [0162] (c) Obtaining explants from the in vitro grown seedlings;
- [0163] (d) Inoculating the explants with *Agrobacterium tumefaciens* strain containing at least one recombinant DNA construct;
- [0164] (e) Cocultivating the explant with the *Agrobacterium* strain;
- [0165] (f) Transferring the explants to a callus forming medium, said medium being supplemented with hormones and containing 2% sucrose;
- [0166] (g) Transferring the explants to a shoot regeneration medium, said medium being supplemented with hormones and containing 2-6% sucrose;
- [0167] (h) Transferring the shoots to a root elongation medium, said medium being supplemented with hormones and containing 1-4%; and
- [0168] (i) Transferring the regenerated shoots into soil and growing them to transgenic *Camelina sativa* plants.

[0169] The methods for transforming *camelina* disclosed in US 2009/0151028 and US 2009/0151023 are incorporated herein by reference.

[0170] Transgenic plants which comprise the polyunsaturated fatty acids synthesized in the process according to the invention can advantageously be marketed directly without there being any need for the oils, lipids or fatty acids synthesized to be isolated.

[0171] Plants for the process according to the invention are listed as meaning intact plants and all plant parts, plant organs or plant parts such as leaf, stem, seeds, root, tubers, anthers, fibers, root hairs, stalks, embryos, calli, cotyledons, petioles, harvested material, plant tissue, reproductive tissue and cell cultures which are derived from the actual transgenic plant and/or can be used for bringing about the transgenic plant. In this context, the seed comprises all parts of the seed such as the seed coats, epidermal cells, seed cells, endosperm or embryonic tissue.

[0172] The compounds produced in the process according to the invention can also be isolated from the organisms, advantageously plants, in the form of their oils, fats, lipids and/or free fatty acids. This can be done via pressing or extraction of the *camelina* plant parts, preferably the plant seeds. In this context, the oils, fats, lipids and/or free fatty acids can be obtained by what is known as cold-beating or cold-pressing without applying heat. To allow for greater ease of disruption of the plant parts, specifically the seeds, they are previously comminuted, steamed or roasted. The seeds which have been pretreated in this manner can subsequently be pressed or extracted with solvents such as warm hexane. Thereafter, the resulting products are processed further, i.e. refined. In this process, substances such as the plant mucilages and suspended matter are first removed. What is known as desliming can be effected enzymatically or, for example, chemico-physically by addition of acid such as phosphoric acid. Thereafter, the free fatty acids are removed by treatment

with a base, for example sodium hydroxide solution. The resulting product is washed thoroughly with water to remove the alkali remaining in the product and then dried. To remove the pigment remaining in the product, the products are subjected to bleaching, for example using filler's earth or active charcoal. At the end, the product is deodorized, for example using steam.

Growing

[0173] In the case of plant (including plant tissue or plant organs) or plant cells, "growing" is understood as meaning, for example, the cultivation on or in a nutrient medium, or of the intact plant on or in a substrate, for example in a hydroponic culture, potting compost or on arable land.

[0174] Further preferred features and embodiments of the present invention will now be described by way of non-limiting example and with reference to the accompanying drawings in which:

[0175] FIG. 1 is a schematic showing the biosynthesis pathway for long chain polyunsaturated fatty acids.

[0176] FIG. 2 shows a schematic of the vector constructs used for *Camelina* transformation.

[0177] FIG. 3 shows neutral loss survey of total seed triglycerols (TAG) from wild type and *Camelina* lines transformed with the five gene construct BC.

[0178] FIG. 4 shows the ESI-MS analysis of wild type and *Camelina* lines transformed with the five gene construct BC.

[0179] FIG. 5 shows acyl composition as determined by precursor ion scanning of phosphatidyl choline for the wild type and *Camelina* lines transformed with the five gene construct BC

[0180] FIG. 6 shows the distribution of acyl chains within phosphatidylcholine of wild type and *Camelina* lines transformed with the five gene construct BC.

[0181] FIG. 7 shows the distribution of acyl chains within phosphatidylethanolamine of wild type and *Camelina* lines transformed with the five gene construct BC.

[0182] FIG. 8 shows the distribution of acyl chains within phosphatidic acid and phosphoinositol of wild type and *Camelina* lines transformed with the five gene construct BC.

[0183] FIG. 9 shows the distribution of acyl chains within phosphatidylserine acid and phosphatidylglycerol of wild type and *Camelina* lines transformed with the five gene construct BC.

[0184] FIGS. 10 and 11 show the acyl-CoA pool of *Arabidopsis* and transgenic *Camelina* seeds harvested at mid-stage of seed development.

EXAMPLE 1

Materials and Methods

Fatty-Acid Analysis

[0185] Fatty acids were extracted and methylated as described Sayanova et al., (1997) Proc Natl Acad Sci USA. 1997 Apr. 15; 94(8):4211-6 and Sayanova et al., (2003) FEBS Lett. 2003 May 8; 542(1-3):100-4. Methyl ester derivatives of total fatty acids extracted were analysed by GC and GC-MS. Data presented as representative numbers derived from replicated analysis.

Acyl-CoA Profiling

[0186] Twenty-milligrams of developing (15 days after flowering) seed material were collected, frozen in liquid nitrogen and extracted after Larson and Graham 2001 (Larson T R, Graham I A. (2001), *Plant J.* 2001 January; 25(1): 115-25), for reverse-phase LC with either quantitative analysis of fluorescent acyl-etheno-CoA derivatives or with electrospray ionization tandem mass spectrometry (multi reaction monitoring) in positive ion mode. For the analysis of etheno-CoA derivatives HPLC (Agilent 1200 LC system; Phenomenex LUNA 150-2 mm C18(2) column) was performed using the methodology and gradient conditions described previously (Larson and Graham 2001); whilst LC-MS/MS+MRM analysis followed the methods described by Haynes et al. 2008 (Agilent 1200 LC system; Gemini C18 column, 2 mm inner diameter, 150 mm with 5 mm particles). For the purpose of identification and calibration, standard acyl-CoA esters with acyl chain lengths from C14 to C20 were purchased from Sigma as free acids or lithium salts.

Lipid Profiling

[0187] The molecular species of TAGs and PLs were analysed by electrospray ionisation triple quadrupole mass spectrometry (API 4000 QTRAP; Applied Biosystems). The molecular species of polar lipid were defined by the presence of a head-group fragment and the mass/charge of the intact lipid ion formed by ESI (Welti et al., 2002, *J Biol Chem.* 2002 Aug. 30; 277(35):31994-2002. Devaiah et al., 2006, *Phytochemistry.* 2006 September; 67(17):1907-24. with modifications described by Xiao et al. 2010; *Plant Cell.* 2010 May; 22(5):1463-82.). Such tandem ESI-MS/MS precursor and product ion scanning, based on head group fragment, do not determine the individual fatty acyl species. Instead, polar lipids are identified at the level of class, total acyl carbons, and total number of acyl carbon-carbon double bonds. Polar lipids were quantified in comparison with a series of polar lipid internal standards. Triacylglycerols (TAGs) measured after Krank et al. (2007, *Methods Enzymol.* 2007; 432:1-20) were defined by the presence of one acyl fragment and the mass/charge of the ion formed from the intact lipid (neutral loss profiling). This allows identification of one TAG acyl species and the total acyl carbons and total number of acyl double bonds in the other two chains. The procedure does not allow identification of the other two fatty acids individually nor the positions (sn-1, sn-2, or sn-3) that individual acyl chains occupy on the glycerol. TAGs were quantified in a manner similar to the polar lipids, including background subtraction, smoothing, integration, isotope deconvolution and comparison of sample peaks with those of the internal standard (using LipidView, Applied Biosystems). However, whereas polar lipids within a class exhibit similar mass spectral response factors, the mass spectral responses of various TAG species are variable, owing to differential ionization of individual molecular TAG species. In the data shown herein, no response corrections were applied to the data. The data were normalized to the internal standards tri15:0 and tri19:0.

EXAMPLE 2

Production of EPA in Transgenic *Camelina*

[0188] We were interested in engineering the accumulation of bona fide omega-3 LC-PUFAs normally associated with fish oils such as eicosapentaenoic acid (EPA; 20:5^{Δ5,8,11,14,17})

and docosahexaenoic acid (DHA; 22:6^{66 4,7,10,13,16,19}). To that end, a modular reconstruction of their biosynthetic pathway (FIG. 1) was undertaken in transgenic *Camelina*. The heterologous biosynthetic activities were all placed under the regulatory control of common seed-specific promoters. In addition, given the variation in codon-usage observed between angiosperms and marine algae, a number of genes were resynthesised with codon-optimisation for expression in Cruciferae.

Constructs Design

[0189] Four constructs containing from 3- to 7-gene cassettes were built using the Gateway® recombination system (Invitrogen). Respective genes were inserted as NcoI/PacI fragments into the promoter/terminator cassettes and then moved into pENTRY vectors (FIG. 2). As shown, the simplest (MC) construct contained a three expression cassettes, comprising 1) a seed specific promoter (the sucrose binding protein SBP1800 promoter), OtΔ6, *Ostreococcus tauri* Δ6-desaturase gene (Domergue et al. *Biochem. J.* 389 (PT 2), 483-490 (2005); AY746357) and CatpA, terminator; 2) a seed specific promoter (USP1 promoter (Bäumlein et al. 1991 *Mol Gen Genet.* 1991 March; 225(3):459-67), PSE1, a Δ6 fatty acid elongase from *Physcomitrella patens* (Zank, et al., *Plant J.* 31 (3), 255-268 (2002); AB238914) and CaMV35S terminator; 3) a seed specific promoter (Cnl, a conlinin1 promoter (Truksa 2003; *Plant Physiol Biochem* 41:141-147), TcΔ5, a Δ5-desaturase from *Thraustochytrium* sp. (Qiu et al. *J Biol Chem.* 2001 Aug. 24; 276(34):31561-6) and OCS, a terminator region of OCS, octopin synthase gene of *A. tumefaciens*.

[0190] The BC construct contained five-gene cassettes including the same 3 gene cassettes as in the MC described above plus two additional gene cassettes consisting of PsΔ12, a Δ12-desaturase gene from *Phytophthora sojae* (see above) and Piω3, a ω3 desaturase gene from *Phytophthora infestans* (Wu et al., 2005 *Nat Biotechnol.* 2005 August; 23(8):1013-7) flanked by Np, a BnNapin promoter and E9 terminator regions.

[0191] To build DHA-1 construct we combined BC construct with additional two-gene cassettes, containing OtElo5, an *Ostreococcus tauri* Δ5 fatty acid elongase (Meyer et al., *J Lipid Res.* 2004 October; 45(10):1899-909) and EhΔ4, a Δ4-desaturase from *Emiliania huxleyi* (Sayanova et al. 2011 *Phytochemistry.* 2011 May; 72(7):594-600) flanked by napin promoters and OCS terminators.

Synthesis of EPA in Transgenic *Camelina*

[0192] In a first iteration, the simplest 3-gene construct (MC) was introduced into transgenic *Camelina* using standard floral infiltration technique to infect inflorescences with *Agrobacterium tumefaciens* strains carrying binary transformation vectors. Table 2 exemplifies the accumulation of non-native omega-3 long chain polyunsaturated fatty acids such as eicosapentaenoic acid (EPA). Total fatty acid composition of seeds from wild-type and transgenic plants of *C.sativa* lines expressing MC construct are shown below, confirming the presence of EPA in transgenics in the range 12.9-17.3% of total seed fatty acids. Note the complete absence of this fatty acid from the wildtype non-transgenic control.

TABLE 2

	16:0	18:0	18:1	LA	GLA	ALA	SDA	20:1	DHGLA	ARA	ETA	EPA	Others
Wt	7.0	3.1	15.1	21.2	0.0	29.6	0.0	14.1	0.0	0.0	0.0	0.0	9.9
Line2	9.3	5.0	4.7	24.7	1.8	12.2	1.8	7.8	0.6	2.4	2.0	16.8	10.9
Line3	9.3	4.9	6.4	25.6	2.1	13.4	2.0	8.3	0.7	2.0	1.8	12.9	10.6
Line 4	9.2	5.6	4.1	21.3	1.4	13.5	1.3	6.2	1.5	2.2	5.1	17.3	11.3

[0193] In a second iteration of engineering *Camelina* with the capacity to accumulate high levels of EPA, we transformed *C. Sativa* with the 5-gene construct BC, again by floral infiltration. As shown in Table 3 below, the total fatty acid composition of T2 seeds from transgenic plants of *C. sativa* expressing BC construct contains very high levels of EPA (in the range 20.0-30.7%). Moreover, as shown in Table 4 below, it was also possible to obtain EPA at a level of 30.7% EPA. This fatty acid is totally absent from WT controls.

TABLE 3

	16:0	18:0	18:1	18:2	GLA	ALA	SDA	20:1	DHGLA	ARA	20:3n3	ETA	EPA	Others	Sum	EPA (MOL %)	
																Average	SD
162a	9.8	7.6	4.6	18.3	2.4	10.8	1.5	6.5	0.5	2.0	1.6	2.4	25.0	7.0	100.0		
162b	8.6	7.1	5.0	18.7	3.6	11.4	2.3	7.4	0.5	1.8	1.4	2.2	22.8	7.1	100.0		
162c	11.3	7.0	4.9	20.4	4.0	9.4	2.1	5.3	0.6	1.9	1.3	2.0	24.0	5.8	100.0	23.9	1.1
26a	9.9	6.2	4.0	19.1	1.9	10.3	1.1	6.4	0.8	2.1	1.6	3.5	26.0	7.0	100.0		
26b	8.9	5.6	4.5	18.6	1.2	14.9	0.8	7.7	1.4	2.0	1.5	4.7	21.6	6.6	100.0		
26c	9.2	5.8	4.8	18.6	1.6	14.9	1.1	7.3	1.2	1.9	1.5	4.2	21.6	6.3	100.0	23.1	2.6
169a	10.3	5.4	4.8	19.8	1.0	15.0	0.7	6.4	1.3	1.8	1.6	4.6	21.3	6.0	100.0		
169b	11.3	6.7	4.0	18.0	1.2	14.4	0.8	5.8	1.1	1.6	1.6	4.5	22.4	6.5	100.0		
169c	11.3	6.5	4.7	19.9	2.2	13.5	1.3	6.5	1.3	1.9	1.4	4.1	18.9	6.5	100.0	20.9	1.8
158a	8.5	8.0	5.3	20.2	3.5	10.7	2.0	7.2	0.6	1.9	1.3	2.5	21.3	7.0	100.0		
158b	10.4	9.0	5.0	19.5	5.9	8.1	3.1	6.4	0.6	1.8	1.2	1.8	19.0	8.2	100.0		
158c	8.9	8.5	5.2	19.8	3.6	9.8	1.9	6.6	0.5	2.1	1.3	2.3	21.6	7.8	100.0	20.6	1.4
216a	7.6	8.1	5.3	21.5	2.1	11.2	1.1	8.1	0.6	1.9	1.5	2.5	19.8	8.5	100.0		
216b	7.8	7.7	5.3	21.2	2.4	10.9	1.2	7.9	0.6	2.0	1.6	2.4	20.7	8.5	100.0		
216c	7.4	7.8	5.2	21.3	1.8	11.2	1.0	8.1	0.6	2.0	1.6	2.6	20.8	8.7	100.0	20.4	0.5
29a	9.2	6.3	4.9	21.2	1.5	13.3	0.7	7.0	0.9	2.1	1.7	3.3	21.2	6.6	100.0		
29b	8.8	6.8	5.7	20.8	1.7	15.5	1.0	7.7	1.1	2.0	1.3	3.5	17.9	6.3	100.0		
29c	8.6	6.2	5.1	20.1	1.5	14.5	0.8	8.0	0.8	2.0	1.5	3.2	21.1	6.5	100.0	20.1	1.9
105a	8.6	8.9	5.3	20.3	2.3	10.1	1.2	7.4	0.5	2.1	1.6	2.0	21.0	8.5	100.0		
105b	8.9	9.8	5.4	20.3	3.2	9.8	1.7	7.2	0.5	1.9	1.4	1.8	19.2	8.9	100.0		
105c	9.2	10.1	5.5	20.8	2.2	8.8	1.0	7.0	0.6	2.3	1.5	1.9	19.8	9.3	100.0	20.0	1.0

TABLE 4

		MOL %		16:0	18:0	18:1	18:2	GLA	ALA	SDA	20:1
T3 seeds	LineBBC_3_26	1 seed/vial	26_10	10.4	6.3	4.0	14.2	2.1	8.2	1.6	6.5
T3 seeds	LineBBC_3_162	1 seed/vial	162_13	11.3	7.3	4.1	19.4	2.6	7.6	1.2	6.2
T3 seeds	LineBBC_3_26	1 seed/vial	26_15	9.9	7.7	4.2	17.1	3.0	9.3	1.4	6.8
T3 seeds	LineBBC_3_26	1 seed/vial	26_19	9.3	6.1	4.2	15.8	1.3	13.8	1.0	7.7
T3 seeds	LineBBC_3_169	1 seed/vial	169_16	10.3	7.2	4.2	20.7	1.9	7.8	0.9	6.0
T3 seeds	LineBBC_3_162	1 seed/vial	162_20	8.9	7.0	5.0	16.6	2.1	12.2	1.3	8.1
		DHGLA	ARA	20:3n3	ETA	EPA	Others	Sum			
T3 seeds	LineBBC_3_26	0.3	1.4	2.1	2.9	30.7	9.2	100.0	NVR1	36	
T3 seeds	LineBBC_3_162	0.3	1.6	1.5	2.1	26.1	8.6	100.0	NVR1	16	
T3 seeds	LineBBC_3_26	0.3	1.6	1.6	2.8	25.8	8.4	100.0	NVR2	6	
T3 seeds	LineBBC_3_26	0.5	1.4	1.9	3.9	24.9	8.0	100.0	NVR2	11	
T3 seeds	LineBBC_3_169	0.5	1.7	1.8	2.9	24.9	9.3	100.0	NVR2	32	
T3 seeds	LineBBC_3_162	0.4	1.7	1.6	2.7	24.6	7.9	100.0	NVR1	24	

Targeted Lipidomic Analysis of Transgenic *Camelina* Accumulating EPA

[0194] To provide further and more detailed characterization of the *Camelina* plants accumulating high levels of EPA

in the seed oil, detailed analysis was carried out using tandem mass spectrometry as detailed below. As shown in FIG. 3, neutral loss surveys of the total seed triacylglycerols (TAG) from either WT or two high EPA lines (162, 26—cf Table 3)

confirmed the presence of EPA in TAGs from lines 162 and 26 and confirmed the complete absence of this fatty acid in WT seed oil. To further define the composition of the TAGs present in the high EPA lines, ESI-MS was used identify their molecular composition, compared with WT. As shown in FIG. 4, several novel TAG species are clearly present in lines 162 and 26 which are not present in WT, notably 58:8, 58:9 and 58:10. Given that the predominant TAG species in WT are 54:5-8, this upward shift represents the accumulation of longer chain fatty acids containing additional double bonds—i.e. EPA is accumulating at 1 (or possibly 2) positions on the glycerol backbone of TAG.

[0195] As a corollary to the analysis of neutral lipids in these *Camelina* lines, we also analysed the acyl composition of phospholipids. Using precursor ion scanning, the acyl composition of phosphatidylcholine (PC, the major phospholipid present in plant seeds) was determined for WT and lines 162 and 26 (FIG. 5). Again major differences were identified between the WT and the high EPA transgenics, including the identification of a series of C38 and C40 lipids were essentially absent from WT.

[0196] This alteration to the composition of phospholipids resulting from the transgenic synthesis and accumulation of EPA was further investigated by more detailed profiling of individual phospholipid classes (FIGS. 6-9). As seen in FIG. 6, this analysis confirmed the presence of a suite of novel PC species, arising from the incorporation of EPA into this phospholipid. It is also clear that a number of endogenous PC species are reduced as a consequence of this accumulation, most notably the reduction in C36 PC species containing 1-4 double bonds. A very similar profile was observed for phosphatidylethanolamine (PE) (FIG. 8), which also showed the accumulation of novel C38 and C40 polyunsaturated species, with a concomitant reduction in the levels of C36 PE species. We profiled the other, more minor, phospholipid species (phosphatidic acid [PA], phosphoinositol [PI], phosphatidylserine [PS] and phosphatidylglycerol [PG]) and observed some more pronounced perturbations. For example, overall levels of all PA species were increased in the transgenic lines, albeit from a very low baseline (FIG. 8). Conversely many C34 and C36 PI species were decreased in the high EPA transgenics, though these lines did also contain some novel

C38 PUFA-containing species (FIG. 8). Interestingly, PS, which normally accumulates di+monounsaturated C20+fatty acids was reduced in the transgenic lines, as were C34/36 PG species (FIG. 9). No novel C38/40 PS species could be detected in our transgenic lines, whereas novel C38 PG PUFA-containing species were observed (FIG. 9).

[0197] Acyl-CoA profiling was also used to define the composition of this key metabolic hub. As can be seen in FIGS. 10 & 11, the acyl-CoA pool of transgenic *Camelina* seeds harvested at mid-stage of seed development revealed the presence of significant levels of EPA-CoA.

EXAMPLE 3

Production of DHA in Transgenic *Camelina*

[0198] Having successfully engineered the significant accumulation of EPA in transgenic *Camelina* seeds, we next attempted to direct the synthesis of DHA. Since DHA is a metabolite of EPA (FIG. 1), having sufficient levels of EPA are a prerequisite for such manipulations. Using the construct detailed in FIG. 2, we generated transgenic *Camelina* plants engineered to accumulate both EPA and DHA.

[0199] Since genotyping of the T2 generation indicated that this material was not homozygous for the transgene, we decided to carry out half-seed analysis, in which a portion of the seed is subject to destructive FAMES analysis, but the residual portion containing the embryo is retained and can be used to regenerate a plant. As shown below in Table 5, the single (half) seed analysis indeed confirmed the presence of transgene nulls (samples 9-11) as would be expected from a non-homozygous population. However, FAMES analysis of total seed lipids did indeed confirm the presence of EPA and DHA, the later up to levels greater than 13% of total fatty acids. The best line showing combined levels of EPA and DHA (C20+omega-3 LC-PUFAs) was at 26.3% of total seed fatty acids. Importantly, this line contained only very low levels of the omega-6 fatty acids ARA, GLA and DHGLA and the omega-3 biosynthetic intermediates SDA, ETA and DPA. Thus this novel *Camelina* oil represents a new and valuable terrestrial source of C20+omega-3 LC-PUFAs normally found in aquatic environments.

TABLE 5

Total fatty acid composition of T2 seeds from transgenic plants of <i>C. sativa</i> best lines expressing DHA-1 construct. (Half seed analysis)													
Half seed analysis on T2 seeds													
MOL %	16:0	18:0	18:1	18:2	GLA	ALA	SDA	20:0	20:1	20:2	DHGLA	ARA	
BBC_OE3	1	15.0	7.5	7.2	23.4	1.6	6.4	0.9	3.5	6.7	1.4	1.3	1.5
	2	12.1	8.0	6.4	20.7	3.2	11.2	2.4	3.6	6.0	1.1	1.0	1.5
	3	15.7	7.5	5.4	18.5	2.5	10.4	2.0	4.0	6.7	1.3	1.0	1.3
	4	14.8	4.9	7.5	18.8	1.6	13.2	1.4	1.8	7.4	1.5	1.0	1.2
	5	11.1	4.8	6.5	23.3	1.9	14.6	1.3	2.5	8.5	1.5	1.5	1.4
	6	11.5	4.4	8.6	23.1	2.3	13.4	1.7	2.1	8.5	1.4	1.7	1.5
	7	11.3	5.0	6.8	23.4	2.1	13.7	1.5	2.5	8.2	1.3	1.3	1.5
	8	13.3	4.8	5.7	19.4	2.1	12.3	1.9	1.9	7.6	1.5	0.9	1.5
	9	9.8	3.8	9.3	23.5	0.2	27.6	0.2	2.7	11.6	1.4	0.1	0.0
	10	12.6	4.9	9.7	28.0	0.0	21.4	0.0	2.9	9.2	2.3	0.0	0.0
	11	11.9	3.9	8.6	23.4	0.0	26.9	0.0	2.8	10.6	2.4	0.0	0.0
	12	15.1	4.8	6.7	21.6	1.7	13.4	1.3	2.0	7.7	1.3	1.3	1.4
	13	13.1	5.4	6.9	24.8	2.1	11.0	1.2	2.7	8.1	1.2	1.4	1.4
	14	12.0	4.9	5.5	17.2	3.2	13.8	3.2	2.2	7.4	1.0	0.7	1.4
	15	10.7	8.0	6.1	21.5	1.9	15.3	1.9	4.0	7.6	1.1	0.8	1.2
	16	12.1	5.7	6.4	18.1	2.3	15.3	2.2	2.7	6.9	1.0	0.7	1.5
	17	10.8	5.4	7.5	22.5	1.7	16.4	1.4	3.2	7.8	1.3	1.2	1.4
	18	14.0	5.0	6.5	23.2	1.8	9.4	1.2	2.5	7.3	1.3	1.2	1.7

TABLE 5-continued

Total fatty acid composition of T2 seeds from transgenic plants of
C. sativa best lines expressing DHA-1 construct. (Half seed analysis)
 Half seed analysis on T2 seeds

Total fatty acid composition of T2 seeds from transgenic plants of <i>C. sativa</i> best lines expressing DHA-1 construct. (Half seed analysis) Half seed analysis on T2 seeds													
19	12.6	4.7	6.5	21.6	1.8	14.4	1.5	2.0	7.5	1.3	1.0	1.4	
20	15.2	6.0	6.8	23.8	1.5	7.8	0.8	3.2	7.3	1.3	1.1	1.5	
MOL %		20:3n3	ETA	EPA	22:0	22:1	DPA	DHA	Others				
BBC_OE3													
	1	0.9	1.9	5.3	0.5	1.0	1.3	4.4	8.4	NVX1 7			
	2	0.8	2.6	5.6	0.6	0.7	1.7	4.2	6.8	NVX1 56			
	3	0.9	2.6	5.2	0.6	0.8	1.4	4.1	8.1	NVX1 9			
	4	1.0	2.7	4.9	0.4	0.9	1.5	4.7	8.6	NVX1 10			
	5	1.1	3.3	5.2	0.4	0.9	1.3	4.3	4.6	NVX1 57			
	6	0.8	3.0	4.8	0.3	0.8	1.1	3.8	5.3	NVX1 13			
	7	1.0	2.8	5.8	0.4	1.0	1.3	5.0	4.2	NVX1 14			
	8	1.2	2.3	7.2	0.4	1.0	1.5	7.3	6.5	NVX1 15			
	9	1.1	0.3	0.4	0.5	3.4	0.0	0.3	3.1	NVX1 58			
	10	0.6	0.0	0.0	0.5	2.5	0.0	0.0	5.5	NVX1 17			
	11	1.0	0.0	0.0	0.5	3.5	0.0	0.0	4.4	NVX1 19			
	12	1.0	2.7	5.1	0.4	0.9	1.3	4.5	5.7	NVX1 20			
	13	0.9	2.5	5.6	0.4	1.0	1.1	4.4	4.8	NVX1 21			
	14	1.2	2.3	8.8	0.4	0.7	2.2	7.5	4.6	NVX1 22			
	15	1.0	2.5	4.8	0.6	1.0	1.8	5.2	3.0	NVX1 59			
	16	1.2	2.6	6.9	0.5	0.7	2.2	7.2	3.9	NVX1 25			
	17	1.1	3.0	5.2	0.4	0.7	1.6	4.4	2.8	NVX1 26			
	18	1.1	2.2	7.0	0.5	1.1	1.4	6.1	5.4	NVX1 27			
	19	1.1	2.6	5.5	0.4	1.0	1.6	5.7	5.6	NVX1 28			
	20	1.0	2.4	5.8	0.5	1.2	1.6	5.3	5.9	NVX1 29			

Line	16:0	18:0	18:1	18:2	GLA	ALA	SDA	20:0	20:1	20:2	DHGLA	
OE_33_2	15.9	5.2	5.8	16.6	1.6	7.4	1.4	0.8	2.7	1.0	0.4	
OE_33_24	13.2	4.2	5.3	15.7	2.6	9.2	2.0	1.1	4.1	1.0	0.6	
OE_33_66	14.0	4.1	6.0	15.3	3.5	9.4	2.9	0.9	3.5	0.9	0.5	
OE_33_11	15.4	5.2	6.2	13.2	4.4	7.5	3.0	1.2	4.2	0.7	0.2	
OE_33_5	14.5	5.0	5.8	15.4	3.1	10.1	2.3	1.1	3.7	0.9	0.5	
OE_33_89	13.3	4.2	6.0	17.6	3.4	10.4	2.7	1.1	4.0	1.1	0.5	
OE_33_91	11.8	3.9	5.3	16.6	2.4	12.9	2.3	1.0	4.1	1.3	0.6	
OE_33_27	12.6	4.5	5.9	17.1	2.5	12.0	2.2	1.2	4.3	0.0	0.8	
OE_33_97	11.9	4.0	6.4	17.6	3.1	10.7	2.4	1.1	4.2	1.1	0.6	
OE_33_13	13.3	4.9	5.7	16.9	2.3	11.2	1.9	1.2	4.1	1.2	0.8	
OE_33_3	13.8	4.5	6.0	18.0	2.2	11.9	2.0	1.0	4.0	1.3	0.8	
OE_33_90	11.4	4.0	5.4	16.9	2.5	13.2	2.6	1.2	4.5	1.3	0.7	
OE_33_31	10.6	4.2	5.6	16.3	2.7	13.3	2.3	1.2	4.4	1.2	0.7	
OE_33_4	15.7	4.4	5.0	16.7	1.9	10.5	1.9	1.1	3.9	1.5	1.0	
OE_33_92	10.8	4.2	5.3	16.4	3.1	14.0	2.6	1.1	4.0	1.0	0.7	
OE_33_15	12.1	4.8	5.8	16.3	2.4	13.1	2.1	1.3	4.9	1.0	0.7	
OE_33_34	10.9	4.1	5.9	18.2	2.8	12.5	2.5	1.1	4.2	1.2	0.8	
OE_33_19	10.2	4.5	6.3	13.4	4.0	12.8	3.3	1.4	5.5	0.8	0.2	
OE_33_74	11.8	4.0	6.0	19.9	3.2	11.1	2.3	1.1	4.2	1.2	0.6	
OE_33_44	11.7	4.5	6.0	17.1	2.3	12.4	2.1	1.3	4.5	1.4	0.7	
OE_33_63	10.7	4.4	5.9	17.1	3.2	12.0	2.4	1.2	4.4	1.2	0.8	
OE_33_23	12.2	4.3	6.2	19.0	2.5	12.6	1.9	1.1	4.4	0.0	0.9	
OE_33_64	11.1	4.4	6.2	18.5	2.8	10.9	2.0	1.2	4.4	1.3	0.8	
OE_33_77	10.9	4.2	6.5	16.5	4.3	11.6	3.3	1.1	4.6	0.9	0.4	
OE_33_7	15.1	5.0	5.8	16.4	2.3	11.7	1.9	1.2	4.5	1.2	0.6	
OE_33_55	10.3	4.8	5.9	16.6	2.8	12.7	2.4	1.5	5.4	1.1	0.6	
OE_33_59	11.1	3.9	5.7	17.2	2.9	14.5	2.6	1.2	5.1	1.1	0.6	
OE_33_93	10.9	4.6	6.2	18.2	2.8	11.9	2.1	1.3	4.4	1.2	0.7	

Line	ARA	20:3n3	ETA	EPA	22:0	22:1	DPA	DHA	Others	
OE_33_2	1.2	1.5	2.7	12.6	0.0	0.0	5.0	13.7	4.6	
OE_33_24	2.1	1.7	3.2	13.0	0.2	0.6	3.8	12.7	3.7	
OE_33_66	1.7	1.4	2.3	12.9	0.0	0.7	3.5	12.5	3.8	
OE_33_11	1.6	1.0	1.7	13.7	0.3	0.5	3.9	11.7	4.3	
OE_33_5	1.8	1.1	2.8	12.5	0.3	0.4	3.6	11.5	3.8	
OE_33_89	1.9	1.4	2.2	12.5	0.0	0.6	3.0	10.7	3.5	
OE_33_91	2.4	1.4	3.1	13.0	0.0	0.5	3.6	10.6	3.3	
OE_33_27	2.3	1.3	3.1	12.1	0.2	0.4	3.5	10.3	3.7	
OE_33_97	2.4	1.3	2.9	12.9	0.0	0.5	3.0	10.3	3.5	
OE_33_13	2.1	1.2	3.2	11.5	0.3	0.4	4.0	10.2	3.8	
OE_33_3	2.2	1.3	3.0	11.1	0.3	0.4	3.5	10.0	2.8	
OE_33_90	2.2	1.3	3.2	12.8	0.0	0.4	3.5	10.0	3.2	
OE_33_31	2.3	1.4	3.3	13.0	0.2	0.4	3.3	9.8	3.7	
OE_33_4	2.8	1.4	3.0	11.4	0.0	0.4	5.1	9.8	2.7	

TABLE 5-continued

Total fatty acid composition of T2 seeds from transgenic plants of <i>C. sativa</i> best lines expressing DHA-1 construct. (Half seed analysis) Half seed analysis on T2 seeds									
OE_33_92	2.3	1.1	3.2	13.6	0.0	0.3	2.9	9.7	3.8
OE_33_15	2.0	1.2	3.0	12.0	0.3	0.5	3.3	9.7	3.6
OE_33_34	2.6	1.3	3.2	12.5	0.2	0.4	3.1	9.6	3.0
OE_33_19	1.8	1.3	1.9	14.3	0.3	0.6	2.7	9.6	5.1
OE_33_74	2.4	1.3	2.7	12.2	0.0	0.5	2.7	9.3	3.4
OE_33_44	2.2	1.5	3.2	12.0	0.3	0.5	3.1	9.3	4.0
OE_33_63	2.6	1.2	3.1	13.0	0.2	0.4	2.9	9.2	4.0
OE_33_23	2.5	1.3	3.2	11.2	0.2	0.4	3.0	9.2	3.9
OE_33_64	2.5	1.3	3.2	12.5	0.3	0.5	3.1	9.2	3.9
OE_33_77	2.4	1.1	2.0	13.3	0.2	0.5	2.7	9.2	4.4
OE_33_7	1.8	1.3	2.9	11.5	0.3	0.4	3.5	9.1	3.5
OE_33_55	2.3	1.3	2.9	12.7	0.3	0.6	3.0	9.0	4.0
OE_33_59	1.9	1.5	3.1	11.2	0.2	0.7	3.2	9.0	3.4
OE_33_93	2.6	1.2	2.9	12.5	0.3	0.5	2.7	9.0	4.0

[0200] To further examine the feasibility of producing EPA and DHA in transgenic *Camelina* seeds, we evaluated additional activities for this capacity—4 examples are shown below.

EXAMPLE 4

EPA-B4.3

[0201] To the original MC construct (FIG. 2; comprising 1) a seed specific promoter (the sucrose binding protein SBP1800 promoter), OtΔ6, *Ostreococcus tauri* Δ6-desaturase gene (Domergue et al. Biochem. J. 389 (PT 2), 483-490 (2005); AY746357) and CatpA, terminator; 2) a seed specific promoter (USP1 promoter (Bäumlein et al. 1991 Mol Gen Genet. 1991 March; 225(3):459-67), PSE1, a Δ6 fatty acid elongase from *Physcomitrella patens* (Zank, et al., Plant J. 31 (3), 255-268 (2002); AB238914) and CaMV35S terminator; 3) a seed specific promoter (Cnl, a conlinin1 promoter (Truksa 2003; Plant Physiol Biochem 41:141-147), TcΔ5, a Δ5-desaturase from *Thraustochytrium* sp. (Qiu et al. J Biol Chem. 2001 Aug. 24; 276(34):31561-6) and OCS, a terminator region of OCS, octopin synthase gene of *A. tumefaciens*) we added Hpw-3, a ω3 desaturase gene from *Hyaloperonospora parasitica* behind the Cnl promoter and in front of OCS, a terminator region of OCS, octopin synthase gene of *A. tumefaciens*

EXAMPLE 5

EPA-B5.1

[0202] We varied the genes present in the original BC construct (FIG. 2), such that the PsΔ12, a Δ2-desaturase gene from *Phytophthora sojae* and Piω3, a ω3 desaturase gene from *Phytophthora infestans* flanked by Np, a BnNapin promoter and E9 terminator regions were retained, but the activities were replaced with: 1) O809d6, a D6-desaturase from *Ostreococcus* RCC809, flanked by the Cnl conlinin1 seed-specific promoter and OCS, a terminator region of OCS, octopin synthase gene of *A. tumefaciens* 2) FcElo6, a Δ6 fatty acid elongase from *Fragilariopsis cylindrus* CCMP 1102, flanked by the Cnl conlinin1 seed-specific promoter and OCS, a terminator region of OCS, octopin synthase gene of *A. tumefaciens* and 3) EmiD5, a Δ5-desaturase from *Emiliana huxleyi* (Sayanova et al., 2011, Phytochemistry 72: 594-600)

flanked by the Cnl conlinin1 seed-specific promoter and OCS, a terminator region of OCS, octopin synthase gene of *A. tumefaciens*

EXAMPLE 6

EPA-B5.2

[0203] We varied the genes present in the original BC construct (FIG. 2), such that the PsΔ12, a Δ12-desaturase gene from *Phytophthora sojae* and Piω3, a ω3 desaturase gene from *Phytophthora infestans* flanked by Np, a BnNapin promoter and E9 terminator regions were retained, but the activities were replaced with: 1) O809d6, a D6-desaturase from *Ostreococcus* RCC809, flanked by the Cnl conlinin1 seed-specific promoter and OCS, a terminator region of OCS, octopin synthase gene of *A. tumefaciens* 2) CeElo6, a Δ6 fatty acid elongase from *Caenorhabditis elegans* (Beaudoin et al., 2000, Proc Natl Acad Sci USA. 2000 Jun. 6; 97(12):6421-6) flanked by the Cnl conlinin1 seed-specific promoter and OCS, a terminator region of OCS, octopin synthase gene of *A. tumefaciens* 3) EmiD5, a Δ5-desaturase from *Emiliana huxleyi* (Sayanova et al., 2011, Phytochemistry 72: 594-600) flanked by the Cnl conlinin1 seed-specific promoter and OCS, a terminator region of OCS, octopin synthase gene of *A. tumefaciens*

EXAMPLE 4

DHA-B7.2

[0204] To the original DHA-1 construct (FIG. 2), the EhD4 D4-desaturase from *Emiliana huxleyi* (Sayanova et al, 2011) was replaced by TpDesk, a D4-desaturase from *Thalassiosira pseudonana* (Tonon et al, 2005 FEBS J. 2005 July; 272(13): 3401-12), under the same regulatory elements (Cnl1, OCS).

[0205] Half-seeds of primary T1 transgenic lines were analysed by GC-FID as described earlier (Example 1—Fatty acid analysis) and examples of the fatty acid profiles observed are shown in Table 6 below. These data indicate that the capacity of *Camelina* to produce EPA and DHA is not limited to the gene sets initially described.

TABLE 6

	line 16	16.1b	16.1d	16.2	16.3	18.0	18:1a	18:1b	b18:2	18.2	GLA	bALA	ALA	SDA	20.0	20.1
DHA-B7.2_1	5	2	1	0	0	4	6	1	1	15	5	0	19	5	3	11
DHA-B7.2_2	5	2	4	1	2	7	3	0	0	15	3	0	13	4	5	12
DHA-B7.2_3	5	2	3	0	1	5	3	0	1	12	6	0	17	9	4	15
DHA-B7.2_4	5	2	1	0	0	6	5	0	1	15	2	0	19	2	4	10
WILDTYPE	5	4	2	0	1	4	5	0	0	14	1	0	27	0	4	17
EPA-B4.3_1	5	2	1	0	0	4	15	0	1	8	0	0	21	1	3	13
EPA-B4.3_2	4	0	0	0	0	3	14	0	0	14	0	0	35	0	2	19
EPA-B4.3_3	5	1	1	0	0	2	10	0	0	14	0	0	38	0	2	17
EPA-B5.1_1	6	1	0	0	0	4	9	0	0	20	2	0	30	5	3	14
EPA-B5.1_2	7	1	0	0	0	5	8	1	0	25	3	0	22	5	4	12
EPA-B5.1_3	6	1	0	0	0	5	10	1	0	24	2	0	27	4	3	12
EPA-B5.1_4	6	1	0	0	0	4	12	1	0	27	3	0	18	5	3	14
EPA-B5.1_5	5	1	0	0	0	3	12	1	0	23	2	0	25	5	3	14
EPA-B5.1_6	6	1	0	1	0	3	11	2	1	26	4	0	18	5	2	11
EPA-B5.1_7	7	1	0	1	0	4	7	1	0	24	0	0	29	1	4	15
EPA-B5.1_8	7	1	0	1	0	6	8	2	0	32	4	0	17	4	3	10
EPA-B5.2_1	7	2	0	0	0	5	7	1	0	27	2	0	16	6	0	4
EPA-B5.2_2	6	1	0	0	0	4	13	0	0	22	1	0	27	4	0	3
EPA-B5.2_3	7	2	0	0	0	4	6	0	0	22	2	0	22	6	0	5
EPA-B5.2_4	7	2	0	0	0	5	8	0	0	24	1	0	27	4	0	3
EPA-B5.2_5	5	1	0	0	0	3	15	0	0	24	1	0	24	4	0	2
EPA-B5.2_6	6	1	0	0	0	3	12	0	0	24	0	0	29	3	0	2
EPA-B5.2_7	7	2	0	0	0	5	6	0	0	19	2	0	22	4	0	6
EPA-B5.2_8	7	2	0	0	0	4	7	0	0	23	1	0	28	4	0	4

	20.1a	20.1c	20.2	DHGLA	ARA	20.3n3	20.4n3	EPA	22.0	22.1	22.2	DPA	DHA	24.0
DHA-B7.2_1	0	2	1	2	0	2	5	1	1	3	4	1	0	1
DHA-B7.2_2	0	3	1	2	0	1	3	3	0	4	5	2	2	1
DHA-B7.2_3	0	2	1	1	0	2	2	0	0	5	4	0	0	2
DHA-B7.2_4	0	2	2	1	1	2	3	6	0	3	3	9	6	0
WILDTYPE	0	0	5	0	0	2	0	0	0	7	3	0	0	2
EPA-B4.3_1	0	1	2	1	2	2	2	11	0	3	2	1	0	1
EPA-B4.3_2	0	0	2	0	0	2	0	0	0	4	0	0	0	1
EPA-B4.3_3	0	0	2	0	0	2	0	0	0	5	0	0	0	2
EPA-B5.1_1	0	0	1	0	0	1	0	1	0	3	0	0	0	0
EPA-B5.1_2	0	0	1	0	0	1	0	2	1	2	0	0	0	0
EPA-B5.1_3	0	0	1	0	0	1	0	1	1	1	0	0	0	0
EPA-B5.1_4	0	0	1	0	0	1	1	2	0	2	0	0	0	0
EPA-B5.1_5	0	0	1	0	0	1	0	1	0	2	0	0	0	0
EPA-B5.1_6	0	0	1	0	1	1	1	4	0	2	0	0	0	0
EPA-B5.1_7	0	0	2	0	0	2	0	0	1	3	0	0	0	0
EPA-B5.1_8	0	0	0	0	0	1	0	3	0	1	0	0	0	0
EPA-B5.2_1	11	0	1	1	1	1	1	7	0	2	0	0	0	1
EPA-B5.2_2	14	0	1	0	0	1	0	1	0	2	0	0	0	1
EPA-B5.2_3	15	0	1	0	0	1	0	4	1	3	0	0	0	1
EPA-B5.2_4	11	0	1	0	0	1	1	3	0	1	0	0	0	1
EPA-B5.2_5	14	0	1	0	0	1	1	3	0	2	0	0	0	0
EPA-B5.2_6	13	0	1	0	0	1	1	1	0	1	0	0	0	1
EPA-B5.2_7	16	0	2	0	1	1	1	2	2	4	0	0	0	1
EPA-B5.2_8	12	0	1	0	0	1	1	2	1	3	0	0	0	1

[0206] All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should

be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

SEQUENCES

SEQ ID NO: 1

(Codon-optimised OtD6 Δ6-desaturase from *Ostreococcus tauri*)
 1 ATGTGTGTTGAGACCGAGAACAACGATGGAATCCCTACTGTGGAGATCGCTTTCGATGGA
 61 GAGAGAGAAAAGAGCTGAGGCTAACGTGAAGTTGTCTGCTGAGAAGATGGAACCTGCTGCT
 121 TTGGCTAAGACCTTCGCTAGAAGATACGTGGTTATCGAGGGAGTTGAGTACGATGTGACC
 181 GATTTCAAACATCCCTGGAGGAACCGTGATTTTCTACGCTCTCTTAACACTGGAGCTGAT
 241 GCTACTGAGGCTTTC AAGGAGTTCACCCACAGATCTAGAAAAGCTAGGAAGGCTTTGGCT
 301 GCTTTCCTCTAGACCTGCTAAGACCGCTAAAGTGGATGATGCTGAGATGCTCCAGGAT
 361 TTCGCTAAGTGGAGAAAAGGAGTTGGAGAGGGACGGATTCTCAAGCCTTCTCCTGCTCAT
 421 GTTGCCTACAGATTCGCTGAGTTGGCTGCTATGTACGCTTGGGAACCTACTTGATGTAC
 481 GCTAGATACGTTGTGCTCCTGTGTTGGTTTACGCTTGCTTTCGGAGCTAGATGTGA
 541 TGGGTTCAACATGAGGGAGGACATTTCTTTGACCGAAACATCTGGTGGATAAGAGA
 601 ATCCAAGCTTTCAGCTGGATTCCGATTGGCTGGATCTGGAGATATGTGAACTCCATG
 661 CACAACAAGCACCATGCTACTCTCAAAAAGTGGAGCAGATATGGATTTGGATACCACT
 721 CCTGCTGTGTCTTCTTCAACACCGCTGTGGAGGATAATAGACCTAGGGGATTTCTAAG
 781 TACTGGCTCAGATTGCAAGCTTGGACCTTCACTCCTGTGACTTCTGGATTGGTGTGCTC
 841 TTCTGGATGTTCTTCTCCATCCTTCTAAGGCTTGAAGGGAGGAAAGTACGAGGAGCTT
 901 GTGTGGATGTTGGCTGCTCATGTGATTAGAACCCTGGACCATTAAAGCTGTTACTGGATTC
 961 ACCGCTATGCAATCTACGACTCTTCTTGGCTACTTCTTGGGTTTCCGGATGCTACTTG
 1021 TTCGCTCACTTCTACTTCTCACACCCATTGGATGTTGTTCTGCTGATGAGCATTG
 1081 TCTTGGGTTAGTACGCTGTGGATCACACCATTGATATCGATCCTTCTCAGGGATGGGT
 1141 AACTGGTTGATGGGATACTTGAACCTGCAAGTATTATCACCTCTTCCCTTCTATGCCT
 1201 CAATTCAGACAACCTGAGGTGTCCAGAAGATTCGTTGCTTTCGCTAAGAAGTGGAACTC
 1261 AACTACAAGGTGATGACTTATGCTGGAGCTTGAAGGCTACTTGGGAAACCTCGATAAT
 1321 GTGGGAAAGCACTACTACGTGCACGGACAACATTTGGAAAAGACCGCTTGA

SEQ ID NO: 2

(OtD6 Δ6-desaturase from *Ostreococcus tauri*)
 MCVETENNDGIPTVEIAFDGERERAEANVKLSAEKMEPAALAKTFARRYVVIEGVEYDVT
 DFKHPGGTVIIFYALSNTGADATEAFKEFHRSRKARKALAALPSRPAKTAKVDDAEMLQD
 FAKWRKELERDGFKPSPAHVAYRFAELAAMYALGTYLMYARYVVS SVLVYACFFGARCG
 WVQHEGGHSSLTGNIWWDKRIQAFTAGFGLAGSGDMWNSMHNKHHTPQKVRHMDLDTT
 PAVAFFNTAVEDNRPRGFSKYWLRQLQAWTFIPVTSGLVLLFWMFFLHPSKALKGGKYEEL
 VWMLAAHVIRTWTIKAVTGFTAMQSYGLFLATSWVSGCYLFAHFSTSHTHLDVVPAD EHL
 SWVRVAVDHTIDIDPSQGWVNWLMGYLNCQVIHHLFPPMPQPRQPEVSRRFVAFKKNWL
 NYKVMTYAGAWKATLGNLDNVGKHYYVHGQHSKTA*

SEQ ID NO: 3

(Codon-optimised PSE1 Δ6-elongase from *Physcomitrella patens*)
 1 ATGGAAGTTGTTGAGAGGTTCTACGGAGAGTTGGATGGAAGGTTTCCCAAGGAGTGAAC
 61 GCTTTGTTGGGATCTTTCGGAGTTGAGTTGACTGATACCCCACTACTAAGGGATTGCCA
 121 CTCGTTGATTCTCCAACCTCAATTGTGTTGGGAGTGTCTGTTTACTTGACCATCGTGATC
 181 GGAGGATGCTTTGGATCAAGGCTAGAGATCTCAAGCCAAGAGCTTCTGAGCCATTCTTG
 241 TTGCAAGCTTTGGTGTGGTGCACAACCTGTTCTGCTTCTGCTTTTACATGTGC

- continued

301 GTGGGTATCGCTTACCAAGCTATCACCTGGAGATATTCCTTGTGGGAAACGCTTATAAC
 361 CCAAAGCACAAAGGAGATGGCTATCCTCGTTTACCTCTTCTACATGTCCAAGTACGTGGAG
 421 TTCATGGATACCGTGATCATGATCCTCAAGAGATCCACCAGACAGATTTCTTTCTCCAC
 481 GTGTACCACCATTCTTCTATCTCCCTTATCTGGTGGGCTATTGCTCATCATGTCCAGGA
 541 GGAGAGGCTTATTGGAGTGTCTCTCAACTCTGGAGTGCATGTGTGATGTACGCTTAC
 601 TACTTCTTGGCTGTCTGCTTGGAGATCTTCCCAAAGCTCAAGAACAAGTACCTCTTCTGG
 661 GGAAGATACCTCACCAATTCCAGATGTTCCAGTTCATGCTCAACTTGGTGCAAGCTTAC
 721 TACGATATGAAAACCAACGCTCCATATCCACAATGGCTCATCAAGATCCTTCTACTAC
 781 ATGATCTCCCTTTGTTCTCTTCGGAACCTCTACGTGCAAAAGTACATCAAGCCATCC
 841 GATGGAAGCAAAGGGAGCTAAGACCGAGTGA

SEQ ID NO: 4

(PSE1 Δ6-elongase from *Physcomitrella patens*)
 MEVVERFYGELDGKVSQGVNALLGSPGVELDTPPTTKGLPLVDSPTPIVLGVSVYLTIVIGLLWIKAR
 DLKPRASEPFLQLVHLVHNLECFALSLYMCGVIAYQATTWRYSLWGNAYNPKHKEMAILVYLFYMSKY
 VEFMDTVIMILKRSTRQISFLHVYHSSISLIWIAIAHHAPGGEAYWSAALNSGVHVLMYAYYFLAACL
 RSSPKLKNKYLFWGRYLQFQMFQFMLNLVQAYYDMKTNAPYQWLIKILFYMISLLFLFGNFYVQKY
 IKPSDGKQKGAKE*

SEQ ID NO: 5

(Codon-optimised TcA5-desaturase from *Thraustochytrium* sp.)
 1 ATGGGAAAAGGATCTGAGGGAAGATCTGCTGCTAGAGAGATGACTGCTGAGGCTAACCGA
 61 GATAAGAGAAAAGACCATCCTCATTGAGGGAGTGTGTACGATGTACCAACTTCAAACAC
 121 CCAGGAGGTTCCATTATTAACCTCCTCACCAGGGAGAAGCTGGAGTTGATGTACCCAA
 181 GCTTACAGAGAGTCCATCAGAGATCCGGAAAGGCTGATAAGTACC TCAAGTCCCTCCCA
 241 AAGTTGGATGCTTCTAAGGTGGAGTCTAGGTTCTCTGCTAAGGAGCAGGCTAGAAGGGAC
 301 GCTATGACCAGGATTACGCTGCTTTCAGAGAGGAGTTGGTTGCTGAGGGATACTTCGAT
 361 CCATCTATCCCACATGATCTACAGAGTGGTGGAGATTGTGGCTTTGTTTCGCTTTGTCT
 421 TTCTGGTTGATGCTAAGGCTTCTCAACCTCTTTGGTTTGGGAGTGGTGTGAACCGA
 481 ATCGCTCAAGGAAGATGCCGATGGGTTATGCATGAGATGGGACACGGATCTTCACTGGA
 541 GTTATCTGGCTCGATGATAGGATGTGCGAGTCTTCTACGGAGTTGGATGTGGAATGTCT
 601 GGCACTACTGGAAGAACCAGCATTCTAAGCACCATGCTGCTCAAACAGATTGGAGCAC
 661 GATGTGGATTTGAACACCTTGCCACTCGTTGCTTTCAACGAGAGAGTTGTGAGGAAGGTT
 721 AAGCCAGGATCTTTGTTGGCTTTGTGGCTCAGAGTTCAGGCTTATTTGTTTCGCTCCAGTG
 781 TCTTGCTTTGATCGGATTTGGATGGACCTTGTACTTGCAACCAAGATATATGCTCAGG
 841 ACCAAGAGACATATGGAGTTTGTGTGGATCTTCGCTAGATATATCGGATGGTTCTCCTTG
 901 ATGGGAGCTTTGGGATATCTCCTGGAACCTCTGTGGGAATGTACCTGCTCTTTCGGA
 961 CTTGGATGCATCTACATCTTCTCCAATTCTGCTGTCTCATAACCAATTTGCCAGTTACC
 1021 AACCCAGAGGATCAATTGCATTGGCTTGGTACGCTGCTGATCATAACCGTGAACATCTCT
 1081 ACCAAGTCTTGGTTGGTTACCTGGTGGATGTCTAACCTCAACTTCCAATTCGAGCATCAT
 1141 TTGTTCCCAACCGCTCCACAATTCAGGTTCAAGGAGATCTCTCAAGAGTTGAGGCTCTC
 1201 TTCAAGAGACATAACCTCCCTTACTACGATTTGCCATACACCTCTGCTGTTTCTACTACC
 1261 TTCGCTAACCTTACTCTGTTGGACATCTGTTGGAGCTGATACCAAGAAGCAGGATTGA

- continued

SEQ ID NO: 6

(TcA5-desaturase from *Thraustochytrium* sp.)
 MGKGSSEGRSAAREMTAEANGDKRKTILIEGVLYDATNFKHPGGSIIINFLTEGEAGVDATQAYREFHQRS
 GKADKYLKSLPKLDASKVESRFSAKEQARRDAMTRDYAAFREELVAEGYFDPSIPHMIYRVVEIVALFA
 LSPFLMSKASPTSLVLGVVMNGIAQGRCGVMHEMHHGSFTGVIWLDLDRMCEFFYGVGCGMSGHYWKNQ
 HSKHHAAPNRLEHDVDLNTLPLVAFNERVVRKVKPGSLALWLRVQAYLPAFVSCLLIIGLWTLYLHPR
 YMLRTRKRHMEFVWI FARYIGWFSLMGALGYSPGTSVGMVYCSFGLGCIYIFLQFAVSHTHLPVTNPEDQ
 LHWLEYAADHTVNI STKSWLVTWMSNLNFQIEHHLFP TAPQFRFKEISPRVEALFKRHNLPPYDLPYT
 SAVSTTFANLYSVGHSSVGADTKKQD*

SEQ ID NO: 7

(Codon-optimised OteLo5 Δ5-elongase from *Ostreococcus tauri*)
 1 ATGTCATGCTTCTGGAGCTTTGTTGCTGCTATTGCTTCGCTGCTTACGCTTACGCTACC
 61 TACGCTTATGCTTTCGAGTGGTCTCATGCTAACGGAATCGATAACGTGGATGCTAGAGAG
 121 TGGATTGGAGCTTTGCTTTGAGACTCCCTGCAATGCTACCACCATGTACCTCTTGTTTC
 181 TGCCTTGTGGGACCTAGATTGATGGCTAAGAGGGAGGCTTTTGATCCTAAGGGATTCATG
 241 CTCGCTTACAACGCTTACCAAACCGCTTTCAACGTTGTGGTGTCTCGGAATGTTTCGCTAGA
 301 GAGATCTCTGGATTGGGACAACTGTTTGGGGATCTACTATGCCTTGGAGCGATAGGAAG
 361 TCCTTCAAGATTTTGTGGGAGTGTGGCTCCATTACAACAATAAGTACCTCGAGTTGTTG
 421 GATACTGTGTTTCATGGTGGCTAGGAAAAGACCAAGCAGCTCTCTTTCTTGCATGTGTAC
 481 CATCATGCTTTGTTGATTGGGCTTGGTGGCTTGTTCATCATGCTACCAACGAT
 541 TGCATCGATGCTTATTCGGAGCTGCTTGCAACTCTTTCATCCACATCGTGATGTA TACTCC
 601 TACTACCTCATGCTGCTTTGGGAATTAGATGCCCTTGGAAAGAGATATATACCCAGGCT
 661 CAGATGTTGCAATTCGTGATCGTGTTCGCTCATGCTGTTTTCGTGTCTCAGACAAAAGCAC
 721 TGCCCTGTACTTTGCTTGGGCACAAATGTTTCGTGATGACAAATATGTTGGTGTCTTTC
 781 GGAACTTCTACCTCAAGGCTTACTCTAACAAGTCTAGGGGAGATGGAGCTTCTTCTGTT
 841 AAGCCTGCTGAGACTACTAGAGCACCTTCTGTGAGAAGAACCAGGTCAGGAAGATCGAT
 901 TGA

SEQ ID NO: 8

(OteLo5 Δ5-elongase from *Ostreococcus tauri*)
 MSASGALLPAIAFAAYAYATYAYAFESHANGIDNVDAREWIGALSRLPAIATMYLLFCLVGPRLMA
 KREAFDPKGFMLAYNAYQTAFNVVVLGMPFAREISGLGQPVWGSTMPWSDRKSFKILLGVWLHYNKYLE
 LLDTVFMVARKKTKQLSFLHVYHHALLIWAWWLVCHLMATNDCIDAYFGAACNSFIHIVMYSYYLMSAL
 GIRCPWKRYITQAQMLQEVIVFAHAVEVLRQKHCPVTLPWAQMFVMTNMLVLFGNFYLKAYSNKS RGDG
 ASSVKPAETTRAPSVRRTRS RSKID*

SEQ ID NO: 9

(Codon-optimised EMoD5 Δ5-desaturase from *Emiliana huxleyi*)
 1 ATGTCATTGGCTGCTAAAGATGCAGCCTCGGCCACTCATCCGCTTGGACCCTAAGTAT
 61 CACGGAGCTACAAATAAGTCAAGAACTGATGCAGCAGACCTTACAGTTAGTTCTATCGAC
 121 ACTTCTAAGGAGATGATCATAAGGGTTCGTGTGTATGATGCTCTGATTTTATTAAGG
 181 CACCCGGGAGGAAGCATTATTAACCTCCTTAGGTTCTGATGCAACAGACGCTTATAAC
 241 AACTTCCATATTAGGCTTAAAAAGCGGATAAAATGTTGAGAGCTTTGCCAAGTAGGCCA
 301 GTAGCGGATGGATTTCGCTAGAGACGCTTTGTCTGCAGACTTCGAGGCCCTGAGAGCCCAA
 361 CTCGAGGCCGAGGTTACTTCGAACCGAATCTGTGGCATGTAGCTTATCGAGTTGCGGAA

- continued

421 GTCGTTGCTATGTACTGGGCGGGTATTAGACTTATCTGGGCGGGTATTGGTTTTTAGGA
 481 GCCATTGTAGCAGGAATAGCTCAGGGGAGATGCGGTTGGCTTCAGCATGAGGGTGGTCAT
 541 TATTCGCTCACAGGTAATATTAACCTTGATCGACACATGCAAATGATTATCTATGGATTA
 601 GGTGCGGAATGTCGGTTGTTATTGGAGAAACCAACATAACAAGCACCATGCGACACCG
 661 CAAAAGTTGGGTGCAGATCCAGACCTTCAAACAATGCCTCTGGTTGCGTTCCATGGACTC
 721 ATCGGTGCTAAGGCTAGGGGAGCAGGAAAGTCGTGGCTAGCATGGCAAGCTCCACTTTTC
 781 TTTGGAGGCGTTATCACAACCTGGTATCTTTTGGTTGGCAGTTCGTCCAACATCCAAAG
 841 CACGCATTGAGAGTAGGAAACCAACTCGAATTAGGCTATATGGCTTTACGATATGCTTTA
 901 TGGTATGCAGCATTGCGTCATCTTGGGCTTGGTGGTCTTTCAGATTGTACGCTTTTTAT
 961 GTGGCAGTCGGAGGTACATATATCTTCACGAACCTTTCGGGTGCTCACACACATAAGGAT
 1021 GTTGTTCACACGATAAGCATATTTCTTGGACCTTGTATTCTGCAAACCATACCACTAAT
 1081 CAATCTAACACACCTCTAGTCAATTGGTGGATGGCCTATCTGAATTTCAAATTGAACAT
 1141 CACCTTTTCCCTAGCATGCCACAATATAACCATCCTAAAATCTGCGGAAGAGTGAAACAA
 1201 TTGTTGAAAAACATGGCGTAGAGTACGATGTCAGAACTTACGCGAAGTCAATGCGTGAT
 1261 ACATACGTGAATCTCTTGGCTGTGGGAAATGCATCTCATTCCCTTCATCAGAGAAACGAG
 1321 GGATTAACGACTAGGGAGTCTGCGGCTGTTAGAGTTACAGGTCATTGA

SEQ ID NO: 10

(EMoD5 A5-desaturase from *Emiliana huxleyi*)

1 MSLAAKDAASAHSSVLDPKYHGATNKSRTDAADLTVSSIDTSKEMIIRGRVYDVSDFIKR
 61 HPGGSIIKLSLGSADATAYNNFHIRSKKADKMLRALPSRPVADGFARDALSADFEALRAQ
 121 LEAEGYFEPNLVHVAIRVAEVVAMYWAGIRLIWAGYWFLGAIVAGIAQGRGWLQHEGGH
 181 YSLTGNIKLDRHMQMI IYGLCGMSGCYWRNQHKNKHATPQKLGADPDLQTMPLVAFHGL
 241 IGAKARGAGKSLAWQAPLFFGGVI TLLVSPGWQFVQHPKHALRVGNQLELGYMALRYAL
 301 WYAAFHGLGLGAFRLYAFYVAVGGTYIFTNFAVSHTHKDVVPHDKHISWTLYSANHTTN
 361 QSNTPLVNWMMAYLNFQIEHRLFPSPMPQYNHPKICGRVKQLFEKHGVEYDVRTYAKSMRD
 421 TYVNLAVGNASHSLHQREGLTTRESAAVRVTGH*

SEQ ID NO: 11

(Codon-optimised PsA12-desaturase from *Phytophthora sojae*)

1 ATGGCTATTTGAACCTGAGGCTGATTCTGCTGCTAACCTCGTACTGATTCTGAGGCT
 61 AAGCAAAGACAATTGGCTGAGGCTGGATACACTCATGTTGAGGGTGTCTCTGCTCCTTTG
 121 CCTTTGGAGTTGCCATTTCTCTCTCAGAGATCTCAGAGCTGCTATTCTTAAGCACTGC
 181 TTCGAGAGATCTTTCGTGACCTCCACTACTACATGATCAAGAACGTGTTGACTTGCCT
 241 GCTTTGTTCTACGCTGCTACCTTCATTGATAGAGCTGGAGCTGCTGCTTATGTTTTGTGG
 301 CCTGTGACTGGTCTTCCAGGGATCTTACTTGACTGGAGTGTGGGTTATCGCTCATGAG
 361 TGTGGACATCAGGCTTATTGCTCTTCTGAGGTGGTGAACAACCTGATTGGACTCGTGTG
 421 CATTCTGCTTTGTTGGTGCTTACCCTCTTGGAGAATCTCTCACAGAAAGCACCATTCC
 481 AACACTGGATCTTGCAGAACGATGAGGTTTTCTGTTCTGTGACCAGATCTGTGTTGGCT
 541 TCTTCTGGAACGAGACCTTGGAGGATCTCTCTCTACCAACTCTACCGTATCGTGATC
 601 ATGTTGGTTGTTGGATGGATGCCTGGATACCTCTTCTCAACGCTACTGGACCTACTAAG
 661 TACTGGGAAAGTCTAGGTCTCACTTCAACCTTACTCCGCTATCTATGCTGATAGGGAG
 721 AGATGGATGATCGTCTCCGATATTTCTTGGTGGCTATGTTGGCTGTTTTGGCTGCT

- continued

781 TTGGTGCACACTTTCTCCTTCAACACCATGGTGAAGTTCTACGTGGTGCCTTACTTCATT
 841 GTGAACGCTTACTTGGTGTGATTACCTACCTCCAACACACCGATACCTACATCCCTCAT
 901 TTCAGAGAGGGAGAGTGGAAATTGGTTGAGAGGAGCTTTGTGCACTGTGGATAGATCATT
 961 GGTCCATTCTCGATTCTGTGGTGCATAGAATCGTGGATACCCATGTTTGCCACCACATC
 1021 TTCTCCAAGATGCCTTTCTATCATTCGAGGAGGCTACCAACGCTATTAAGCCTCTCCTC
 1081 GGAAAGTTCTACTTGAAGGATACCACTCCTGTTCTGTTGCTCTCTGGAGATCTTACACC
 1141 CATTGCAAGTTCGTTGAGGATGATGGAAAGGTGGTGTCTACAAGAACAAGCTCTAG

SEQ ID NO: 12

(PsA12-desaturase from *Phytophthora sojae*)
 MAILNPEADS AANLATDSEAKQRLAEAGYTHVEGAPAPLPLELPHFSLRDLRAAI PKHCFERSFVTST
 YYMIKNVLTCAALFYAATFIDRAGAAAYVLWPVYVFFQGSYLTGVVIAHECGHQAYCSSEVVNNLIGL
 VLHSALLVPYHSWRISHRKHHSNTGSCENDEVFVPVTRSVLASSWNETLEDSPLYQLYRI VYMLVVGWM
 PGYLFFNATGPTKYWGKSRSHFNPSAIYADRERWMI VLSDFLVAMLAVLAALVHTFSFNTMVKFYV
 PYFIVNAYLVLITYLQHTDTYIPHFREGAWNWRGALCTVDRSPGPFSDSVVHRIVDTHVCHHIFSKMP
 FYHCEEATNAIKPLLKGFYLDKTPVPVALWRSYTHCKFVEDDGKVPFYKNKL*

SEQ ID NO: 13

(Codon-optimised pi(w3)-desaturase from *Phytophthora infestans*)
 1 ATGGCTACAAAGGAGGCTTACGTTTCCCAACTCTCACCAGATCAAGAGATCTCCTCCCA
 61 AAGGATTGCTTCGAGGCTTCTGTGCCTTTGTCTCTCTACTACTGTGAGATGCTTGGTT
 121 ATTGCTGTGGCTTTGACCTTCGGATTGAACTACGCTAGAGCTTTGCCAGAGGTTGAGTCT
 181 TTCTGGGCTTTGGATGCTGCTTTGTGCACTGGATATATCCTCCTCCAGGAATTGTGTT
 241 TGGGGATTCTTCACTGTTGGACACGATGCTGGACACGGAGCTTTCTCTAGATACCACCTC
 301 TTGAACTTCGTTGTGGGAACCTTCATGCATCTCTCATCTTGACCCCATTCGAGTCTTGG
 361 AAGTTGACCACAGACACCACCACAAGAACCAGGAAACATCGATAGAGATGAGGTGTT
 421 TACCCACAGAGAAAGGCTGATGATCACCCATTGTCCAGGAACCTGATCTTGGCTTTGGGA
 481 GCTGCTGGCTTGTCTTATTTGGTGGAGGATCCCACCAAGAAAGGTGAACCACTTCAAC
 541 CCATTGAGCCACTTTTGTGAGACAAGTGTCCGCTGTGGTTATCTCTTTGCTCGCTCAC
 601 TTCTTCTGTTGCTGACTCTCTATCTACTTGTCTCTCCAGTTGGGACTTAAGACCATGGCT
 661 ATCTACTACTACGGACCAGTTTTCGTGTTCCGATCTATGTTGGTGATTACCACCTTCTTG
 721 CACCACAACGATGAGGAGACTCCATGGTATGCTGATTCTGAGTGGACTTACGTGAAGGGA
 781 AACTTGTCTCTGTGGATAGATCTTACGGTGTCTCATCGATAAACCCTCCCACAACATC
 841 GGAACCTACCAGATCCACCACCTTTCCTCAATTATCCACACTACAAGCTCAAGAAGGCT
 901 ACTGCTGCTTTCCACCAAGCTTTCCAGAGCTTGTGAGAAAGTCCGATGAGCCAATCATC
 961 AAGGCTTTCTCAGAGTGGGAAGTTGTATGCTAACTACGGAGTGGTTGATCAAGAGGCT
 1021 AAGCTCTTCACTTTGAAGGAGGCTAAGGCTGCTACTGAAGCTGCTGCTAAGACCAAGTCT
 1081 ACCTGA

SEQ ID NO: 14

(pi(w3)-desaturase from *Phytophthora infestans*)
 1 MATKEAYVFPPTLTEIKRSLPKDCFEASVPLSLYTVRCLVIAVALTFGLNYARALPEVES
 61 FWALDAALCTGYILLQGI VFWGFFTVGH DAGHGAFSRYHLLNFVVGTFMHSLLILTPFESW
 121 KLTHRHHKNTGNIDRDEVFYPQRKADHPLSRNLILALGAAWLALYLVGFFPRKVNHFN
 181 PFEPLFVRQVSAVVISLLABFFVAGLSYLSLQLGLKTMAYYYGPFVFPVGSMLVITTF

- continued

241 HHNDEETPWYADSEWTVYKGNLSSVDRSYGALIDNLSHNIGTHQIHHLFPIIPHYKLKKA
 301 TAAFHQAFPELVRKSDEPIIKAFFRVGRLYANYGVVDQEAFLTLKEAKAATEAAAKTKS
 361 T*

SEQ ID NO: 15

(Codon-optimized EhD4 A4-desaturase from *Emiliana huxleyi*)
 1 ATGGGGGTGCAGGCGCTTCGGAAGCAGAGAGGCCAAAGTGGACACTATCCACGGAAGA
 61 CACGTTGATGTGCAAGTTTAGACACCCTGGAGGTAATATCATTGAATTGTTCTATGGC
 121 ATGGATAGTACATCCGCTTTCGAGCAATTTACGGACATCATAAGGGGCATGGAAGATG
 181 CTC AAGGCTCTTCTACCAAGGAGGTTGACCCAGCTGACGTCACAGCAACCTCAAGAA
 241 CATGTCGCGGAGATGACCAGACTTATGACATCCTGGAGAGAAAGGGTTTATTCAAGCCT
 301 CGTCCGGTTGCATCTGGCATATATGGACTTGCCAGTAGTTGCTGCTATAGTTGCATGCATT
 361 GCATGTGCTCCGCACGCACCCGTTCTGTCGGGGATTGGTTTAGGGTCTTGTGGGCCAA
 421 TCGCGTTTCTTCGAGCATATGGGGGACATAGGGAGTGGGGGTCAGGTATTCTTTCTTG
 481 CTC CAACACTTCTTTGAGGGTTTACTAAAGGGAGGATCAGCTAGCTGGTGGAGAACAGA
 541 CATAATAAGCATCATGCGAAAACCAATGTTCTTGAGAGGATGGTGACCTTCGAACTACT
 601 CCATTCTTTGCGTGGGACCCGACTCTCGCTAAAAAGGTGCCGGATTGGTCTCTGAAGACA
 661 CAAGCTTTCACCTTCTCCAGCACTAGGAGCCTATGTTTTCGTTTTCGCTTTCACAATT
 721 AGAAAAACGCTGTGGTGAAAAAATCTGGCACGAACCTGCTCTAATGATTGCTCATTAC
 781 GCAATGTTCTACTATGCCCTGCAGTTGGCTGGAGCCAGTTGGGTTCTGGACTTGCAATT
 841 TACTGCACAGGTTACGCATGGCAGGAATCTACCTCGGATTCTTCTCGGTTTGAGCCAC
 901 TTTGCAGTCGAGAGAGTACCAAGCACAGCGACATGGCTCGAAAGCTCAATGATAGGTTCA
 961 TGGCAGGAATCTACCTCGGATTCTTCTCGGTTTGAGCCACTTTGCAGTCGAGAGAGTA
 1021 CCAAGCACAGCGACATGGCTCGAAAGCTCAATGATAGGTACGGTAGACTGGGAGGTTCA
 1081 TCTGCTTTTGTGGTTATGTTCTGGTTTCTGAAATATCCAAATGAACATCACATGGCC
 1141 CCTCAAATGCCTATGAAAAATCTGAGACAGATCAGGGCAGATTGTAAGGCTAGTGCTGAG
 1201 AAACCTCGGCTTGCCATATAGAGAGTTGTCATTCGCAGGTGCTGTCAAACCTCATGATGGTA
 1261 GGTCTCTGGAGACTGGAAGAGACGAATTACAGCTCCGAAGTGATCGAAGAAAGTACTCA
 1321 AGAACCCAGGCTTACATGGCGGCTGCTTCAGCTGTTGTTGAAAACTGAAGGCAGATTAA

SEQ ID NO: 16

(EhD4 A4-desaturase from *Emiliana huxleyi*)
 1 MGGAGASEAERPkwTIIHGRHVDVSKFRHPGGNIIELFYGMDSTSAFEQPHGHKGAWKM
 61 LKALPTKEVDPADVPPQPEHVAEMTRLMTSWRERGLFKPRPVASGIYGLAVVAIVACI
 121 ACAPHAPVLSGIGLGS CWAQCFLQHMGGHREWGVRYSFLLQHFEGLLKGSASWWRNR
 181 HNKHHAKTNVLGEDGLRTPFFAWDPTLAKKVPDWSLKTQAF TFLPALGAYVVFVFAFTI
 241 RKYAVVKKLWHELALMIAHYAMFYALQLAGASLGSLAFYCTGYAWQGIYLGFFFLSH
 301 FAVERVPSTATWLESSMIGSWQGIYLGFFFLSHFAVERVPSTATWLESSMIGTVDWGGG
 361 SAFCGYVSGFLNIQIEHMAPQMPMENLRQIRADCKASAEKLG LPYRELSFAGAVKLMV
 421 GLWRTGRDELQLRSRRKYSRTQAYMAAASAVVENLKAD*

- continued

SEQ ID NO: 17

(Codon-optimized $\Delta 4$ -desaturase from *Thraustochytrium* sp., ATCC21685)

1 ATGACTGTTGGATACGATGAGGAGATCCCATTCGAGCAAGTTAGGGCTCATAACAAGCCA
 61 GATGATGCTTGGTGTGCTATTCATGGACACGTGTACGATGTTACCAAGTTCGCTTCTGTT
 121 CATCCAGGAGGAGATATTATCTTGCTCGCTGCTGGAAAGGAAGCTACTGTGCTCTACGAG
 181 ACCTACCATGTTAGAGGAGTGTCTGATGCTGTGCTCAGAAAGTACAGAATCGGAAAGTTG
 241 CCAGATGGACAAGGAGGAGCTAACGAGAAGGAGAAGAGAACCTTGTCTGGATTGTCTCT
 301 GCTTCTACTACACTGGAACCTCCGATTTCTACAGAGTGATGAGGGAGAGAGTTGTGGCT
 361 AGATTGAAGGAGAGAGGAAAGGCTAGAAGAGGAGGATACGAGTTGTGGATCAAGGCTTTC
 421 TTGCTCCTTGTGGATTCTGGTCTCTCTTTACTGGATGTGCACCCCTCGATCCATCTTTC
 481 GGAGCTATCTTGGCTGCTATGTCTTTGGGAGTGTTCGCTGCTTTTGTGGAACCTGCATC
 541 CAACATGATGGAAACCATGGAGCTTTCGCTCAATCTAGATGGGTTAACAAAGGTGGCAGGA
 601 TGGACTTTGGATATGATCGGAGCTTCTGGAATGACTTGGGAGTTCACCATGTGTTGGGA
 661 CATCACCCATACACTAACTTGATCGAGGAGGAGAACCGATTGCAAAAGGTGTCCGGAAAG
 721 AAGATGGATACCAAGTTGGCTGATCAAGAGTCTGATCCAGATGTGTTCTCCACCTACCCA
 781 ATGATGAGATTGCATCCATGGCATCAGAAGAGATGGTATCAGAGTTCCAGCATATCTAC
 841 GGACCATTCATCTTCGGATTTCATGACCATCAACAAGGTGGTACTCAAGATGTTGGAGTG
 901 GTGTTGAGAAAGAGGCTCTTCCAAATCGATGCTGAGTGCAGATATGCTTCCCAATGTAC
 961 GTTGTAGGTTCTGGATCATGAAGGCTTTGACCGTGTGTACATGGTTGCTCTCCCATGT
 1021 TATATGCAAGGACCATGGCATGGATTGAAGCTCTTCGCTATCGCTCATTTCACTTGC
 1081 GAGGTTTTCGGCTACCATGTTTCATCGTGAAACCATTATCGAGGAGTGTCTTACGCTTCT
 1141 AAGGATGCTGTTAAGGGAACATGAGCTCCACCAAGACTATGCATGGAGTGACCCCAATG
 1201 AACCACTAGAAAGGAGGTTGAGGCTGAGGCTTCTAAGTCTGGAGCTGTGGTTAAGTCT
 1261 GTGCCATTGGATGATTGGGCTGCTGTTCAATGCCAACCTCTGTGAAGTGGTCTGTTGGA
 1321 TCTTGGTTCTGGAACCATTTCTCTGGAGGACTCAACCATCAATCGAGCATCATCTCTTC
 1381 CCAGGATTGTCTCACGAGACCTACTACACATCCAAGATGTGGTTCAATCTACCTGTGCT
 1441 GAGTACGGAGTTCATACCAACATGAGCCATCTTGTGGACTGCTTACTGGAAGATGCTC
 1501 GAACATTTGAGACAATTGGGAAACGAGGAGACTCACGAGTCTTGGCAAAGAGCTGCTTGA

SEQ ID NO: 18

($\Delta 4$ -desaturase from *Thraustochytrium* sp., ATCC21685)

1 MTVGYDEEIPFEQVRAHNKPDDAWCAIHGHVYDVTKFASVHPGGDILLAAAGKEATVLYE
 61 TYHVRGVSDAVLRKYRIGKLPDQGGANEKEKRTL SGLSSASYTWN SDFYRVMRERVVA
 121 RLKERGKARRGGYELWIKAFLLLVGFWS SLYWMCTLDPSFGAILAAMSLGVFAAFVGTCTI
 181 QHDGNHGAFQSRWVNKVAGWTLDMIGASGMTWEFQHVLGHHPYTNLIEEENGLQKVS GK
 241 KMDTKLADQESDPDFSTYPMMLRHPWHQKRWYHRPQH IYGPFI FGPMTINKVVTQDVGV
 301 VLRKRLFQIDAECRYASPMYVARFWIMKALTVLYMVALPCYMQGPWHGLKLF AIAHFTCG
 361 EVLATMFIVNHIIEGVSYASKDAVKGTMAPPKTMHGVTPMNNRKEVEAEASKSGAVVKS
 421 VPLDDWAAVQCQTSVNW SVGSWFWNHFSGGLNHQIEHHLFPGLSHETYYHIQDVVQSTCA
 481 EYGVYPYQHEPSLWTAYWKMLEHLRQLGNEETHESWQRAA*

- continued

SEQ ID NO: 19

(codon optimised O809D6 $\Delta 6$ -desaturase from *Ostreococcus* RCC809)
 ATGGGAAGGGAGCAAGGAACCCAGGAGCAAGGCATGGAAGTCAACATTGGAGCCTCACGCAGTGGCA
 AAGTCATTCGATAGGAGATGGGTTAAGGTGGATGGAGTTGAATACGATGTGACTGATTTCAAGCATCCT
 GGAGGTAGTGTATATACTACATGCTTTCTAACACAGGTGCTGATGCAACCGAAGCTTTTAAGGAGTTC
 CATTACAGGAGTAAGAAAGCTAGGAAAGCACTTGCCTCAAGAGAACCAGAGGATGCTTCA
 CCAGTTGAAGATGCAAACATGCTCAAGGATTTTCGCTAAGTGGAGAAAGGATCTCGAAAGGGAGGGATTT
 TTCAAACCTTCTCCAGCTCATGTGGCATATAGATTTGCTGAGCTTGCCTGCAATGTTTCGCTCTCGGTACA
 GCATTAATGTACGCTAGATGGCAGCAACTTCTGTTTTCTGACAGCTTGTCTTTTGGAGCAAGATGC
 GGTGGGTTCAACATGAGGGAGGTCCTCTTATTGACTGGATCAATCTGGTGGATAAGAGAATACAG
 GCTTTTACAGCAGGATTCGCTCTCGCTAGTTCTGGTGATATGTGAATTTAATGCATAACAAGCATCAC
 GCAACCCCTCAAAAAGTTAGGCACGATATGGATTTGGATACTACACCAGCTGTTGCATTTTTCAATACT
 GCTGTGGAAGAGAACAGACCTAGGAAGTTTTCTAACTTTGGTTGAGAGTTCAGGCTTGGACCTTCGTT
 CCTGTGACTTCAGGACTCGTCTTTGGCTTGGATGTATCTTACATCCAAGACACATTGCAAGAAGG
 AAGAATTACGAAGAGGCTGCATGGATCGTTGCTGCACATGTGATAAGGACATCAGTTATTAAGCTGTG
 ACAGGATATAGTTGGATAACCTGTTACGGTCTCTTTTTAAGTACCATGTGGGTTTCTGGATGCTATCTT
 TTTGCTCATTTCTCAACAGTCATACTCACCTTGATGTTGTGCCTTCAGATAAGCATTGAGTTGGGTT
 AGATATGCTGTGGATCACACTATTGATATCGATCCATCTAAATCAGTTGTGAATTGGCTTATGGGTTAC
 TTGAACTGTCAGGTTATCCATCACTTGTTCCTGATATGCCACAATTGAGACAGCCAGAAGTTCTAGA
 AGGTTTGTGTCATTTCGTAAGAAATGGAATCTCAACTACAAGGTTATGCTTTATTACGGAGCTTGGAAA
 GCAACATTTCGTAACCTTAACGAAGTTGGAAAGCACTACTATATTCAGGGTTCTCAAATCACAAAAAAG
 ACCGTGTAA

SEQ ID NO: 20

(O809D6 $\Delta 6$ -desaturase from *Ostreococcus* RCC809)
 1 MGKGARNPGARAWKSTLEPHAVAKSFDRRWVKVDGVEYDVTDFKHPGGSVIYYMLSNLNTGA
 61 DATEAFKEFHYSKARKALALPQREPEDASPVEDANMLKDFAKWRKDLEREGFFKPSF
 121 AHVAYRFAELAAMPALGTALMYARWHATSVPVTACFFGARCGWVQHEGGHSSLTGSIWWD
 181 KRIQAFTAGFGLASSGDMWNLNHNKHHATPQKVRHMDLDLTPAVAFFNTAVEENRPRKF
 241 SKLWLRVQAWTFVPTVSLVLLAWMYLLHPRHIARRKNYEEAAWIVAHHVIRTSVIKAVT
 301 GYSWITCYGLFLSTMWVSGCYLFAHFSTSHTHLDVVPSPDKHLSWVR YAVDHTIDIDPSKS
 361 VVNWLMGYLNCQVIHHLFPDMPQFRQPEVSRFRVSPFAKKWNLNYKVMSSYYGAWKATFGNL
 421 NEVGKHYIYQSQITKKTIV-

SEQ ID NO: 21

(codon-optimised FcEL06 $\Delta 6$ -Elongase from *Fragilariopsis* *cylindrus* CCMP 1102)
 ATGGATGAATACAAGGCAACTTTAGAGAGTGTGGAGATGCTATAATAACAATGGGCAGATCCTGAGAGT
 CAATTTACTGGTTTTACAAGGGATGGTTTTCTTACAGATTTACCTCAGCTTTTTCAGTATAGCACTTGTT
 TACGTGTGTTTCGTTATTATCGGTAGTCAAGTTATGAAGGTGCTTCTGCTATTGATCCTTACCCAATA
 AAGTTTTTCTACAATGTTTCTCAGATCATGTTGTGTGCATACATGACTATAGAAGCTTGCCTTTTGGCA
 TATAGAAACGGATACACAATCATGCCTTGTGTTGGTTATAATAGGATGATCCAGCTATAGGAAACCTC
 TTATGGCTCTTTTACGTTTCAAAAGTGTGGGATTTCTGGGATACCATCTTCATTGTTCTTGGTAAGAAA
 TGGAGACAACCTCAGTTTCTTACATGTGTATCATCACACTACAATCTTCTCTTACTGGTTAAATGCT

- continued

AACGTTTTCTATGATGGAGATATATACCTTACAATCGCATTGAATGTTTCATACATACTGTGATGTAC
 ACATACTACTTTATCTGTATGCACACCAAGGATAAGAAAACCTGGAAAGTCTTTGCCTATATGGTGAAG
 TCTTCACTCACACTTTTGAATTATTTTCAGTTCATCACCATGATGTCACAGGGACTCTATTTAATAATT
 TTCGGTTGCGAGAGTTTGTCTATAAGGGTTACCGCTACTTACGTTGTGTACATACTTTCTTTGTTTTTC
 CTCTTCGCTCAATTTTTCGTGGCATCTTACATGCAGCCAAAGAAATCAAAAACCTGCTTGA

SEQ ID NO: 22

(FcELO6 Δ6-Elongase from *Fragilariopsis cylindrus* CCMF
 1102)

1 MDEYKATLESVGDALIIQWADPESQFTGFTKGWFLTDPTSAFSAIALVYVLFVIIIGSQVMKV
 61 LPATDPYPIKFFYNVQSIMLCAYMTIEACLLAYRNGYTIMPCVGYNRDDPAIGNLLWLFY
 121 VSKVDFDWDITIFIVLGGKWRQLSFLHVYHHTTIFLFWLNNANVFYDGIYLTIALNGFIH
 181 TVMYTYFYICMHTKDKKTGKSLPIWKKSSLTLLQLPQFITMMSQGLYLIIFGCESLSIRV
 241 TATYVVYILSLFFLFAQFFVASYMOPKKSHTA-

SEQ ID NO: 23

(codon-optimised CeELO6 Δ6-elongase from *Caenorhabditis*
elegans)

ATGGCTCAGCACCCACTCGTTCAGAGTTACTTGATGTTAAATTCGATACAAAGAGGTCGTGGCAATA
 GCAACTCATGGTCTCAAAAATTTCCCTGATGCTGAAGGAAGAAAGTTTTTCGAGATCATTTGATGTT
 ACTATTCAAGCTAGTATACTCTACATGGTTGTGGTTTTTGGTACTAAATGGTTCATGAGAAACAGGCAA
 CCTTTCAGTTAAACAATCCCACTTAACATATGGAACCTTCAATTTGGCTGCATTCTCAATCGCTGGAGCA
 GTGAAGATGACCCCTGAGTTTTTCGGAACATATGCTAACAAGGGTATTTGGCATCATACTGTAAGGTT
 TTCGATTTACCAAAGGAGAAAACGGTTACTGGGTTTGGCTTTTCATGGCTAGTAAGCTTTTTGAGTTG
 GTGGATACTATCTTCTTGTTTTTGAGAAAAGGCCACTCATGTTCTCCATTGGTACCATCACATCCTC
 ACAATGATATACGCTTGGTACTCTCACCTCTTACCCAGGATTCACAGATACGGTATTTACTTGAAC
 TTTGTGGTTCCAGCATTATGTAATCTTATTAATCTTCCAGATCAATGAAGATCAGGGTTCCAGGATTT
 ATTGCTCAAGCAATCACAAGTTTACAAATAGTGCAGTTCATTATCTCTTGTGCTGTTCTTGCACATTTG
 GGTATCTCATGCATTTTACCAATGCTAACTGCGATTTTGAACCTTCTGTGTTCAAATGGCTGTTTTT
 ATGGATACTACATACCTCGCACTCTTCTGTAATTTCTTCTTCTCAGTCATATGTTCTCAGGGGTGTAAG
 GATAAGTACAAAGCTGTTCCAAAGAAAAGAAATAACTGA

SEQ ID NO: 24

(CeELO6 Δ6-elongase from *Caenorhabditis elegans*)

1 MAQHPLVQRLLDVKFDTKRFVAIATHGPKNFPDAEGRKFFADHFDVTIQASILYMVVVFVFG
 61 TKWFMNRNRPQFLTIPLNIWNFILAAPSIAGAVKMTPEFFGTIANKGIVASYKVFDFTK
 121 GENGYVWVWLFMASKLFELVDITIFLVLRKRPLMFLHWYHHILMTMIYAWYSHPLTPGFNRYG
 181 IYLNPFVVAHAFMYSYFLRSMKIRVPGFIAQAITSLQIVQFIIISCAVLAHLGYLMHFTNAN
 241 CDFEPSVFKLAVFMDTTYLALFVNFFLQSYVLRGGKDKYKAVPKKNN-

SEQ ID NO: 25

(codon-optimised TpDesK Δ4-desaturase from *Thalassiosira*
pseudonana)

ATGGGTAATGGTAATCTTCCAGCATCTACAGCACAACTCAAGTCAACAAGTAAACCTCAACAGCAACAC
 GAGCACAGAACAACTCAGTAAATCTGAATTGGCACAACATAACACTCCTAAGTCTGCTTGGTGTGCAGTT
 CATTCAACTCTGCTACAGATCCAAGTCACTCTAATAACAACAGCATGCACACCTTGTGATATT
 ACAGATTTTCGCTTCTAGACATCCAGGAGGAGATTTGATCTTTTGGCTTCCAGAAAAGATGCAAGTGTG
 CTCTTCGAGACCTACCACCTAGGGGAGTTCCAACTTCATTAATCAAAGCTTTCAGATCGGTGTTATG

- continued

GAAGAGGAAGCTTTTAGAGATAGTTTCTACTCTTGGACAGATTCTGATTTCTACACCGTTCTTAAGAGA
 AGGGTTTGGAAAGATTAGAGGAAAGGGGACTTGATAGAAAGGGTTCAAAGAGATTTGGATCAAGGCT
 TTATTTCTCTTAGTTGGATTCTGGTACTGTCTTTACAAGATGTACACTACATCAGATATAGATCAATAC
 GGAATAGCTATTGCATATAGTATCGAATGGTACTTTGCTGCATTATCGGTACATGCATACAACAT
 GATGGAACCACCGTGTCTTTCGCACAGAACAAGCTTTTGAACAAGTTGGCTGGATGGACACTCGATATG
 ATCGGTGCTTCTGCATTACCTGGGAATTGCAGCATATGCTCGGTATCACCCCTTACACTAATGTTCTT
 GATGGAGTGGAGGAAGAGAGAAAAGGGGAGAGGATGTGGCTTTGGAAGAGAAGGATCAAGAGTCA
 GATCCAGATGTTTTCTTCTTCCCTCTCATGAGAATGCATCCACATCACCCACTAGTTGGTACCAT
 AAATATCAGCACCTTTATGCTCCTCCACTTTGCAATTAATGACCCCTGCTAAGGTGTTTCAACAGGAT
 TTCGAAGTTGCAACATCGGAAGATTGTACCATATTGATGCTAACGTTAGATATGGTTCAAGTTTGGAAAT
 GTGATGAGATTCTGGGCTATGAAAGTTATCACAAATGGGATACATGATGGGTTTGCCTATTTACTTTCAT
 GGAGTTCTCAGGGGAGTGGGCTTTTTCTGTTATCGGACACCTTGCATGTGGTGAACCTTTAGCTACTATG
 TTCATAGTTAACCATGTGATTGAGGGAGTGGTTATGGTACAAAAGATCTTGTGGAGGTGCATCTCAC
 GGAGATGAAAAGAAAATGTGAAAGCTACAACCGTTTTAGGTGATACCCCAATGGAGAAAAC TAGAGAA
 GAGGCTCTCAAGTCAAACAGTAACAACAACAAGAAAAGGGAGAAAAGAACTCAGTTCTAGTGTGCCA
 TTTAATGATTGGGCTGCAGTGAATGCCAGACTTCTGTTAACTGGTCTCCTGGTTCATGGTTTTGGAAT
 CATTTAGTGGAGGTTTGTCTCACCAATCGAGCATCACCTCTCCCAAGTATATGTCATACTAACTAC
 TGCCACATTCAGATGTTGTGGAATCTACATGTGCTGAGTACGGTGTGCCATATCAGTCTGAATCAAAC
 TTGTTCTGTGCATACGGAAAGATGATCTCACATTTGAAGTTCTCGGTAAGGCTAAGTGCAGTGA

SEQ ID NO: 26

(TpDesK A4-desaturase from *Thalassiosira pseudonana*)

1 MGNGLPASTAQLKSTSKPQQQHEHRTISKSELAQHNTPKSAWCAVHSTPATDPSHSNNK
 61 QHAHLVLDITDFASRHPGGDLILLASGKDASVLPETYHPRGVPTSLIQKLQIGVMEEBFA
 121 RDSFYSWTSDSDFYTLKRRVVERLEERGLDRRSKEIWKALFLLVGFWYCLYKMYTSD
 181 IDQYGIATAYSIGMGTFAAFIGTCIQHDGNHGAFQNKLLNKLAWTLDMIGASAFWEL
 241 QHMLGHPYTNVLDGVEEERKERGEDVALEEKDQESDPDVFSSFPLMRMHPHHTTSWYHK
 301 YQHLYAPPLFALMTLAKVFQDQFEVATSGRLYHIDANVRYGSVWVNMRFWAMKVIITMGYM

SEQ ID NO: 27

(codon-optimised Hpw-3, a w3-desaturase from
Hyaloperonospora parasitica)

1 ATGGCTACTAAACAATCAGTTGCTTTTCTACTTTGACTGATCTTAAAGATCTCTTCCT
 61 TCTGAGTGTGTTGAATCTTCTTTCCTCTTTACTATACTTAGATCTTTGGTT
 121 TTTGCTGGTCTCTTCTGCTTCTCTTTCTTACGCTCTTGTCAACCTTTGGTTCAAAC
 181 TTTTACCCTCTTAGAGTTGCTCTTATTGCTGGATACACTGTTTTTCAAGGAGTTATTTTC
 241 TGGGGATTTTCACTATTGGTCATGATGCTGGTATGGTCTTTTTCTAGATATCCTGTT
 301 CTTAACTCACTGTTGGAACACTTATGCATCTCTTATTTGACTCCTTTTGAATCTTGG
 361 AAGTTGACTCATAGACATCATCATAAAACACTGGAAATATCGATAGAGATGAGATCTTC
 421 TACCCFCAAAGAGAATCTGATGATCATCTGTTTCTAGACATCTTACTTTCACCTTGGGA
 481 GCTGCTGGTTCGCTTACCTTGTGAGGGTTTTCCACCTAGAAAATTGAATCATTACAAT
 541 CCTTTCGAGCCATTGTTGAGAGAAGAGTTTCTGCTGTTGTTATCTCTATCTTTGGCTCAG
 601 TTTTTCGTTGCAGGATTTGCTATTTACTTGTGTTTCCAGGTTGGAGTTCCAGGCTGTTGCT
 661 CTTTACTATTACGGTCTATCTCGTTTTTGGTACTATGCTTGTATTACTACTTTTCTT

- continued

721 CATCATAACGATGAAGAGACTCCTTGGTACGGTGATGAGGATTGGTCTTACGTTAAGGGT
 781 AACTTGTCTTCTGTTGATAGATCTTACGGTCTCTTATCGATAACTTGTCTCATAACATC
 841 GGTACTCATCAAGTTCATCATCTTTTCCCAATCATCCCTCATTACAAATTAAGCCTGCT
 901 ACAGCTGCTTTCAGAAGAGCTTCCACATCTTGTAGAAAGTCTGATGAAAGAATTTG
 961 CAGGCTTTTACAGAATTGGTAGATTGTATGCTAAATATGGTGTGCTGATTCTTCTGCT
 1021 AAATTGTTTACATTGAAGGAAGCTCAACTTACTTCTAAAGCTGCTTCTGATGCTAAAGCT
 1081 GCTTGA

SEQ ID NO: 28

(Hpw-3, a w3-desaturase from *Hyaloperonospora parasitica*)

1 MATKQSVAPPTLTDLKRSLPSECFESSLPLSLYTLRSLVFAGSLAVLSYALAQPLVQN
 61 FYPLRVALIAGYTVFQGVIFWGFPTIGHDAGHGAFSRYPVLNFTVGLMHSLLILTPFESW
 121 KLTHRHHKNTGNIDRDEIFYPQRESDDHPVSRHLTFTLGAAWFAYLVEGFPPRKLNHYN
 181 PFEPLFERRVSAVVISILAQFFVAGLSIYLCFQVGVQAVALLYYPGFVFPGLMLVITTFPL
 241 HHNDEETPWYGDWEDWSYVKGNLSSVDRSYGPLIDNLSHNIGTHQVHHLFPIIPHYKPKPA
 301 TAAFRRAFPHLVRKSDERILQAFYRIGRLYAKYGVADSSAKLFTLKEAQLTСКАASDAKA
 361 A-

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 28

<210> SEQ ID NO 1

<211> LENGTH: 1371

<212> TYPE: DNA

<213> ORGANISM: *Ostreococcus tauri*

<400> SEQUENCE: 1

atgtgtgttg agaccgagaa caacgatgga atccctactg tggagatcgc tttcgatgga 60
 gagagagaaa gagctgaggc taacgtgaag ttgtctgctg agaagatgga acctgctgct 120
 ttggctaaga ccttcgctag aagatacgtg gttatcgagg gagttgagta cgatgtgacc 180
 gatttcaaac atccctggagg aaccgtgatt ttctacgctc tctctaacac tggagctgat 240
 gctactgagg ctttcaagga gttccaccac agatctagaa aggotaggaa ggctttggct 300
 gctttgcctt ctagacctgc taagaccgct aaagtggatg atgctgagat gctccaggat 360
 ttcgctaagt ggagaaagga gttggagagg gacggattct tcaagccttc tcctgctcat 420
 gttgcttaca gattcgctga gttggctgct atgtacgctt tgggaaccta cttgatgtac 480
 gctagatacg ttgtgcctc tgtgttggtt tacgcttgct tcttcggagc tagatgtgga 540
 tgggttcaac atgagggagg acattcttct ttgaccggaa acatctggtg ggataagaga 600
 atccaagctt tcaactgctg attcggattg gctggatctg gagatatgtg gaactccatg 660
 cacaacaagc accatgctac tcctcaaaaa gtgaggcagc atatggattt ggataccact 720
 cctgctgttg ctttcttcaa caccgctgtg gaggataata gacctagggg attctctaag 780
 tactggctca gattgcaagc ttggacctc attcctgtga cttctggatt ggtgttgctc 840
 ttctggatgt tcttctcca tccttctaag gctttgaagg gaggaaagta cgaggagctt 900
 gtgtggatgt tggctgctca tgtgattaga acctggacca ttaaggctgt tactggattc 960

-continued

```

accgctatgc aatcctacgg actcttcttg gctacttctt gggtttccgg atgctacttg 1020
ttcgctcact tctctacttc tcacacccat ttggatggtg ttctgctga tgagcatttg 1080
tcttgggtta ggtacgctgt ggatcacacc attgatatcg atccttctca gggatggggt 1140
aactggttga tgggatactt gaactgccaa gtgattcacc acctcttccc ttctatgcct 1200
caattcagac aacctgaggt gtccagaaga ttcggtgctt tcgctaagaa gtggaacctc 1260
aactacaagg tgatgactta tgctggagct tggaaggcta ctttgggaaa cctcgataat 1320
gtgggaaagc actactacgt gcacggacaa cattctggaa agaccgcttg a 1371

```

<210> SEQ ID NO 2

<211> LENGTH: 456

<212> TYPE: PRT

<213> ORGANISM: *Ostreococcus tauri*

<400> SEQUENCE: 2

```

Met Cys Val Glu Thr Glu Asn Asn Asp Gly Ile Pro Thr Val Glu Ile
1           5           10           15
Ala Phe Asp Gly Glu Arg Glu Arg Ala Glu Ala Asn Val Lys Leu Ser
20           25           30
Ala Glu Lys Met Glu Pro Ala Ala Leu Ala Lys Thr Phe Ala Arg Arg
35           40           45
Tyr Val Val Ile Glu Gly Val Glu Tyr Asp Val Thr Asp Phe Lys His
50           55           60
Pro Gly Gly Thr Val Ile Phe Tyr Ala Leu Ser Asn Thr Gly Ala Asp
65           70           75           80
Ala Thr Glu Ala Phe Lys Glu Phe His His Arg Ser Arg Lys Ala Arg
85           90           95
Lys Ala Leu Ala Ala Leu Pro Ser Arg Pro Ala Lys Thr Ala Lys Val
100          105          110
Asp Asp Ala Glu Met Leu Gln Asp Phe Ala Lys Trp Arg Lys Glu Leu
115          120          125
Glu Arg Asp Gly Phe Phe Lys Pro Ser Pro Ala His Val Ala Tyr Arg
130          135          140
Phe Ala Glu Leu Ala Ala Met Tyr Ala Leu Gly Thr Tyr Leu Met Tyr
145          150          155          160
Ala Arg Tyr Val Val Ser Ser Val Leu Val Tyr Ala Cys Phe Phe Gly
165          170          175
Ala Arg Cys Gly Trp Val Gln His Glu Gly Gly His Ser Ser Leu Thr
180          185          190
Gly Asn Ile Trp Trp Asp Lys Arg Ile Gln Ala Phe Thr Ala Gly Phe
195          200          205
Gly Leu Ala Gly Ser Gly Asp Met Trp Asn Ser Met His Asn Lys His
210          215          220
His Ala Thr Pro Gln Lys Val Arg His Asp Met Asp Leu Asp Thr Thr
225          230          235          240
Pro Ala Val Ala Phe Phe Asn Thr Ala Val Glu Asp Asn Arg Pro Arg
245          250          255
Gly Phe Ser Lys Tyr Trp Leu Arg Leu Gln Ala Trp Thr Phe Ile Pro
260          265          270
Val Thr Ser Gly Leu Val Leu Leu Phe Trp Met Phe Phe Leu His Pro
275          280          285

```

-continued

Ser Lys Ala Leu Lys Gly Gly Lys Tyr Glu Glu Leu Val Trp Met Leu
 290 295 300

Ala Ala His Val Ile Arg Thr Trp Thr Ile Lys Ala Val Thr Gly Phe
 305 310 315 320

Thr Ala Met Gln Ser Tyr Gly Leu Phe Leu Ala Thr Ser Trp Val Ser
 325 330 335

Gly Cys Tyr Leu Phe Ala His Phe Ser Thr Ser His Thr His Leu Asp
 340 345 350

Val Val Pro Ala Asp Glu His Leu Ser Trp Val Arg Tyr Ala Val Asp
 355 360 365

His Thr Ile Asp Ile Asp Pro Ser Gln Gly Trp Val Asn Trp Leu Met
 370 375 380

Gly Tyr Leu Asn Cys Gln Val Ile His His Leu Phe Pro Ser Met Pro
 385 390 395 400

Gln Phe Arg Gln Pro Glu Val Ser Arg Arg Phe Val Ala Phe Ala Lys
 405 410 415

Lys Trp Asn Leu Asn Tyr Lys Val Met Thr Tyr Ala Gly Ala Trp Lys
 420 425 430

Ala Thr Leu Gly Asn Leu Asp Asn Val Gly Lys His Tyr Tyr Val His
 435 440 445

Gly Gln His Ser Gly Lys Thr Ala
 450 455

<210> SEQ ID NO 3

<211> LENGTH: 873

<212> TYPE: DNA

<213> ORGANISM: Physcomitrella patens

<400> SEQUENCE: 3

```

atggaagtgt ttgagagggt ctacggagag ttggatggaa aggtttccca aggagtgaac    60
gctttgttgg gatccttcgg agttgagttg actgataccc caactactaa gggattgcca    120
ctcgttgatt ctccaactcc aattgtgttg ggagtgctg tttacttgac catcgtgatc    180
ggaggattgc tttggatcaa ggctagagat ctcaagccaa gagcttctga gccattcttg    240
ttgcaagctt tgggtgttgg gcacaacttg ttctgcttcg ctttgtctct ttacatgtgc    300
gtgggtatcg cttaccaagc tatcacctgg agatattcct tgtggggaaa cgcttataac    360
ccaaagcaca aggagatggc tatcctcgtt tacctcttct acatgtccaa gtacgtggag    420
ttcatggata cegtgatcat gatcctcaag agatccacca gacagatttc tttcctccac    480
gtgtaccacc attcttctat ctcccttacc tgggtgggcta ttgctcatca tgctccagga    540
ggagaggcct attggagtgc tgctctcaac tctggagtgc atgtgttgat gtacgcttac    600
tacttcttgg ctgcttgctt gagatcttcc ccaaagctca agaacaagta cctcttctgg    660
ggaagatacc tcaccaaat ccagatgttc cagttcatgc tcaacttggg gcaagcttac    720
tacgatatga aaaccaacgc tccatatcca caatggctca tcaagatcct cttctactac    780
atgatctccc tcttgttctt cttcggaaac ttctacgtgc aaaagtacat caagccatcc    840
gatggaaagc aaaagggagc taagaccgag tga                                873

```

<210> SEQ ID NO 4

<211> LENGTH: 290

<212> TYPE: PRT

<213> ORGANISM: Thraustochytrium sp.

-continued

<400> SEQUENCE: 4

Met Glu Val Val Glu Arg Phe Tyr Gly Glu Leu Asp Gly Lys Val Ser
 1 5 10 15
 Gln Gly Val Asn Ala Leu Leu Gly Ser Phe Gly Val Glu Leu Thr Asp
 20 25 30
 Thr Pro Thr Thr Lys Gly Leu Pro Leu Val Asp Ser Pro Thr Pro Ile
 35 40 45
 Val Leu Gly Val Ser Val Tyr Leu Thr Ile Val Ile Gly Gly Leu Leu
 50 55 60
 Trp Ile Lys Ala Arg Asp Leu Lys Pro Arg Ala Ser Glu Pro Phe Leu
 65 70 75 80
 Leu Gln Ala Leu Val Leu Val His Asn Leu Phe Cys Phe Ala Leu Ser
 85 90 95
 Leu Tyr Met Cys Val Gly Ile Ala Tyr Gln Ala Ile Thr Trp Arg Tyr
 100 105 110
 Ser Leu Trp Gly Asn Ala Tyr Asn Pro Lys His Lys Glu Met Ala Ile
 115 120 125
 Leu Val Tyr Leu Phe Tyr Met Ser Lys Tyr Val Glu Phe Met Asp Thr
 130 135 140
 Val Ile Met Ile Leu Lys Arg Ser Thr Arg Gln Ile Ser Phe Leu His
 145 150 155 160
 Val Tyr His His Ser Ser Ile Ser Leu Ile Trp Trp Ala Ile Ala His
 165 170 175
 His Ala Pro Gly Gly Glu Ala Tyr Trp Ser Ala Ala Leu Asn Ser Gly
 180 185 190
 Val His Val Leu Met Tyr Ala Tyr Tyr Phe Leu Ala Ala Cys Leu Arg
 195 200 205
 Ser Ser Pro Lys Leu Lys Asn Lys Tyr Leu Phe Trp Gly Arg Tyr Leu
 210 215 220
 Thr Gln Phe Gln Met Phe Gln Phe Met Leu Asn Leu Val Gln Ala Tyr
 225 230 235 240
 Tyr Asp Met Lys Thr Asn Ala Pro Tyr Pro Gln Trp Leu Ile Lys Ile
 245 250 255
 Leu Phe Tyr Tyr Met Ile Ser Leu Leu Phe Leu Phe Gly Asn Phe Tyr
 260 265 270
 Val Gln Lys Tyr Ile Lys Pro Ser Asp Gly Lys Gln Lys Gly Ala Lys
 275 280 285
 Thr Glu
 290

<210> SEQ ID NO 5

<211> LENGTH: 1320

<212> TYPE: DNA

<213> ORGANISM: *Thraustochytrium* sp.

<400> SEQUENCE: 5

atgggaaaag gatctgaggg aagatctgct gctagagaga tgactgctga ggctaacgga 60
 gataagagaa agaccatcct cattgagga gtgtgtacg atgctaccaa cttcaaacac 120
 ccaggaggtt ccattattaa cttcctcacc gagggagaag ctggagtga tgctacccaa 180
 gcttacagag agttccatca gagatccgga aaggctgata agtacctcaa gtcctccca 240

-continued

```

aagttggatg cttctaaggt ggagtctagg ttctctgcta aggagcaggc tagaaggac 300
gctatgacca gggattacgc tgctttcaga gaggagtgg ttgctgaggg atacttcgat 360
ccatctatcc cacacatgat ctacagagtg gtggagattg tggctttggt cgctttgtct 420
ttctggttga tgtctaaggt ttctccaacc tctttggttt tgggagtggg gatgaacgga 480
atcgctcaag gaagatgctg atgggttatg catgagatgg gacacggatc tttcactgga 540
gttatctggc tegatgatag gatgtgctgag ttcttctacg gagttggatg tggaatgtct 600
ggacactact ggaagaacca gcatttcaag caccatgctg ctccaaacag attggagcac 660
gatgtggatt tgaacacctt gccactcgtt gctttcaacg agagagtgtg gaggaagggt 720
aagccaggat ctttgttggc tttgtggctc agagttcagg cttatttgtt cgctccagtg 780
tcttgcttgt tgatcggatt gggatggacc ttgtacttgc acccaagata tatgctcagg 840
accaagagac atatggagtt tgtgtggatc ttcgctagat atatcggatg gttctccttg 900
atgggagctt tgggatatto tcttggaaact tctgtgggaa tgtacctctg ctctttcgga 960
cttgatgca tctacatctt cctccaattc gctgtgtctc ataccattt gccagttacc 1020
aaccagagg atcaattgca ttgcttgag tacgctgctg atcataccgt gaacatctct 1080
accaagtctt ggttggttac ctggtggatg tctaacctca acttccaaat cgagcatcat 1140
ttgttcccaa cgcctccaca attcaggttc aaggagatct ctccaagagt tgaggctctc 1200
ttcaagagac ataacctccc ttaactacgat ttgccataca cctctgctgt ttctactacc 1260
ttcgctaacc tctactctgt tggacattct gttggagctg ataccaagaa gcaggattga 1320

```

<210> SEQ ID NO 6

<211> LENGTH: 439

<212> TYPE: PRT

<213> ORGANISM: Thraustochytrium sp.

<400> SEQUENCE: 6

```

Met Gly Lys Gly Ser Glu Gly Arg Ser Ala Ala Arg Glu Met Thr Ala
1          5          10          15
Glu Ala Asn Gly Asp Lys Arg Lys Thr Ile Leu Ile Glu Gly Val Leu
20          25          30
Tyr Asp Ala Thr Asn Phe Lys His Pro Gly Gly Ser Ile Ile Asn Phe
35          40          45
Leu Thr Glu Gly Glu Ala Gly Val Asp Ala Thr Gln Ala Tyr Arg Glu
50          55          60
Phe His Gln Arg Ser Gly Lys Ala Asp Lys Tyr Leu Lys Ser Leu Pro
65          70          75          80
Lys Leu Asp Ala Ser Lys Val Glu Ser Arg Phe Ser Ala Lys Glu Gln
85          90          95
Ala Arg Arg Asp Ala Met Thr Arg Asp Tyr Ala Ala Phe Arg Glu Glu
100         105         110
Leu Val Ala Glu Gly Tyr Phe Asp Pro Ser Ile Pro His Met Ile Tyr
115         120         125
Arg Val Val Glu Ile Val Ala Leu Phe Ala Leu Ser Phe Trp Leu Met
130         135         140
Ser Lys Ala Ser Pro Thr Ser Leu Val Leu Gly Val Val Met Asn Gly
145         150         155         160
Ile Ala Gln Gly Arg Cys Gly Trp Val Met His Glu Met Gly His Gly
165         170         175

```

-continued

Ser Phe Thr Gly Val Ile Trp Leu Asp Asp Arg Met Cys Glu Phe Phe
 180 185 190

Tyr Gly Val Gly Cys Gly Met Ser Gly His Tyr Trp Lys Asn Gln His
 195 200 205

Ser Lys His His Ala Ala Pro Asn Arg Leu Glu His Asp Val Asp Leu
 210 215 220

Asn Thr Leu Pro Leu Val Ala Phe Asn Glu Arg Val Val Arg Lys Val
 225 230 235

Lys Pro Gly Ser Leu Leu Ala Leu Trp Leu Arg Val Gln Ala Tyr Leu
 245 250 255

Phe Ala Pro Val Ser Cys Leu Leu Ile Gly Leu Gly Trp Thr Leu Tyr
 260 265 270

Leu His Pro Arg Tyr Met Leu Arg Thr Lys Arg His Met Glu Phe Val
 275 280 285

Trp Ile Phe Ala Arg Tyr Ile Gly Trp Phe Ser Leu Met Gly Ala Leu
 290 295 300

Gly Tyr Ser Pro Gly Thr Ser Val Gly Met Tyr Leu Cys Ser Phe Gly
 305 310 315 320

Leu Gly Cys Ile Tyr Ile Phe Leu Gln Phe Ala Val Ser His Thr His
 325 330 335

Leu Pro Val Thr Asn Pro Glu Asp Gln Leu His Trp Leu Glu Tyr Ala
 340 345 350

Ala Asp His Thr Val Asn Ile Ser Thr Lys Ser Trp Leu Val Thr Trp
 355 360 365

Trp Met Ser Asn Leu Asn Phe Gln Ile Glu His His Leu Phe Pro Thr
 370 375 380

Ala Pro Gln Phe Arg Phe Lys Glu Ile Ser Pro Arg Val Glu Ala Leu
 385 390 395 400

Phe Lys Arg His Asn Leu Pro Tyr Tyr Asp Leu Pro Tyr Thr Ser Ala
 405 410 415

Val Ser Thr Thr Phe Ala Asn Leu Tyr Ser Val Gly His Ser Val Gly
 420 425 430

Ala Asp Thr Lys Lys Gln Asp
 435

<210> SEQ ID NO 7
 <211> LENGTH: 903
 <212> TYPE: DNA
 <213> ORGANISM: *Ostreococcus tauri*

<400> SEQUENCE: 7

```

atgtctgctt ctggagcttt gttgctgct attgctttcg ctgcttacgc ttacgctacc    60
tacgcttatg ctttcgagtg gtctcatgct aacggaatcg ataacgtgga tgctagagag    120
tggattggag ctttgccttt gagactccct gcaattgcta ccaccatgta cctcttgctc    180
tgccttgctg gacctagatt gatggctaag agggaggcct ttgatcctaa gggattcatg    240
ctcgcctaca acgcctacca aaccgctttc aacgttgtgg tgctcggaat gttcgcctaga    300
gagatctctg gattgggaca acctgtttgg ggatctacta tgccttgag cgataggaag    360
tcctcaaga tttgttggg agtgtgctc cattacaaca ataagtacct cgagttgttg    420
gatactgtgt tcatggtggc taggaaaaag accaagcagc tctctttctt gcatgtgtac    480
    
```

-continued

```

catcatgctt tgttgatttg ggcttggtgg cttgtttgtc atctcatggc taccaacgat    540
tgcacatgat cttatttcgg agctgcttgc aactctttca tccacatcgt gatgtactcc    600
tactacctca tgtctgcttt gggaattaga tgccttgga agagatatat caccaggct      660
cagatgttgc aattcgtgat cgtgttcgct catgctgttt tctgtctcag acaaaagcac    720
tgcctgttta ctttgccttg ggcacaaatg ttcgtgatga caaatatggt ggtgctcttc    780
ggaaacttct acctcaaggc ttactctaac aagtctaggg gagatggagc ttcttctggt    840
aagcctgctg agactactag agcaccttct gtgagaagaa ccaggctccag gaagatcgat    900
tga                                                                           903

```

```

<210> SEQ ID NO 8
<211> LENGTH: 300
<212> TYPE: PRT
<213> ORGANISM: Ostreococcus tauri

```

```

<400> SEQUENCE: 8

```

```

Met Ser Ala Ser Gly Ala Leu Leu Pro Ala Ile Ala Phe Ala Ala Tyr
1      5      10      15
Ala Tyr Ala Thr Tyr Ala Tyr Ala Phe Glu Trp Ser His Ala Asn Gly
20     25     30
Ile Asp Asn Val Asp Ala Arg Glu Trp Ile Gly Ala Leu Ser Leu Arg
35     40     45
Leu Pro Ala Ile Ala Thr Thr Met Tyr Leu Leu Phe Cys Leu Val Gly
50     55     60
Pro Arg Leu Met Ala Lys Arg Glu Ala Phe Asp Pro Lys Gly Phe Met
65     70     75     80
Leu Ala Tyr Asn Ala Tyr Gln Thr Ala Phe Asn Val Val Val Leu Gly
85     90     95
Met Phe Ala Arg Glu Ile Ser Gly Leu Gly Gln Pro Val Trp Gly Ser
100    105    110
Thr Met Pro Trp Ser Asp Arg Lys Ser Phe Lys Ile Leu Leu Gly Val
115    120    125
Trp Leu His Tyr Asn Asn Lys Tyr Leu Glu Leu Leu Asp Thr Val Phe
130    135    140
Met Val Ala Arg Lys Lys Thr Lys Gln Leu Ser Phe Leu His Val Tyr
145    150    155    160
His His Ala Leu Leu Ile Trp Ala Trp Trp Leu Val Cys His Leu Met
165    170    175
Ala Thr Asn Asp Cys Ile Asp Ala Tyr Phe Gly Ala Ala Cys Asn Ser
180    185    190
Phe Ile His Ile Val Met Tyr Ser Tyr Tyr Leu Met Ser Ala Leu Gly
195    200    205
Ile Arg Cys Pro Trp Lys Arg Tyr Ile Thr Gln Ala Gln Met Leu Gln
210    215    220
Phe Val Ile Val Phe Ala His Ala Val Phe Val Leu Arg Gln Lys His
225    230    235    240
Cys Pro Val Thr Leu Pro Trp Ala Gln Met Phe Val Met Thr Asn Met
245    250    255
Leu Val Leu Phe Gly Asn Phe Tyr Leu Lys Ala Tyr Ser Asn Lys Ser
260    265    270
Arg Gly Asp Gly Ala Ser Ser Val Lys Pro Ala Glu Thr Thr Arg Ala

```

-continued

275	280	285	
Pro Ser Val Arg Arg Thr Arg Ser Arg Lys Ile Asp			
290	295	300	

<210> SEQ ID NO 9
 <211> LENGTH: 1368
 <212> TYPE: DNA
 <213> ORGANISM: Emiliana huxleyz

<400> SEQUENCE: 9

```

atgtcattgg ctgctaaga tgcagcctcg gcccaactcat ccgtcttggg ccctaagtat    60
cacggagcta caaataagtc aagaactgat gcagcagacc ttacagttag ttctatcgac    120
acttctaagg agatgatcat aaggggtcgt gtgtatgatg tctctgattt tattaaaagg    180
caccggggag gaagcattat taaactctcc ttaggttctg atgcaacaga cgcttataac    240
aacttcata ttaggtctaa aaaagcggat aaaatgttga gagctttgcc aagtagggcca    300
gtagcggatg gattcgctag agacgctttg tctgcagact tcgaggccct gagagcccaa    360
ctcgaggccg aaggttactt cgaaccgaat ctgtggcatg tagcttatcg agttgcgtaa    420
gtcgttgcta tgtactgggc ggttattaga cttatctggg cgggttattg gtttttagga    480
gccattgtag caggaatagc tcaggggaga tgcggttggc ttcagcatga ggggtgtcat    540
tattcgctca caggaatat taaacttgat cgacacatgc aaatgattat ctatggatta    600
ggttgcgtaa tgtccggttg ttattggaga aaccaacata acaagcacca tgcgacaccg    660
caaaagtgg gtgcagatcc agaccttcaa acaatgcctc tgggtgcgctt ccatggactc    720
atcggtgcta aggctagggg agcaggaagc tcgtggctag catggcaagc tccacttttc    780
tttgaggcgc ttatcacaac cctggtatct tttggttggc agttcgtcca acatccaaag    840
cacgcattga gagtaggaaa ccaactcgaa ttaggctata tggtcttacg atatgcttta    900
tggtatgcag cattcggctc tcttgggctt ggtggtgctt tcagattgta cgctttttat    960
gtggcagtcg gaggtacata tatcttcacg aactttgctg tgtctcacac acataaggat   1020
gttgttccac acgataagca tatttcttgg accttgattt ctgcaaacca taccactaat   1080
caatctaaca cacctctagt caattggtgg atggcctatc tgaattttca aattgaacat   1140
caccttttcc ctagcatgcc acaatataac catcctaaaa tctgcggaag agtgaacaaa   1200
ttgtttgaaa aacatggcgt agagtacgat gtcagaactt acgcgaagtc aatgcgtgat   1260
acatacgtga atctcttggc tgtgggaaat gcactcatt cccttcatca gagaaacgag   1320
ggattaacga ctaggagtc tgcggctggt agagttacag gtcattga                   1368

```

<210> SEQ ID NO 10
 <211> LENGTH: 455
 <212> TYPE: PRT
 <213> ORGANISM: Emiliana huxleyz

<400> SEQUENCE: 10

Met Ser Leu Ala Ala Lys Asp Ala Ala Ser Ala His Ser Ser Val Leu			
1	5	10	15
Asp Pro Lys Tyr His Gly Ala Thr Asn Lys Ser Arg Thr Asp Ala Ala			
20	25	30	
Asp Leu Thr Val Ser Ser Ile Asp Thr Ser Lys Glu Met Ile Ile Arg			
35	40	45	

-continued

Gly Arg Val Tyr Asp Val Ser Asp Phe Ile Lys Arg His Pro Gly Gly
 50 55 60
 Ser Ile Ile Lys Leu Ser Leu Gly Ser Asp Ala Thr Asp Ala Tyr Asn
 65 70 75 80
 Asn Phe His Ile Arg Ser Lys Lys Ala Asp Lys Met Leu Arg Ala Leu
 85 90 95
 Pro Ser Arg Pro Val Ala Asp Gly Phe Ala Arg Asp Ala Leu Ser Ala
 100 105 110
 Asp Phe Glu Ala Leu Arg Ala Gln Leu Glu Ala Glu Gly Tyr Phe Glu
 115 120 125
 Pro Asn Leu Trp His Val Ala Tyr Arg Val Ala Glu Val Val Ala Met
 130 135 140
 Tyr Trp Ala Gly Ile Arg Leu Ile Trp Ala Gly Tyr Trp Phe Leu Gly
 145 150 155 160
 Ala Ile Val Ala Gly Ile Ala Gln Gly Arg Cys Gly Trp Leu Gln His
 165 170 175
 Glu Gly Gly His Tyr Ser Leu Thr Gly Asn Ile Lys Leu Asp Arg His
 180 185 190
 Met Gln Met Ile Ile Tyr Gly Leu Gly Cys Gly Met Ser Gly Cys Tyr
 195 200 205
 Trp Arg Asn Gln His Asn Lys His His Ala Thr Pro Gln Lys Leu Gly
 210 215 220
 Ala Asp Pro Asp Leu Gln Thr Met Pro Leu Val Ala Phe His Gly Leu
 225 230 235 240
 Ile Gly Ala Lys Ala Arg Gly Ala Gly Lys Ser Trp Leu Ala Trp Gln
 245 250 255
 Ala Pro Leu Phe Phe Gly Gly Val Ile Thr Thr Leu Val Ser Phe Gly
 260 265 270
 Trp Gln Phe Val Gln His Pro Lys His Ala Leu Arg Val Gly Asn Gln
 275 280 285
 Leu Glu Leu Gly Tyr Met Ala Leu Arg Tyr Ala Leu Trp Tyr Ala Ala
 290 295 300
 Phe Gly His Leu Gly Leu Gly Gly Ala Phe Arg Leu Tyr Ala Phe Tyr
 305 310 315 320
 Val Ala Val Gly Gly Thr Tyr Ile Phe Thr Asn Phe Ala Val Ser His
 325 330 335
 Thr His Lys Asp Val Val Pro His Asp Lys His Ile Ser Trp Thr Leu
 340 345 350
 Tyr Ser Ala Asn His Thr Thr Asn Gln Ser Asn Thr Pro Leu Val Asn
 355 360 365
 Trp Trp Met Ala Tyr Leu Asn Phe Gln Ile Glu His His Leu Phe Pro
 370 375 380
 Ser Met Pro Gln Tyr Asn His Pro Lys Ile Cys Gly Arg Val Lys Gln
 385 390 395 400
 Leu Phe Glu Lys His Gly Val Glu Tyr Asp Val Arg Thr Tyr Ala Lys
 405 410 415
 Ser Met Arg Asp Thr Tyr Val Asn Leu Leu Ala Val Gly Asn Ala Ser
 420 425 430
 His Ser Leu His Gln Arg Asn Glu Gly Leu Thr Thr Arg Glu Ser Ala
 435 440 445
 Ala Val Arg Val Thr Gly His

-continued

450	455
<p><210> SEQ ID NO 11 <211> LENGTH: 1197 <212> TYPE: DNA <213> ORGANISM: <i>Phytophthora sojae</i></p>	
<p><400> SEQUENCE: 11</p>	
atggctat	ttt tgaacctga ggctgattct gctgctaacc tcgctactga ttctgaggct 60
aagcaaagac aattggctga ggctggatac actcatggtg aggggtgctcc tgctcctttg 120	
cctttggagt tgccctcaatt ctctctcaga gatctcagag ctgctattcc taagcactgc 180	
ttcgagagat ctttcgtgac ctccacctac tacatgatca agaacgtggt gacttgcgct 240	
gctttgttct acgctgctac ctccattgat agagctggag ctgctgctta tgttttgggg 300	
cctgtgtact ggttcttcca gggatcttac ttgactggag tgtgggttat cgcctcatgag 360	
tgtggacatc aggccttattg ctctctcagag gtgggtgaaca acttgattgg actcgtggtg 420	
cattctgctt tgttggtgcc ttaccactct tggagaatct ctcacagaaa gcaccattcc 480	
aacctggat cttgcgagaa cgatgaggtt ttcgttccctg tgaccagatc tgtggtggct 540	
tcttcttga acgagaccct ggaggattct cctctctacc aactctaccg tatcgtgtac 600	
atgttggtt tggatggat gcctggatac ctctcttca acgctactgg acctactaag 660	
tactggggaa agtctaggtc tcacttcaac ccttactccg ctatctatgc tgataggagg 720	
agatggatga tctgctctc cgatattttc ttgggtggct tgttgctgtt tttggctgct 780	
ttgggtgcaca ctttctcctt caacaccatg gtgaagtctt acgtggtgcc ttacttcatt 840	
gtgaacgctt acttggtgtt gattacctac ctccaacaca cggataccta catccctcat 900	
ttcagagagg gagagtggaa ttggttgaga ggagctttgt gcaactgtgga tagatcattt 960	
ggctccattcc tgcattctgt ggtgcataga atcgtggata cccatgtttg ccaccacatc 1020	
ttctccaaga tgcctttcta tcattgcgag gaggctacca acgctattaa gcctctctc 1080	
ggaaagtctt acttgaagga taccactctt gttcctggtg ctctctggag atcttacacc 1140	
cattgcaagt tctgtgagga tgatggaaag gtggtgttct acaagaacaa gctctag 1197	

<p><210> SEQ ID NO 12 <211> LENGTH: 398 <212> TYPE: PRT <213> ORGANISM: <i>Phytophthora sojae</i></p>	
<p><400> SEQUENCE: 12</p>	
Met Ala Ile Leu Asn Pro Glu Ala Asp Ser Ala Ala Asn Leu Ala Thr	1 5 10 15
Asp Ser Glu Ala Lys Gln Arg Gln Leu Ala Glu Ala Gly Tyr Thr His	20 25 30
Val Glu Gly Ala Pro Ala Pro Leu Pro Leu Glu Leu Pro His Phe Ser	35 40 45
Leu Arg Asp Leu Arg Ala Ala Ile Pro Lys His Cys Phe Glu Arg Ser	50 55 60
Phe Val Thr Ser Thr Tyr Tyr Met Ile Lys Asn Val Leu Thr Cys Ala	65 70 75 80
Ala Leu Phe Tyr Ala Ala Thr Phe Ile Asp Arg Ala Gly Ala Ala Ala	85 90 95

-continued

Tyr Val Leu Trp Pro Val Tyr Trp Phe Phe Gln Gly Ser Tyr Leu Thr
 100 105 110

Gly Val Trp Val Ile Ala His Glu Cys Gly His Gln Ala Tyr Cys Ser
 115 120 125

Ser Glu Val Val Asn Asn Leu Ile Gly Leu Val Leu His Ser Ala Leu
 130 135 140

Leu Val Pro Tyr His Ser Trp Arg Ile Ser His Arg Lys His His Ser
 145 150 155 160

Asn Thr Gly Ser Cys Glu Asn Asp Glu Val Phe Val Pro Val Thr Arg
 165 170 175

Ser Val Leu Ala Ser Ser Trp Asn Glu Thr Leu Glu Asp Ser Pro Leu
 180 185 190

Tyr Gln Leu Tyr Arg Ile Val Tyr Met Leu Val Val Gly Trp Met Pro
 195 200 205

Gly Tyr Leu Phe Phe Asn Ala Thr Gly Pro Thr Lys Tyr Trp Gly Lys
 210 215 220

Ser Arg Ser His Phe Asn Pro Tyr Ser Ala Ile Tyr Ala Asp Arg Glu
 225 230 235 240

Arg Trp Met Ile Val Leu Ser Asp Ile Phe Leu Val Ala Met Leu Ala
 245 250 255

Val Leu Ala Ala Leu Val His Thr Phe Ser Phe Asn Thr Met Val Lys
 260 265 270

Phe Tyr Val Val Pro Tyr Phe Ile Val Asn Ala Tyr Leu Val Leu Ile
 275 280 285

Thr Tyr Leu Gln His Thr Asp Thr Tyr Ile Pro His Phe Arg Glu Gly
 290 295 300

Glu Trp Asn Trp Leu Arg Gly Ala Leu Cys Thr Val Asp Arg Ser Phe
 305 310 315 320

Gly Pro Phe Leu Asp Ser Val Val His Arg Ile Val Asp Thr His Val
 325 330 335

Cys His His Ile Phe Ser Lys Met Pro Phe Tyr His Cys Glu Glu Ala
 340 345 350

Thr Asn Ala Ile Lys Pro Leu Leu Gly Lys Phe Tyr Leu Lys Asp Thr
 355 360 365

Thr Pro Val Pro Val Ala Leu Trp Arg Ser Tyr Thr His Cys Lys Phe
 370 375 380

Val Glu Asp Asp Gly Lys Val Val Phe Tyr Lys Asn Lys Leu
 385 390 395

<210> SEQ ID NO 13
 <211> LENGTH: 1084
 <212> TYPE: DNA
 <213> ORGANISM: Phytophthora infestans

<400> SEQUENCE: 13

```

atggctacaa aggaggctta cgttttccca actctcaccg agatcaagag atctctccca    60
aaggattgct teggagcttc tgtgctttg tctctctact acaactgtgag atgcttggtt    120
attgctgtgg ctttgacctt cggattgaac tacgctagag ctttgccaga ggttgagtct    180
ttctgggctt tggatgctgc tttgtgcact ggatatatcc tctctcaggg aattgtgttc    240
tggggattct tcaactgttg acacgatgct ggacacggag ctttctctag ataccacctc    300
ttgacttcgt tgtgggacct tcatgcactc tctcatcttg accccattcg agtcttgtaa    360
    
```

-continued

```

gttgaccac agacaccacc acaagaacac cggaaacac gatagagatg aggtgttcta 420
cccacagaga aaggctgatg atcaccatt gtccaggaac ttgatcttgg ctttgggagc 480
tgcttggtt gcttatttgg tggagggatt cccaccaaga aaggtgaacc acttcaacc 540
attcgagcca ctttttgtga gacaagtgc cgctgtggtt atctcttgc tcgctcaact 600
cttcgttgc ggactctcta tctacttgc tctccagtg ggacttaaga ccatggctat 660
ctactactac ggaccagttt tcgtgttcgg atctatgttg gtgattacca cttcttgc 720
ccacaacgat gaggagactc catggatgc tgattctgag tggacttacg tgaagggaaa 780
ctgtctctc gtggatagat cttacgtgc tctcatgat aacctctccc acaacatcgg 840
aactcaccag atccaccacc tcttccaat tatccacac tacaagctca agaaggctac 900
tgctgcttc caccaagctt tcccagagct tgtgagaaag tccgatgagc caatcatcaa 960
ggctttctc agagtgggaa ggtgtgatgc taactacgga gtggttgatc aagaggctaa 1020
gctcttcact ttgaaggagg ctaaggctgc tactgaagct gctgctaaga ccaagtctac 1080
ctga 1084

```

<210> SEQ ID NO 14

<211> LENGTH: 361

<212> TYPE: PRT

<213> ORGANISM: *Phytophthora infestans*

<400> SEQUENCE: 14

```

Met Ala Thr Lys Glu Ala Tyr Val Phe Pro Thr Leu Thr Glu Ile Lys
1      5      10      15
Arg Ser Leu Pro Lys Asp Cys Phe Glu Ala Ser Val Pro Leu Ser Leu
20     25     30
Tyr Tyr Thr Val Arg Cys Leu Val Ile Ala Val Ala Leu Thr Phe Gly
35     40     45
Leu Asn Tyr Ala Arg Ala Leu Pro Glu Val Glu Ser Phe Trp Ala Leu
50     55     60
Asp Ala Ala Leu Cys Thr Gly Tyr Ile Leu Leu Gln Gly Ile Val Phe
65     70     75     80
Trp Gly Phe Phe Thr Val Gly His Asp Ala Gly His Gly Ala Phe Ser
85     90     95
Arg Tyr His Leu Leu Asn Phe Val Val Gly Thr Phe Met His Ser Leu
100    105    110
Ile Leu Thr Pro Phe Glu Ser Trp Lys Leu Thr His Arg His His His
115    120    125
Lys Asn Thr Gly Asn Ile Asp Arg Asp Glu Val Phe Tyr Pro Gln Arg
130    135    140
Lys Ala Asp Asp His Pro Leu Ser Arg Asn Leu Ile Leu Ala Leu Gly
145    150    155    160
Ala Ala Trp Leu Ala Tyr Leu Val Glu Gly Phe Pro Pro Arg Lys Val
165    170    175
Asn His Phe Asn Pro Phe Glu Pro Leu Phe Val Arg Gln Val Ser Ala
180    185    190
Val Val Ile Ser Leu Leu Ala His Phe Phe Val Ala Gly Leu Ser Ile
195    200    205
Tyr Leu Ser Leu Gln Leu Gly Leu Lys Thr Met Ala Ile Tyr Tyr Tyr
210    215    220

```

-continued

Gly Pro Val Phe Val Phe Gly Ser Met Leu Val Ile Thr Thr Phe Leu
225 230 235 240
His His Asn Asp Glu Glu Thr Pro Trp Tyr Ala Asp Ser Glu Trp Thr
245 250 255
Tyr Val Lys Gly Asn Leu Ser Ser Val Asp Arg Ser Tyr Gly Ala Leu
260 265 270
Ile Asp Asn Leu Ser His Asn Ile Gly Thr His Gln Ile His His Leu
275 280 285
Phe Pro Ile Ile Pro His Tyr Lys Leu Lys Lys Ala Thr Ala Ala Phe
290 295 300
His Gln Ala Phe Pro Glu Leu Val Arg Lys Ser Asp Glu Pro Ile Ile
305 310 315
Lys Ala Phe Phe Arg Val Gly Arg Leu Tyr Ala Asn Tyr Gly Val Val
325 330 335
Asp Gln Glu Ala Lys Leu Phe Thr Leu Lys Glu Ala Lys Ala Ala Thr
340 345 350
Glu Ala Ala Ala Lys Thr Lys Ser Thr
355 360

<210> SEQ ID NO 15

<211> LENGTH: 1380

<212> TYPE: DNA

<213> ORGANISM: Emiliana huxleyi

<400> SEQUENCE: 15

atgggggggtg cagcgcttc ggaagcagag aggccaaagt ggacaactat ccacggaaga 60
cacgttgatg tgtcaaagt tagacaccct ggaggaata tcattgaatt gttctatggc 120
atggatagta catccgcttt cgagcaattt cacggacatc ataagggggc atggaagatg 180
ctcaaggctc ttctaccaa ggaggttgac ccagctgacg tocccacagca acctcaagaa 240
catgtcgcgg agatgaccag acctatgaca tcctggagag aaaggggttt attcaagcct 300
cgctcggttg catctggcat atatggactt gcagtagttg ctgctatagt tgcattgatt 360
gcatgtgctc cgcacgcacc ggttctgtcg gggattggtt tagggctctg ttgggcccaa 420
tgcggtttct tgcagcatat ggggggacat agggagtggg gggtcaggta ttctttcttg 480
ctccaacact tctttgaggg ttactactaa ggaggatcag ctactctggtg gaggaacaga 540
cataataagc atcatgcaa aaccaatggt cttggagagg atggtgacct tcgaactact 600
ccattctttg cgtgggaccc gactctcgct aaaaagggtc cggattggtc tctgaagaca 660
caagctttca ctttctccc agcactagga gcctatggtt tggttttcgc tttcacaatt 720
agaaaatcac ctgtggtgaa aaaactctgg cacgaacttg ctctaatgat tgctcattac 780
gcaatgttct actatgccct gcagttggct ggagccagtt tgggttctgg acttgcattt 840
tactgcacag gttacgcatg gcagggaaac tacctcggat tcttcttcgg tttgagccac 900
tttgagctc agagagtacc aagcacagcg acatggctcg aaagctcaat gataggttca 960
tggcagggaa tctacctcgg attctcttc ggtttgagcc actttgcagt cgagagagta 1020
ccaagcacag cgacatggct cgaaagctca atgataggtta cggtagactg gggaggttca 1080
ctctgttttt gtggttatgt ttctggtttc ttgaatatcc aaattgaaca tcacatggcc 1140
cctcaaatgc ctatggaaaa tctgagacag atcagggcag attgtaaggc tagtgctgag 1200

-continued

```

aaactcggct tgccatatag agagttgtca ttcgcaggtg ctgtcaaact catgatgta 1260
ggctcttggga ggactggaag agacgaatta cagctccgaa gtgatcgaag aaagtactca 1320
agaaccagg cttacatggc ggctgcttca gctgttggg aaaatctgaa ggcagattaa 1380

```

<210> SEQ ID NO 16

<211> LENGTH: 459

<212> TYPE: PRT

<213> ORGANISM: Emiliana huxleyi

<400> SEQUENCE: 16

```

Met Gly Gly Ala Gly Ala Ser Glu Ala Glu Arg Pro Lys Trp Thr Thr
 1          5          10
Ile His Gly Arg His Val Asp Val Ser Lys Phe Arg His Pro Gly Gly
 20          25          30
Asn Ile Ile Glu Leu Phe Tyr Gly Met Asp Ser Thr Ser Ala Phe Glu
 35          40          45
Gln Phe His Gly His His Lys Gly Ala Trp Lys Met Leu Lys Ala Leu
 50          55          60
Pro Thr Lys Glu Val Asp Pro Ala Asp Val Pro Gln Gln Pro Gln Glu
 65          70          75          80
His Val Ala Glu Met Thr Arg Leu Met Thr Ser Trp Arg Glu Arg Gly
 85          90          95
Leu Phe Lys Pro Arg Pro Val Ala Ser Gly Ile Tyr Gly Leu Ala Val
100          105          110
Val Ala Ala Ile Val Ala Cys Ile Ala Cys Ala Pro His Ala Pro Val
115          120          125
Leu Ser Gly Ile Gly Leu Gly Ser Cys Trp Ala Gln Cys Gly Phe Leu
130          135          140
Gln His Met Gly Gly His Arg Glu Trp Gly Val Arg Tyr Ser Phe Leu
145          150          155          160
Leu Gln His Phe Phe Glu Gly Leu Leu Lys Gly Gly Ser Ala Ser Trp
165          170          175
Trp Arg Asn Arg His Asn Lys His His Ala Lys Thr Asn Val Leu Gly
180          185          190
Glu Asp Gly Asp Leu Arg Thr Thr Pro Phe Phe Ala Trp Asp Pro Thr
195          200          205
Leu Ala Lys Lys Val Pro Asp Trp Ser Leu Lys Thr Gln Ala Phe Thr
210          215          220
Phe Leu Pro Ala Leu Gly Ala Tyr Val Phe Val Phe Ala Phe Thr Ile
225          230          235          240
Arg Lys Tyr Ala Val Val Lys Lys Leu Trp His Glu Leu Ala Leu Met
245          250          255
Ile Ala His Tyr Ala Met Phe Tyr Tyr Ala Leu Gln Leu Ala Gly Ala
260          265          270
Ser Leu Gly Ser Gly Leu Ala Phe Tyr Cys Thr Gly Tyr Ala Trp Gln
275          280          285
Gly Ile Tyr Leu Gly Phe Phe Phe Gly Leu Ser His Phe Ala Val Glu
290          295          300
Arg Val Pro Ser Thr Ala Thr Trp Leu Glu Ser Ser Met Ile Gly Ser
305          310          315          320
Trp Gln Gly Ile Tyr Leu Gly Phe Phe Phe Gly Leu Ser His Phe Ala
325          330          335

```

-continued

Val Glu Arg Val Pro Ser Thr Ala Thr Trp Leu Glu Ser Ser Met Ile
 340 345 350

Gly Thr Val Asp Trp Gly Gly Ser Ser Ala Phe Cys Gly Tyr Val Ser
 355 360 365

Gly Phe Leu Asn Ile Gln Ile Glu His His Met Ala Pro Gln Met Pro
 370 375 380

Met Glu Asn Leu Arg Gln Ile Arg Ala Asp Cys Lys Ala Ser Ala Glu
 385 390 395 400

Lys Leu Gly Leu Pro Tyr Arg Glu Leu Ser Phe Ala Gly Ala Val Lys
 405 410 415

Leu Met Met Val Gly Leu Trp Arg Thr Gly Arg Asp Glu Leu Gln Leu
 420 425 430

Arg Ser Asp Arg Arg Lys Tyr Ser Arg Thr Gln Ala Tyr Met Ala Ala
 435 440 445

Ala Ser Ala Val Val Glu Asn Leu Lys Ala Asp
 450 455

<210> SEQ ID NO 17

<211> LENGTH: 1560

<212> TYPE: DNA

<213> ORGANISM: *Thraustochytrium* sp., ATCC21685

<400> SEQUENCE: 17

```

atgactgttg gatac gatga ggagatccca ttcgagcaag ttagggctca taacaagcca      60
gatgatgctt ggtgtgctat tcatggacac gtgtacgatg ttaccaagtt cgcttctgct      120
catccaggag gagatattat cttgctcgct gctggaaagg aagctactgt gctctacgag      180
acctaccatg ttagaggagt gtctgatgct gtgctcagaa agtacagaat cggaaagttg      240
ccagatggac aaggaggagc taacgagaag gagaagagaa ccttgtctgg attgtctctc      300
gcttcttact acacctggaa ctccgatttc tacagagtga tgaggagag agttgtggct      360
agattgaagg agagaggaaa ggctagaaga ggaggatacg agttgtggat caaggctttc      420
ttgctccttg ttggattctg gtctctcttt tactggatgt gcacctcga tccatctttc      480
ggagctatct tggctgctat gtctttggga gtgttcgctg cttttgttgg aacctgcate      540
caacatgatg gaaacctatg agctttcgtc caatctagat gggtaacaa ggtggcagga      600
tggactttgg atatgatcgg agcttctgga atgacttggg agttccaaca tgtgttggga      660
catcaccatc acactaactt gatcggaggg gagaacggat tgcaaaaggt gtcgggaaag      720
aagatggata ccaagttggc tgatcaagag tctgatccag atgtgttctc cacctacca      780
atgatgagat tgcattccat gcatcagaag agatggtatc acaggttcca gcatatctac      840
ggaccattca tcttcggatt catgaccatc aacaaggtgg tgactcaaga tgttgagtg      900
gtgttgagaa agaggctctt ccaaatcgat gctgagtgea gatatgcttc ccaaatgtac      960
gttgctaggt tctggatcat gaaggctttg accgtgttgt acatggttgc tctcccatgt     1020
tatatgcaag gaccatggca tggattgaag ctcttcgcta tcgctcattt cacttgcgga     1080
gaggtttttg ctaccatggt catcgtgaac cacattatcg agggagtgtc ttacgcttct     1140
aaggatgctg ttaaggaac tatggctcca ccaaagacta tgcattggagt gacccaatg     1200
aacaacacta gaaaggaggt tgaggctgag gcttctaagt ctggagctgt ggttaagtct     1260
gtgccattgg atgattgggc tgctgttcaa tgccaaacct ctgtgaactg gtctgttggga     1320

```

-continued

```

tcttgggtct ggaaccattt ctctggagga ctcaaccatc aaatcgagca tcattctcttc 1380
ccaggattgt ctcaegagac ctactaccac atccaagatg tggttcaatc tacctgtgct 1440
gagtacggag ttccatacca acatgagcca tctttgtgga ctgcttactg gaagatgctc 1500
gaacatttga gacaattggg aaacgaggag actcagcagc cttggcaaag agctgcttga 1560

```

<210> SEQ ID NO 18

<211> LENGTH: 519

<212> TYPE: PRT

<213> ORGANISM: *Thraustochytrium* sp., ATCC21685

<400> SEQUENCE: 18

```

Met Thr Val Gly Tyr Asp Glu Glu Ile Pro Phe Glu Gln Val Arg Ala
1           5           10           15
His Asn Lys Pro Asp Asp Ala Trp Cys Ala Ile His Gly His Val Tyr
20          25          30
Asp Val Thr Lys Phe Ala Ser Val His Pro Gly Gly Asp Ile Ile Leu
35          40          45
Leu Ala Ala Gly Lys Glu Ala Thr Val Leu Tyr Glu Thr Tyr His Val
50          55          60
Arg Gly Val Ser Asp Ala Val Leu Arg Lys Tyr Arg Ile Gly Lys Leu
65          70          75          80
Pro Asp Gly Gln Gly Gly Ala Asn Glu Lys Glu Lys Arg Thr Leu Ser
85          90          95
Gly Leu Ser Ser Ala Ser Tyr Tyr Thr Trp Asn Ser Asp Phe Tyr Arg
100         105         110
Val Met Arg Glu Arg Val Val Ala Arg Leu Lys Glu Arg Gly Lys Ala
115         120         125
Arg Arg Gly Gly Tyr Glu Leu Trp Ile Lys Ala Phe Leu Leu Leu Val
130         135         140
Gly Phe Trp Ser Ser Leu Tyr Trp Met Cys Thr Leu Asp Pro Ser Phe
145         150         155         160
Gly Ala Ile Leu Ala Ala Met Ser Leu Gly Val Phe Ala Ala Phe Val
165         170         175
Gly Thr Cys Ile Gln His Asp Gly Asn His Gly Ala Phe Ala Gln Ser
180         185         190
Arg Trp Val Asn Lys Val Ala Gly Trp Thr Leu Asp Met Ile Gly Ala
195         200         205
Ser Gly Met Thr Trp Glu Phe Gln His Val Leu Gly His His Pro Tyr
210         215         220
Thr Asn Leu Ile Glu Glu Glu Asn Gly Leu Gln Lys Val Ser Gly Lys
225         230         235         240
Lys Met Asp Thr Lys Leu Ala Asp Gln Glu Ser Asp Pro Asp Val Phe
245         250         255
Ser Thr Tyr Pro Met Met Arg Leu His Pro Trp His Gln Lys Arg Trp
260         265         270
Tyr His Arg Phe Gln His Ile Tyr Gly Pro Phe Ile Phe Gly Phe Met
275         280         285
Thr Ile Asn Lys Val Val Thr Gln Asp Val Gly Val Val Leu Arg Lys
290         295         300
Arg Leu Phe Gln Ile Asp Ala Glu Cys Arg Tyr Ala Ser Pro Met Tyr
305         310         315         320

```


-continued

Val Ala Arg Phe Trp Ile Met Lys Ala Leu Thr Val Leu Tyr Met Val
 325 330 335

Ala Leu Pro Cys Tyr Met Gln Gly Pro Trp His Gly Leu Lys Leu Phe
 340 345 350

Ala Ile Ala His Phe Thr Cys Gly Glu Val Leu Ala Thr Met Phe Ile
 355 360 365

Val Asn His Ile Ile Glu Gly Val Ser Tyr Ala Ser Lys Asp Ala Val
 370 375 380

Lys Gly Thr Met Ala Pro Pro Lys Thr Met His Gly Val Thr Pro Met
 385 390 395 400

Asn Asn Thr Arg Lys Glu Val Glu Ala Glu Ala Ser Lys Ser Gly Ala
 405 410 415

Val Val Lys Ser Val Pro Leu Asp Asp Trp Ala Ala Val Gln Cys Gln
 420 425 430

Thr Ser Val Asn Trp Ser Val Gly Ser Trp Phe Trp Asn His Phe Ser
 435 440 445

Gly Gly Leu Asn His Gln Ile Glu His His Leu Phe Pro Gly Leu Ser
 450 455 460

His Glu Thr Tyr Tyr His Ile Gln Asp Val Val Gln Ser Thr Cys Ala
 465 470 475 480

Glu Tyr Gly Val Pro Tyr Gln His Glu Pro Ser Leu Trp Thr Ala Tyr
 485 490 495

Trp Lys Met Leu Glu His Leu Arg Gln Leu Gly Asn Glu Glu Thr His
 500 505 510

Glu Ser Trp Gln Arg Ala Ala
 515

<210> SEQ ID NO 19
 <211> LENGTH: 1320
 <212> TYPE: DNA
 <213> ORGANISM: *Ostreococcus* RCC809

<400> SEQUENCE: 19

```

atgggaaagg gagcaaggaa cccaggagca agggcatgga agtcaacatt ggagcctcac    60
gcagtgccaa agtcattcga taggagatgg gttaagggtg atggagtga atacgatgtg    120
actgatttca agcactctgg aggtagtgtt atatactaca tgctttctaa cacaggtgct    180
gatgcaaccg aagcttttaa ggagttccat tacaggagta agaaagctag gaaagcactt    240
gctgcattgc ctcaaagaga accagaggat gcttcaccag ttgaagatgc aaacatgctc    300
aaggatttgc ctaagtggag aaaggatctc gaaagggagg gatTTTTCAA accttctcca    360
gctcatgtgg catatagatt tgctgagctt gctgcaatgt tcgctctcgg tacagcatta    420
atgtacgcta gatggcaagc aacttctggt ttcgtgacag cttgTTTTCTT tggagcaaga    480
tgcggttggg ttcaacatga gggaggtcac tcttcattga ctggatcaat ctggtgggat    540
aagagaatac aggcTTTTAC agcaggatcc ggtctcgcta gttctggtga tatgtggaat    600
ttaatgcata acaagcatca cgcaaccctc caaaaagtta ggcacgatat ggatttggat    660
actacaccag ctgttgcatt tttcaactact gctgtggaag agaacagacc taggaagttt    720
tctaaacttt ggttgagagt tcaggcttgg accttctgctc ctgtgacttc aggactcgtg    780
cttttgctt ggatgtatct cttacatcca agacacattg caagaaggaa gaattacgaa    840
    
```

-continued

```

gaggctgcat ggatcgttgc tgcacatgtg ataaggacat cagttattaa agctgtgaca   900
ggatataggt ggataacctg ttacggctctc tttttaagta ccatgtgggt tctggatgc   960
tatctttttg ctcatttctc aaccagtcac actcaccttg atgttgtgcc ttcagataag  1020
catttgagtt gggtagata tgcgtgggat cacactattg atatcgatcc atctaaatca  1080
gttgtgaatt ggcttatggg ttacttgaac tgcacaggta tccatcactt gtttcctgat  1140
atgccacaat tcagacagcc agaagtttct agaaggtttg tgcattcgc taagaaatgg  1200
aatctcaact acaaggttat gtcttattac ggagcttga aagcaacatt cgtaaacctt  1260
aacgaagttg gaaagcacta ctatattcag ggttctcaaa tcacaaaaaa gaccgtgtaa  1320

```

<210> SEQ ID NO 20

<211> LENGTH: 439

<212> TYPE: PRT

<213> ORGANISM: *Ostreococcus* RCC809

<400> SEQUENCE: 20

```

Met Gly Lys Gly Ala Arg Asn Pro Gly Ala Arg Ala Trp Lys Ser Thr
 1          5          10          15
Leu Glu Pro His Ala Val Ala Lys Ser Phe Asp Arg Arg Trp Val Lys
 20          25          30
Val Asp Gly Val Glu Tyr Asp Val Thr Asp Phe Lys His Pro Gly Gly
 35          40          45
Ser Val Ile Tyr Tyr Met Leu Ser Asn Thr Gly Ala Asp Ala Thr Glu
 50          55          60
Ala Phe Lys Glu Phe His Tyr Arg Ser Lys Lys Ala Arg Lys Ala Leu
 65          70          75          80
Ala Ala Leu Pro Gln Arg Glu Pro Glu Asp Ala Ser Pro Val Glu Asp
 85          90          95
Ala Asn Met Leu Lys Asp Phe Ala Lys Trp Arg Lys Asp Leu Glu Arg
100          105          110
Glu Gly Phe Phe Lys Pro Ser Pro Ala His Val Ala Tyr Arg Phe Ala
115          120          125
Glu Leu Ala Ala Met Phe Ala Leu Gly Thr Ala Leu Met Tyr Ala Arg
130          135          140
Trp His Ala Thr Ser Val Phe Val Thr Ala Cys Phe Phe Gly Ala Arg
145          150          155          160
Cys Gly Trp Val Gln His Glu Gly Gly His Ser Ser Leu Thr Gly Ser
165          170          175
Ile Trp Trp Asp Lys Arg Ile Gln Ala Phe Thr Ala Gly Phe Gly Leu
180          185          190
Ala Ser Ser Gly Asp Met Trp Asn Leu Met His Asn Lys His His Ala
195          200          205
Thr Pro Gln Lys Val Arg His Asp Met Asp Leu Asp Thr Thr Pro Ala
210          215          220
Val Ala Phe Phe Asn Thr Ala Val Glu Glu Asn Arg Pro Arg Lys Phe
225          230          235          240
Ser Lys Leu Trp Leu Arg Val Gln Ala Trp Thr Phe Val Pro Val Thr
245          250          255
Ser Gly Leu Val Leu Leu Ala Trp Met Tyr Leu Leu His Pro Arg His
260          265          270
Ile Ala Arg Arg Lys Asn Tyr Glu Glu Ala Ala Trp Ile Val Ala Ala

```

-continued

275	280	285
His Val Ile Arg Thr Ser Val Ile Lys Ala Val Thr Gly Tyr Ser Trp		
290	295	300
Ile Thr Cys Tyr Gly Leu Phe Leu Ser Thr Met Trp Val Ser Gly Cys		
305	310	315
Tyr Leu Phe Ala His Phe Ser Thr Ser His Thr His Leu Asp Val Val		
325	330	335
Pro Ser Asp Lys His Leu Ser Trp Val Arg Tyr Ala Val Asp His Thr		
340	345	350
Ile Asp Ile Asp Pro Ser Lys Ser Val Val Asn Trp Leu Met Gly Tyr		
355	360	365
Leu Asn Cys Gln Val Ile His His Leu Phe Pro Asp Met Pro Gln Phe		
370	375	380
Arg Gln Pro Glu Val Ser Arg Arg Phe Val Ser Phe Ala Lys Lys Trp		
385	390	395
Asn Leu Asn Tyr Lys Val Met Ser Tyr Tyr Gly Ala Trp Lys Ala Thr		
405	410	415
Phe Gly Asn Leu Asn Glu Val Gly Lys His Tyr Tyr Ile Gln Gly Ser		
420	425	430
Gln Ile Thr Lys Lys Thr Val		
435		

<210> SEQ ID NO 21

<211> LENGTH: 819

<212> TYPE: DNA

<213> ORGANISM: Fragilariopsis cylindrus CCMP 1102

<400> SEQUENCE: 21

```

atggatgaat acaaggcaac tttagagagt gtgggagatg ctataataca atgggcagat      60
cctgagagtc aatttactgg ttttacaag ggatggtttc ttacagattt cacctcagct      120
ttcagtatag cacttgttta cgtggttttc gttattatcg gtagtcaagt tatgaaggtg      180
cttctcgeta ttgateccta cccaataaag tttttctaca atgtttctca gatcatggtg      240
tgtgcataca tgactataga agcttgccct ttggcatata gaaacggata cacaatcatg      300
ccttggtgtg gttataatag ggatgatcca gctataggaa acctcttatg gctcttttac      360
gtttcaaaag tgtgggattt ctgggatacc atcttcattg ttcttggtaa gaaatggaga      420
caactcagtt tcttacatgt gtatcatcac actacaatct ttctcttcta ctggttaaat      480
gctaacgttt tctatgatgg agatatatac cttacaatcg cattgaatgg tttcatacat      540
actgtgatgt acacatacta ctttatctgt atgcacacca aggataagaa aactggaaaag      600
tctttgceta tatggtggaa gtcttcactc acacttttgc aattatttca gttcatcacc      660
atgatgtcac agggacteta ttttaataatt ttcggttgcg agagtttgc tataagggtt      720
accgctactt acgttggtga catactttct ttgtttttcc tcttcgctca atttttcgtg      780
gcattttaca tgcagccaaa gaaatcaaaa actgcttga      819

```

<210> SEQ ID NO 22

<211> LENGTH: 272

<212> TYPE: PRT

<213> ORGANISM: Fragilariopsis cylindrus CCMP 1102

<400> SEQUENCE: 22

-continued

Met Asp Glu Tyr Lys Ala Thr Leu Glu Ser Val Gly Asp Ala Ile Ile
 1 5 10 15
 Gln Trp Ala Asp Pro Glu Ser Gln Phe Thr Gly Phe Thr Lys Gly Trp
 20 25 30
 Phe Leu Thr Asp Phe Thr Ser Ala Phe Ser Ile Ala Leu Val Tyr Val
 35 40 45
 Leu Phe Val Ile Ile Gly Ser Gln Val Met Lys Val Leu Pro Ala Ile
 50 55 60
 Asp Pro Tyr Pro Ile Lys Phe Phe Tyr Asn Val Ser Gln Ile Met Leu
 65 70 75 80
 Cys Ala Tyr Met Thr Ile Glu Ala Cys Leu Leu Ala Tyr Arg Asn Gly
 85 90 95
 Tyr Thr Ile Met Pro Cys Val Gly Tyr Asn Arg Asp Asp Pro Ala Ile
 100 105 110
 Gly Asn Leu Leu Trp Leu Phe Tyr Val Ser Lys Val Trp Asp Phe Trp
 115 120 125
 Asp Thr Ile Phe Ile Val Leu Gly Lys Lys Trp Arg Gln Leu Ser Phe
 130 135 140
 Leu His Val Tyr His His Thr Thr Ile Phe Leu Phe Tyr Trp Leu Asn
 145 150 155 160
 Ala Asn Val Phe Tyr Asp Gly Asp Ile Tyr Leu Thr Ile Ala Leu Asn
 165 170 175
 Gly Phe Ile His Thr Val Met Tyr Thr Tyr Tyr Phe Ile Cys Met His
 180 185 190
 Thr Lys Asp Lys Lys Thr Gly Lys Ser Leu Pro Ile Trp Trp Lys Ser
 195 200 205
 Ser Leu Thr Leu Leu Gln Leu Phe Gln Phe Ile Thr Met Met Ser Gln
 210 215 220
 Gly Leu Tyr Leu Ile Ile Phe Gly Cys Glu Ser Leu Ser Ile Arg Val
 225 230 235 240
 Thr Ala Thr Tyr Val Val Tyr Ile Leu Ser Leu Phe Phe Leu Phe Ala
 245 250 255
 Gln Phe Phe Val Ala Ser Tyr Met Gln Pro Lys Lys Ser Lys Thr Ala
 260 265 270

<210> SEQ ID NO 23

<211> LENGTH: 867

<212> TYPE: DNA

<213> ORGANISM: *Caenorhabditis elegans*

<400> SEQUENCE: 23

```

atggctcagc acccaactcgt tcagagggtta cttgatgtta aattcgatac aaagagggttc      60
gtggcaatag caactcatgg tctcaaaaat ttccctgatg ctgaaggaag aaagtttttc      120
gcagatcatt tcgatgttac tattcaagct agtataactct acatgggtgt ggtttttggt      180
actaaatggt tcatgagaaa caggcaacct ttccaggtta caatcccact taacatatgg      240
aacttcattt tggctgcatt ctcaatcgct ggagcagtga agatgacccc tgagtttttc      300
ggaactattg ctaacaaggg tattgtggca tcatactgta aggttttcga tttcaccaaa      360
ggagaaaacg gttactgggt ttggcttttc atggctagta agctttttga gttggtggat      420
actatcttcc ttgttttgag aaaaaggcca ctcatgttcc tccattggtta ccatcacatc      480
ctcacaatga tatacgtctg gtactctcac cctcttacc caggattcaa cagatacgggt      540

```

-continued

```

atttacttga actttgtggt tcacgcattc atgtactctt attacttctt cagatcaatg 600
aagatcaggg ttccaggatt tattgtctca gcaatcacia gtttaciaat agtgcagttc 660
attatctctt gtgctgttct tgcacatttg ggttatctca tgcactttac caatgctaac 720
tgcgattttg aaccttctgt gttcaaatg gctgttttta tggatactac atacctcgca 780
ctcttcgtga atttcttctt tcagtcatat gttctcaggg gtggaagga taagtacaaa 840
gctgttccaa agaaaaagaa taactga 867

```

<210> SEQ ID NO 24

<211> LENGTH: 288

<212> TYPE: PRT

<213> ORGANISM: *Caenorhabditis elegans*

<400> SEQUENCE: 24

```

Met Ala Gln His Pro Leu Val Gln Arg Leu Leu Asp Val Lys Phe Asp
1      5      10      15
Thr Lys Arg Phe Val Ala Ile Ala Thr His Gly Pro Lys Asn Phe Pro
20     25     30
Asp Ala Glu Gly Arg Lys Phe Phe Ala Asp His Phe Asp Val Thr Ile
35     40     45
Gln Ala Ser Ile Leu Tyr Met Val Val Val Phe Gly Thr Lys Trp Phe
50     55     60
Met Arg Asn Arg Gln Pro Phe Gln Leu Thr Ile Pro Leu Asn Ile Trp
65     70     75     80
Asn Phe Ile Leu Ala Ala Phe Ser Ile Ala Gly Ala Val Lys Met Thr
85     90     95
Pro Glu Phe Phe Gly Thr Ile Ala Asn Lys Gly Ile Val Ala Ser Tyr
100    105    110
Cys Lys Val Phe Asp Phe Thr Lys Gly Glu Asn Gly Tyr Trp Val Trp
115    120    125
Leu Phe Met Ala Ser Lys Leu Phe Glu Leu Val Asp Thr Ile Phe Leu
130    135    140
Val Leu Arg Lys Arg Pro Leu Met Phe Leu His Trp Tyr His His Ile
145    150    155    160
Leu Thr Met Ile Tyr Ala Trp Tyr Ser His Pro Leu Thr Pro Gly Phe
165    170    175
Asn Arg Tyr Gly Ile Tyr Leu Asn Phe Val Val His Ala Phe Met Tyr
180    185    190
Ser Tyr Tyr Phe Leu Arg Ser Met Lys Ile Arg Val Pro Gly Phe Ile
195    200    205
Ala Gln Ala Ile Thr Ser Leu Gln Ile Val Gln Phe Ile Ile Ser Cys
210    215    220
Ala Val Leu Ala His Leu Gly Tyr Leu Met His Phe Thr Asn Ala Asn
225    230    235    240
Cys Asp Phe Glu Pro Ser Val Phe Lys Leu Ala Val Phe Met Asp Thr
245    250    255
Thr Tyr Leu Ala Leu Phe Val Asn Phe Phe Leu Gln Ser Tyr Val Leu
260    265    270
Arg Gly Gly Lys Asp Lys Tyr Lys Ala Val Pro Lys Lys Lys Asn Asn
275    280    285

```

-continued

```

<210> SEQ ID NO 25
<211> LENGTH: 1653
<212> TYPE: DNA
<213> ORGANISM: Thalassiosira pseudonana

<400> SEQUENCE: 25
atgggtaatg gtaatcttcc agcatctaca gcacaactca agtcaacaag taaacctcaa      60
cagcaacacg agcacagAAC aatcagtaaa tctgaattgg cacaacataa cactcctaag      120
tctgcttggt gtgcagttca ttcaactcct gctacagatc caagtcactc taataacaaa      180
cagcatgcac accttgtttt ggatattaca gatttctgct ctagacatcc aggaggagat      240
ttgattcttt tggcttcagg aaaagatgca agtgtgctct togagaccta ccaccctagg      300
ggagttccaa cttcattaat tcaaaagcct cagatcgggt ttatggaaga ggaagctttt      360
agagatagtt tctactcttg gacagattct gatttctaca cgttcttaa gagaagggtt      420
gtgaaaagat tagaggaaa gggacttgat agaaggggtt caaaagagat ttggatcaag      480
gctttatttc tcttagttgg attctggtae tgtctttaca agatgtacac tacatcagat      540
atagatcaat acggaatagc tattgcatat agtatcggaa tgggtacttt tgctgcatcc      600
atcggtcatc gcatacaaca tgatggaaac cacgggtgctt tcgcacagaa caagcttttg      660
aacaagttgg ctggatggac actcgatatg atcgggtgctt ctgcattcac ctgggaattg      720
cagcatatgc tcggctatca cccttacct aatgttcttg atggagtgga ggaagagaga      780
aaagaaaagg gagaggatgt ggctttggaa gagaaggatc aagagtcaga tccagatgtt      840
ttctcttcat tccctctcat gagaatgcat ccacatcaca ccaactagttg gtaccataaa      900
tatcagcacc tttatgctcc tccactcttt gcattaatga cccttgctaa ggtgtttcaa      960
caggatttcg aagttgcaac atctggaaga ttgtaccata ttgatgctaa cgtagatat      1020
ggttcagttt ggaatgtgat gagattctgg gctatgaaag ttatcacaat gggatacatg      1080
atgggtttgc ctatttactt tcatggagtt ctcaggggag tgggtctttt cgttatcgga      1140
caccttgcat gtgggtgaac cttagctact atgttcatag ttaacatgt gattgagggga      1200
gtgagttatg gtacaaaaga tctgtttgga ggtgcatctc acggagatga aaagaaaatt      1260
gtgaagccta caaccgtttt aggtgatacc ccaatggaga aaactagaga agaggctctc      1320
aagtcaaaca gtaacaacaa caagaaaaag ggagaaaaga actcagttcc tagtgtgcca      1380
tttaatgatt gggctgcagt gcaatgccag acttctgtta actggtctcc tggttcatgg      1440
ttttggaatc atttcagtgg aggtttgtct caccaaatcg agcatcacct cttcccaagt      1500
atatgtcata ctaactactg ccacattcaa gatgtttgtgg aatctacatg tgctgagtac      1560
gggtgtccat atcagctctga atcaaaactg ttcggtgcat acggaaagat gatctcacat      1620
ttgaagttcc tcgtaaggc taagtgcgag tga                                     1653

```

```

<210> SEQ ID NO 26
<211> LENGTH: 360
<212> TYPE: PRT
<213> ORGANISM: Thalassiosira pseudonana

```

```

<400> SEQUENCE: 26
Met Gly Asn Gly Asn Leu Pro Ala Ser Thr Ala Gln Leu Lys Ser Thr
1           5           10           15
Ser Lys Pro Gln Gln Gln His Glu His Arg Thr Ile Ser Lys Ser Glu
20           25           30

```

-continued

Leu Ala Gln His Asn Thr Pro Lys Ser Ala Trp Cys Ala Val His Ser
 35 40 45

Thr Pro Ala Thr Asp Pro Ser His Ser Asn Asn Lys Gln His Ala His
 50 55 60

Leu Val Leu Asp Ile Thr Asp Phe Ala Ser Arg His Pro Gly Gly Asp
 65 70 75 80

Leu Ile Leu Leu Ala Ser Gly Lys Asp Ala Ser Val Leu Phe Glu Thr
 85 90 95

Tyr His Pro Arg Gly Val Pro Thr Ser Leu Ile Gln Lys Leu Gln Ile
 100 105 110

Gly Val Met Glu Glu Glu Ala Phe Arg Asp Ser Phe Tyr Ser Trp Thr
 115 120 125

Asp Ser Asp Phe Tyr Thr Val Leu Lys Arg Arg Val Val Glu Arg Leu
 130 135 140

Glu Glu Arg Gly Leu Asp Arg Arg Gly Ser Lys Glu Ile Trp Ile Lys
 145 150 155 160

Ala Leu Phe Leu Leu Val Gly Phe Trp Tyr Cys Leu Tyr Lys Met Tyr
 165 170 175

Thr Thr Ser Asp Ile Asp Gln Tyr Gly Ile Ala Ile Ala Tyr Ser Ile
 180 185 190

Gly Met Gly Thr Phe Ala Ala Phe Ile Gly Thr Cys Ile Gln His Asp
 195 200 205

Gly Asn His Gly Ala Phe Ala Gln Asn Lys Leu Leu Asn Lys Leu Ala
 210 215 220

Gly Trp Thr Leu Asp Met Ile Gly Ala Ser Ala Phe Thr Trp Glu Leu
 225 230 235 240

Gln His Met Leu Gly His His Pro Tyr Thr Asn Val Leu Asp Gly Val
 245 250 255

Glu Glu Glu Arg Lys Glu Arg Gly Glu Asp Val Ala Leu Glu Glu Lys
 260 265 270

Asp Gln Glu Ser Asp Pro Asp Val Phe Ser Ser Phe Pro Leu Met Arg
 275 280 285

Met His Pro His His Thr Thr Ser Trp Tyr His Lys Tyr Gln His Leu
 290 295 300

Tyr Ala Pro Pro Leu Phe Ala Leu Met Thr Leu Ala Lys Val Phe Gln
 305 310 315 320

Gln Asp Phe Glu Val Ala Thr Ser Gly Arg Leu Tyr His Ile Asp Ala
 325 330 335

Asn Val Arg Tyr Gly Ser Val Trp Asn Val Met Arg Phe Trp Ala Met
 340 345 350

Lys Val Ile Thr Met Gly Tyr Met
 355 360

<210> SEQ ID NO 27
 <211> LENGTH: 1086
 <212> TYPE: DNA
 <213> ORGANISM: Hyaloperonospora parasitica

<400> SEQUENCE: 27

atggctacta aacaatcagt tgccttttccct acctttgactg atctttaaag atctcttccct 60
 tctgagtgtt ttgaatcttc tttgcctctt tctctttact atacacttag atcttttggtt 120

-continued

```

tttgctgggt ctcttgctgt ttctctttct tacgctcttg ctcaaccttt ggttcaaac 180
ttttaccctc ttagagttgc tcttattgct ggatacactg tttttcaagg agttattttc 240
tggggatttt tcaactattg tcatgatgct ggatcatggg ctttttctag atatcctggt 300
cttaacttca ctggttgaac acttatgcat tctcttattt tgactccttt tgaatcttgg 360
aagttgactc atagacatca tcataaaaac actggaaata tcgatagaga tgagatcttc 420
taccctcaaa gagaatctga tgatcctcct gtttctagac atcttacttt cactcttggg 480
gctgcttggg tcgcttacct tggtaggggt tttccacctg gaaaattgaa tcattacaat 540
cctttcgagc cattgttcca gagaagagtt tctgctgttg ttatctctat cttggctcag 600
tttttcgttg caggattgtc tatttacttg tgtttccagg ttggagttca ggctgttgc 660
ctttactatt acggctctat cttcgttttt ggtactatgc ttgttattac tacttttctt 720
catcataacg atgaagagac tccttggtag ggtgatgagg attggtetta cgtaagggt 780
aacttgtctt ctggtgatag atcttacggg cctcttatcg ataactgtc tcataacatc 840
ggctactcatc aagttcatc tcttttccca atcatccctc attacaaatt aaagcctgct 900
acagctgctt tcagaagagc tttcccatc cttggttagaa agtctgatga aagaattttg 960
caggcttttt acagaattgg tagattgtat gctaaatag gtgttgcgta ttcttctgct 1020
aaattgttta cattgaagga agctcaactt acttctaaag ctgcttctga tgctaaagct 1080
gcttga 1086

```

<210> SEQ ID NO 28

<211> LENGTH: 361

<212> TYPE: PRT

<213> ORGANISM: Hyaloperonospora parasitica

<400> SEQUENCE: 28

```

Met Ala Thr Lys Gln Ser Val Ala Phe Pro Thr Leu Thr Asp Leu Lys
1           5           10          15
Arg Ser Leu Pro Ser Glu Cys Phe Glu Ser Ser Leu Pro Leu Ser Leu
20          25          30
Tyr Tyr Thr Leu Arg Ser Leu Val Phe Ala Gly Ser Leu Ala Val Ser
35          40          45
Leu Ser Tyr Ala Leu Ala Gln Pro Leu Val Gln Asn Phe Tyr Pro Leu
50          55          60
Arg Val Ala Leu Ile Ala Gly Tyr Thr Val Phe Gln Gly Val Ile Phe
65          70          75          80
Trp Gly Phe Phe Thr Ile Gly His Asp Ala Gly His Gly Ala Phe Ser
85          90          95
Arg Tyr Pro Val Leu Asn Phe Thr Val Gly Thr Leu Met His Ser Leu
100         105         110
Ile Leu Thr Pro Phe Glu Ser Trp Lys Leu Thr His Arg His His His
115        120        125
Lys Asn Thr Gly Asn Ile Asp Arg Asp Glu Ile Phe Tyr Pro Gln Arg
130        135        140
Glu Ser Asp Asp His Pro Val Ser Arg His Leu Thr Phe Thr Leu Gly
145        150        155        160
Ala Ala Trp Phe Ala Tyr Leu Val Glu Gly Phe Pro Pro Arg Lys Leu
165        170        175
Asn His Tyr Asn Pro Phe Glu Pro Leu Phe Glu Arg Arg Val Ser Ala

```


-continued

Val	Val	Ile	Ser	Ile	Leu	Ala	Gln	Phe	Phe	Val	Ala	Gly	Leu	Ser	Ile	180	185	190
		195					200					205						
Tyr	Leu	Cys	Phe	Gln	Val	Gly	Val	Gln	Ala	Val	Ala	Leu	Tyr	Tyr	Tyr			
	210					215					220							
Gly	Pro	Ile	Phe	Val	Phe	Gly	Thr	Met	Leu	Val	Ile	Thr	Thr	Phe	Leu	225		230
					230					235					240			
His	His	Asn	Asp	Glu	Glu	Thr	Pro	Trp	Tyr	Gly	Asp	Glu	Asp	Trp	Ser			245
				245					250					255				
Tyr	Val	Lys	Gly	Asn	Leu	Ser	Ser	Val	Asp	Arg	Ser	Tyr	Gly	Pro	Leu			260
			260					265					270					
Ile	Asp	Asn	Leu	Ser	His	Asn	Ile	Gly	Thr	His	Gln	Val	His	His	Leu			275
							280					285						
Phe	Pro	Ile	Ile	Pro	His	Tyr	Lys	Leu	Lys	Pro	Ala	Thr	Ala	Ala	Phe			290
						295					300							
Arg	Arg	Ala	Phe	Pro	His	Leu	Val	Arg	Lys	Ser	Asp	Glu	Arg	Ile	Leu			305
					310					315					320			
Gln	Ala	Phe	Tyr	Arg	Ile	Gly	Arg	Leu	Tyr	Ala	Lys	Tyr	Gly	Val	Ala			325
				325					330					335				
Asp	Ser	Ser	Ala	Lys	Leu	Phe	Thr	Leu	Lys	Glu	Ala	Gln	Leu	Thr	Ser			340
				340				345					350					
Lys	Ala	Ala	Ser	Asp	Ala	Lys	Ala	Ala										355
							360											

1. A recombinant *camelina* plant or cell comprising one or more polynucleotides encoding a $\Delta\delta$ -desaturase, a $\Delta 6$ -elongase and a $\Delta 5$ -desaturase operably linked with one or more regulatory sequences.

2. A recombinant *camelina* plant or cell according to claim 1 which further comprises one or more polynucleotides encoding a $\Delta 12$ -desaturase and/or a $\omega 3$ desaturase operably linked with one or more regulatory sequences.

3. A recombinant *camelina* plant according to claim 1 wherein the plant is a seed.

4. A recombinant *camelina* plant or cell according to claim 1 wherein the desaturase and elongase enzymes are independently derived from algae, bacteria, mould or yeast.

5. A recombinant *camelina* plant or cell according to claim 1 wherein the $\Delta 6$ -desaturase comprises an amino acid sequence having at least 50% identity to SEQ ID NO:2 or SEQ ID NO:20, the $\Delta\beta$ -elongase comprises an amino acid sequence having at least 50% identity to SEQ ID NO:4, SEQ ID NO: 22 or SEQ ID NO:24, and the $\Delta\delta$ -desaturase comprises an amino acid sequence having at least 50% identity to SEQ ID NO:6 or SEQ ID NO: 10.

6. A recombinant *camelina* plant or cell according to claim 1 wherein the $\Delta\beta$ -desaturase is derived from *Ostreococcus tauri*, the $\Delta 6$ -elongase is derived from *Physcomitrella patens* and the $\Delta\delta$ -desaturase is derived from *Thraustochytrium* sp.

7. A method for producing eicosapentaenoic acid (EPA) comprising growing a plant or cell according to claim 1 under conditions wherein said desaturase and elongase enzymes are expressed and EPA is produced in said plant or cell.

8. A method for producing plant seed oil comprising growing a plant or cell according to claim 1 under conditions wherein said desaturase and elongase enzymes are expressed and a plant seed oil is produced in said plant or cell.

9. A plant seed oil produced by the method of claim 8.

10. A plant seed oil according to claim 9 wherein EPA constitutes at least 5%, at least 10%, at least 15%, at least 20%, at least 25% or at least 30% (mol %) of the total fatty acid content of said oil.

11. A plant seed oil wherein the EPA constitutes at least 15% (mol %) of the total fatty acid content of said oil, and the γ -linolenic (GLA) constitutes less than 10% (mol %) of the total fatty acid content of said oil.

12. A plant seed oil according to claim 11 wherein the EPA constitutes at least 20% (mol %) of the total fatty acid content of said oil.

13. A plant seed oil according to claim 12 wherein the EPA constitutes 20% to 31% (mol %) of the total fatty acid content of said oil.

14. A plant seed oil according to claim 11 wherein the GLA constitutes less than 7% (mol %) of the total fatty acid content of said oil.

15. A plant seed oil according to claim 14 wherein the GLA constitutes 1% to 6% (mol %) by weight of the total fatty acid content of said oil.

16. A plant seed oil according to claim 11 wherein the ratio of the molar percentages of EPA to γ -linolenic (GLA) is about 3:1 to about 22:1, preferably about 5:1 to about 20:1.

17. A plant seed oil according to claim 11 wherein the oil is produced by the method of claim 8.

18. A recombinant *camelina* plant or cell comprising one or more polynucleotides encoding a $\Delta\theta$ -desaturase, a $\Delta\delta$ -elongase, a $\Delta\delta$ -desaturase, a $\Delta\delta$ -elongase and a $\Delta 4$ -desaturase operably linked with one or more regulatory sequences.

19. A recombinant *camelina* plant or cell according to claim 18 which further comprises one or more polynucle-

otides encoding a A12-desaturase and/or a ω3 desaturase operably linked with one or more regulatory sequences.

20. A recombinant *camelina* plant according to claim **18** wherein the plant is a seed.

21. A recombinant *camelina* plant or cell according to claim **18** wherein the desaturase and elongase enzymes are independently derived from algae, bacteria, mould or yeast.

22. A recombinant *camelina* plant or cell according to claim **18** wherein the Δδ-desaturase comprises an amino acid sequence having at least 50% identity to SEQ ID NO:2 or SEQ ID NO:20, the A6-elongase comprises an amino acid sequence having at least 50% identity to SEQ ID NO:4, SEQ ID NO: 22 or SEQ ID NO:24, the Δδ-desaturase comprises an amino acid sequence having at least 50% identity to SEQ ID NO:6 or SEQ ID NO: 10, the Δδ-elongase comprises an amino acid sequence having at least 50% identity to SEQ ID NO:8 and the A4-desaturase comprises an amino acid sequence having at least 50% identity to SEQ ID NO:16, SEQ ID NO: 18 or SEQ ID NO:26.

23. A recombinant *camelina* plant or cell according to claim **18** wherein the Δθ-desaturase is derived from *Ostreococcus tauri*, the Δ6-elongase is derived from *Physcomitrella patens*, the Δδ-desaturase is derived from *Thraustochytrium* sp., the Δδ-elongase is derived from *Ostreococcus tauri* and the AΔ4-desaturase is derived from *Emiliana huxleyi* or *Thraustochytrium* sp

24. A method for producing docosahexaenoic acid (DHA) comprising growing a plant or cell according to claim **18** under conditions wherein said desaturase and elongase enzymes are expressed and DHA is produced in said plant or cell.

25. A method for producing EPA comprising growing a plant or cell according to claim **18** under conditions wherein said desaturase and elongase enzymes are expressed and EPA is produced in said plant.

26. A method for producing a *camelina* oil comprising growing a plant or cell according to claim **18** wherein said desaturase and elongase enzymes are expressed and oil is produced in said plant or cell.

27. A plant seed oil produced by the method of claim **26**.

28. A plant seed oil according to claim **27** wherein DHA constitutes at least 3%, at least 5%, at least 7%, at least 10%, or at least 13% (mol %) of the total amount of fatty acid present in said oil.

29. A plant seed oil wherein DHA constitutes at least 3%, at least 5%, at least 7%, at least 10%, or at least 13% (mol %) of the total fatty acid content of said oil and the γ-linolenic (GLA) constitutes less than 5% (mol %) of the total fatty acid content of said oil.

30. A plant seed oil according to claim **29** wherein the DHA constitutes at least 13% (mol %) of the total fatty acid content of said oil.

31. A plant seed oil according to claim **30** wherein the DHA constitutes 5% to 15%, 10% to 15% or 10% to 13.7% (mol %) of the total fatty acid content of said oil.

32. A plant seed oil according to claim **29** wherein the GLA constitutes less than 3.5% (mol %) of the total fatty acid content of said oil.

33. A plant seed oil according to claim **29** wherein the GLA constitutes 0.5% to 5% (mol %) of the total fatty acid content of said oil.

34. A plant seed oil according to claim **29** wherein the GLA constitutes 1.5% to 3.5% (mol %) of the total fatty acid content of said oil.

35. A plant seed oil according to claim **29** wherein the ratio of the percentages by weight of EPA to DHA is about 0.8:1 to about 1.4:1.

36. A plant seed oil according to claim **29** wherein the ratio of the molar percentages of the sum of (EPA+DHA) to GLA is about 20:1 to about 3:1, or about 7:1 to about 7:1.

37. A plant seed oil according to claim **29** wherein the oil is produced by the method of claim **26**.

38.-41. (canceled)

42. A feedstuff, food, cosmetic or pharmaceutical comprising the oil as defined in claim **9**.

43. A feedstuff, food, cosmetic or pharmaceutical comprising the oil as defined in claim **27**.

* * * * *